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Over the last decade, the emergence of a vast range of new/novel/emerging psychoactive
substances (NPS) has progressively changed drug market scenarios, which have shifted from the
‘street’ to a ‘virtual’/online environment.
Several definitions of NPS are in use, with the term ‘new’ not necessarily referring to new
inventions but to substances that have recently been made available, possibly including failed
pharmaceuticals or old patents which have been ‘rediscovered’ as ‘recreational’ molecules. Conversely,
the term ‘novel’ can refer to something newly created, an old drug that has come back into fashion,
or a known NPS molecule being used in an innovative or unusual way and hence presenting
a ‘novelty’ appeal (Corkery et al., 2018) [1]. Though misleading, the terms ‘legal highs’ and
‘research chemicals’ have been used alternately to describe these molecules. NPS includes synthetic
cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids,
tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists,
a range of prescribed medications, psychoactive plants/herbs, and a large series of image- and
performance-enhancing drugs (IPED) (Schifano et al., 2015) [2]. Overall, users are typically attracted
to NPS because of curiosity and the diffusion of social media users’ experiences, easy availability or
affordability from online drug shops, legality, intense psychoactive effects, and the likely lack of detection
in routine drug screenings (Schifano et al., 2015) [2].
Between 2004 and 2017, some 700–800 examples of NPS were reported by related European and
international drug agencies (UNODC, 2018 [3]; EMCDDA, 2018 [4]), with most molecules identiﬁed
being synthetic cannabinoids, synthetic cathinones, phenethylamine derivatives, and synthetic opioids.
However, it could be argued that the NPS scenario is much larger than that outlined by those molecules
which have been seized or formally identiﬁed by EU and international agencies. Since the online NPS
scenario typically predicts the real life NPS scenario (Schifano et al., 2015) [2], identifying what is being
discussed online by web-based NPS enthusiasts, or ‘e-psychonauts’ (Orsolini et al., 2015) [5], may well
be of interest. With this in mind, a crawling/navigating software (i.e., the ‘NPS.Finder®’) was recently
designed by our group. In November 2017, it started to automatically scan, on a 24/7 basis, a vast
range of psychonaut web forums for NPS. After a year of operation, it has been possible to estimate that
the online/psychonaut web forum NPS scene may include some 4000 different molecules. The most
popular examples of NPS mentioned in psychonaut forums have included synthetic cannabimimetics,
synthetic opioids, phenethylamines, designer benzodiazepines, and prescribed drugs.
NPS use, especially for synthetic cannabinoids and novel psychedelics, has been associated with
a range of untoward medical consequences, including vomiting, seizures, cardiovascular complications,
and kidney failure (Schifano et al., 2017) [6]. By contrast, the main focus of this special issue is on the
major psychopathological consequences of NPS use. Indeed, due to their complex pharmacodynamics,
there are increasing levels of concern about the onset of acute or chronic psychopathological issues
associated with NPS intake.
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The occurrence of psychosis has been related to: (a) increased central dopamine levels, typically
seen with novel psychedelic phenethylamines, novel stimulants and synthetic cathinones; (b) significant
cannabinoid CB1 receptor activation, which is associated with high potency synthetic cannabimimetics;
(c) 5-HT2A receptor activation, seen with latest generation phenethylamines, tryptamine derivatives and
hallucinogenic plants; (d) antagonist activity at n-methyl-D-aspartate/NMDA receptors, observed with
ketamine, methoxetamine/MXE, and their latest derivatives; and (e) k-opioid receptor activation,
which is typically associated with both Salvia divinorum and Mitragyna speciosa/‘Kratom’ intake.
By considering the above, this special issue of Brain Sciences aims to provide an overview of a range
of NPS-related issues. More precisely, Sahai et al. [7] present original preclinical data relating in silico and
in vitro assessment of the psychoactive properties of a few dissociative diarylethylamines. Miolo et al. [8]
focus on specific analytical chemistry issues relating to amphetamine-type stimulants and ketamine,
while Parrott [9] argues that there are similarities betweenwell-known recreational drugs andNPS in terms
of mood fluctuations/psychobiological instability issues. Conversely, Cohen and Weinstein [10] present original
cognitive psychopharmacology data relating to the use of organic and synthetic cannabinoids. From a clinical
point of view, Bonaccorso et al. [11] introduce a case series of synthetic cannabinoid users presenting
to acute psychiatric services with psychosis; Frisoni et al. [12] comment on the medical consequences
of novel opioid intake; Martinotti et al. [13] provide a thorough overview of hallucinogen-persisting
perceptual disorder, a clear issue of interest for NPS users; Schifano et al. [14] reflect on the misuse
and abuse of prescribed medicines (e.g., benzodiazepine derivatives, methylphenidate look-alikes,
and fentanyl analogues) in the NPS context; and Gittins et al. [15] provide empirical data relating NPS
use by clients seeking treatment in the UK. Both Wadsworth et al. [16] and Miliano et al. [17] comment
extensively on the role of the open/deep web in shaping and promoting changes in NPS scenarios. Finally,
both Metastasio et al. [18] and Catalani et al. [19] offer original data which sheds further light on the
expanding phenomenon of IPED misuse/abuse.
In conjunction with constant changes in basic structures from which emerging molecules can
be derived, designed, and synthesized, the NPS market will continue to expand. This will pose
a challenge, since NPS-related toxidromes are, per se, complex and unpredictable, and clinicians need
to aim to be better educated in recognizing NPS-related toxicity issues. Drug control policies should be
improved worldwide, and the list of examples of NPS should be constantly updated as improvements
in analytical chemistry detection methods occur. Given the implications of NPS for mental health,
psychiatric services should adapt to new drug scenarios while drafting new treatment strategies.
Conﬂicts of Interest: The author declares no conﬂict of interest.
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Abstract: Background: Octodrine is the trade name for Dimethylhexylamine (DMHA), a central
nervous stimulant that increases the uptake of dopamine and noradrenaline. Originally developed as
a nasal decongestant in the 1950’s, it has recently been re-introduced on the market as a pre-workout
and ‘fat-burner’ product but its use remains unregulated. Our work provides the ﬁrst observational
cross-sectional analytic study on Octodrine as a new drug trend and its associated harms after a gap
spanning seven decades. Methods: A comprehensive multilingual assessment of literature, websites,
drug fora and other online resources was carried out with no time restriction in English, German,
Russian and Arabic. Keywords included Octodrine’s synonyms and chemical isomers. Results:
Only ﬁve relevant publications emerged from the literature search, with most of the available
data on body building websites and fora. Since 2015, Octodrine has been advertised online as
“the next big thing” and “the god of stimulants,” with captivating marketing strategies directed
at athletes and a wider cohort of users. Reported side-effects include hypertension, dyspnoea and
hyperthermia. Conclusions: The uncontrolled use of Octodrine, its physiological and psychoactive
effects raise serious health implications with possible impact on athletes and doping practices.
This new phenomenon needs to be thoroughly studied and monitored.
Keywords: octodrine; dimethylhexylamine; DMHA; ambredin; ﬁtness; novel psychoactive substance;
performance and image-enhancing drugs; anti-obesity agents; weight loss
1. Introduction
The evolution of trends within drug use has recently been marked by a rapid expansion in the
number of commercially-available psychoactive substances [1], with an increased number of young
users [2] and relevant psychiatric consequences [3]. This includes both a proliferation of new drugs
(‘research chemicals’ or ‘RC’s) with a distinct pharmacology and very little associated research evidence
on their physiological or side effects, as well as an increase in the abuse of diverted prescription
Brain Sci. 2018, 8, 34; doi:10.3390/brainsci8020034 www.mdpi.com/journal/brainsci4
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medications [4,5] Octodrine sits somewhere between these two trends, being a traditionally-developed
pharmaceutical but with no current, legitimate medical application.
The so-called “Performance and Image-Enhancing Drugs” (PIEDs) taken to enhance human
abilities in a myriad of spheres, are one important emerging facet within this. These include
substances with a perceived ability to enhance physical performance, psychological status, appearance,
cognitive abilities and social relations and as such are sometimes referred to as ‘lifestyle drugs’ [6–10].
The concept of PIEDs is now well established and is acknowledged particularly in relation to the world
of athletics [11,12]. The most well-known PIEDs are the anabolic steroids, peptides and hormones but
their use is increasingly giving way to other types of substance to achieve speciﬁc goals. These can be
physical in nature (e.g., tanning, weight loss, muscle gain, speed, strength, performance) or cognitive,
such as the use of nootropics for professional or academic performance [13,14], or for social gain, where
various categories of substance as a ‘social lubricant’ for social anxiety support). Over the past decade,
more than 800 NPS were identiﬁed in over 102 countries by the EMCDDA and the UNODC Early
Warning Systems [15,16] as well as our ongoing monitoring activities [1] and their number is constantly
growing. Some of these compounds may represent a serious issue for public health and are changing
the face of debates around doping by playing unfairly on the narrow line between legal and illegal [12].
The globalization of the online drugs market has made this a widespread phenomenon, reaching a
new cohort of users, which includes not only the body builders and time-pressured professionals, who
were initially associated with this trend but also students and others of all demographics [12,17,18].
In November 2016, Octodrine was found in an athlete engaged in a bodybuilding competition,
later disqualiﬁed as he also tested positive for anabolic and stimulant drugs, included in the World
Anti-doping Agency's (WADA) List of Prohibited Substances (Section S6 and S1) [19,20]. Octodrine is
a psychoactive central nervous system stimulant. It is an amphipathic primary amine (Figure 1) [21]
known under many names, including dimethyl hexylamine (DMHA) and 2-amino-6-methylheptane,
2-metil-5-amino-eptano. Its structure presents some similarities with that of other illegal stimulants
like, AMP Citrate (DMBA), Ephedrine and 1.3-DMMA itself. With DMAA and AMP Citrate already
phasing or phased out of current supplements, this drug was brought back on market as an alternative
in pre-workout and ‘fat-burner’ products in 2016. Octrodrine was originally developed in the
United States as an aerosolized treatment for bronchitis, laryngitis and other conditions [22–24].
Its pharmacology was studied in the early 1950s, was investigated as an antitumor drug and
used to be available as a nasal decongestant under the tradenames Vaporpac and Tickle Tackel
Inhaler [25]. Sympathomimetic effects of DMHA were explained as alpha adrenergic agonist-mediated
via G-protein-coupled receptors (GPCRs) [26]. Limited human data is available just from preliminary
studies, while studies on activity and acute toxicity had been conducted on animals (cats, rabbits,
dogs and pigs) [27–32]. Octodrine was found to increase the pain threshold, cardiac rate (positive
chronotropic effect) and myocardial contractility (positive inotropic effect) [33–35]. The safety of
Octodrine as an individual drug remains unknown due to the lack of any placebo-controlled trial
but animal experiments suggest a potential for adverse cardiovascular effects. Structurally, there are
two forms of DMHA: the naturally occurring 2-amino-5methylpetane and the synthetically derived
2-amino-6-methylheptane. The natural version can be found in extracts of Juglans Regia (Walnut
Bark), Aconitum Kusnezofﬁi’s and Kigelia Africana and it is often used for hunting purposes [36–43].
The synthetic version is the most widely used because less expensive and toxic to produce. It is
therefore assumed that the DMHA used in supplements is synthetic. As of right now, this molecule is
not on the 2016 WADA banned substances list but it ﬁts perfectly in the category of the well-known
Performance and Image Enhancing Drugs (PIEDs). Coveted by elite track and ﬁeld athletes, DMHA is
marketed to a broader demographic including beginners and non-professionals.
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Figure 1. Chemical structure (A) and molecular lipophilicity potential (MLP) surface (B) of octodrine
molecule (hydrophobic surfaces are depicted in red and polar surfaces are in blue) [21].
Considering the existing knowledge gap spanning seven decades and the re-emergence of
Octodrine as a new drug trend, it was felt the need to further investigate the phenomenon in different
communities, while exploring issues related to its e-commerce, consumption, motivations of use and
potential negative impacts to health, among other features.
2. Materials and Methods
A literature review on Octodrine was carried out in the following databases: Scopus, Medline,
EBSCO and Google Scholar (Figure 2). A list of keywords was compiled in accordance with a
preliminary pilot study of literature and databases on the surface web and online e-commerce websites.
Terms included: “Octodrine,” “Ambredin & Vaporpac,” “2-aminoisoheptane,” “Dimethylhexylamine,”
“DMHA,” “2-amino-6-methylheptane,” “6-methyl-2-heptylamine,” “2-metil-5-amino-eptano,”
“5-methyl-2-heptylamine,””Dimethylhexylamine,” “Aconitum kusnezofﬁi, “Aconite extract,” among
others. The keywords also included synonyms of Octodrine in other languages and names of chemical
isomers. Searches were carried out in English, Italian, German, Arabic and Russian.







 
Databases: Scopus, Medline, EBSCO, and Google 
Scholar 
Search terms: “Octodrine”, “Ambredin & 
Vaporpac”, “2-aminoisoheptane”, 
“Dimethylhexylamine”, “DMHA”, “2-amino-6-
methylheptane”, “6-methyl-2-heptylamine”, “2-
metil-5-amino-eptano”, “5-methyl-2-
heptylamine”,”Dimethylhexylamine”, “Aconitum 
kusnezoffii,  “Aconite extract 
Google trends Sources: Bodybuilding Website, 
(Bio)Chemistry, Pharmaceutical 
Websites, Blogs and Online Fora 
Search terms: 
“Octodrine”, “2-
aminoisoheptane”, 
“aminoisoheptane” 
and “DMHA” 
Period: January 
2004-January 2018 
Regions: worldwide 
Analysis of scientific literature Analysis of trends Analysis of anecdotal cases 
Totally - 33 publications 
Clinical and pharmacological aspects – 
14 publications 
Chemical studies – 13 publications 
Patent – 1 publication 
Regulating documents – 5 publications 
Online 
trading 
platforms 
– 147  
Blogs and 
Online 
Fora 
– 9  
Figure 2. Algorithm of the analysis.
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No time restrictions were applied to the searches. Inclusion and exclusion criteria for literature
data selection are deﬁned in Table 1. Considering the lack of scientiﬁc investigations in the ﬁeld and
the absence of experimental and/or interventional studies in humans, additional qualitative systematic
searches were carried out in the world-wide web to investigate the extent of diffusion of Octodrine,
trading strategies for its distribution and the nature of the self-reported (subjective) experiences by
users in English, German, Arabic and Russian. These included bodybuilding websites, chemistry
and chemists’ websites, pharmaceutical companies, online e-commerce stores as well as a range of
fora posts/threads. The web snapshot was carried out on a regular basis (between November 2016
- January 2018) using a Google search. Only publicity available information was considered for the
study and no posts/other contributions to fora discussions were made by the researchers. Additional
data were also obtained by consulting Google Trends [44].
Table 1. Inclusion and exclusion criteria for selection of articles and the web analysed in this study.
Inclusion Criteria
1. Studies and publication related to Octodrine
2. Studies and publication of octodrine-related compounds and chemicals, in which Octodrine is
an ingredient
3. Studies and publication in which octodrine is marginally included
4. English, German and Russian languages
5. All years of publication (no date restriction)
6. Surface web
7. Grey (unpublished) literature, including master’s and doctorate theses
8. Fitness and body building websites
9. (Bio)chemistry, pharmacy and pharmaceutical websites
10. Online drug fora
11. Human and animal studies
12. Observational and experimental studies
Exclusion Criteria
1. Duplicate Articles
2. Initial screening for relevance (reading the title and abstract)
3. Articles found to be irrelevant by analysing the full article
4. Low scoring for an article on CASP critical appraisal tool (poor quality of appraised manuscript)
Ethical approval for this the study was granted by the School of Pharmacy Ethics Committee,
University of Hertfordshire, Hatﬁeld, United Kingdom (November 2013; PHAEC/10-42).
3. Results
3.1. Medical and Paramedical Database, Grey Literature
Various articles emerged from our literature searching but only eight of them [23,24,27–31,33]
referred to Octodrine, Octodrine derivatives and Octodrine-related compounds in the entire
scholarly-published literature (Table 2).
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Table 2. Pharmacological and clinical properties of Octodrine (analysis of articles).
Reference Author Year ofPublication
Name of Studied Substance
or Medicament Key Findings
Respiratory system
[28] Charlier, R.;Philippot, E. 1950
theophylline-diethylenediamine
ethanoate
The aerosol with Octodrine demonstrated the property
to increase respiratory volume
[29] Charlier, R. 1951 2-amino-6-methyl-heptane
Animal experiment (dog) revealed bronchodilation,
increased nasal and lung volume caused by
2-amino-6-methyl-heptane
[23] Gode, J. 1958 Ambredin Identiﬁcation of bronchospasmolitic properties of
Ambredin medicament consisting of Aceverine
Hydrochloride, Octodrine Phosphate and Theophylline[24] Tschudin, M.L. 1960 Ambredin
Cardiovascular system
[30] Fellows, E.J. 1947 2-amino-6-methylheptane
2-amino-6-methylheptane hydrochloride caused an
increase in cardiac rate and amplitude of contraction in
animal experiment (dog)
[27] Marsh, D.F.;Herring, D.A. 1951 Methyl-2-heptylamine
Compared to others sympathomimetic amines,
6-Methyl-2-heptylamine focused the myocardial
stimulant activity and increased force of myocardial
contraction along with heart rate
[29] Charlier, R. 1951 2-amino-6-methyl-heptane
Animal experiment (with dog) revealed growth in
arterial blood pressure after the exposure of
2-amino-6-methyl-heptane
[34] Oelkers, H.A. 1967 2-amino-6-methylheptane(+)-camphor-10-sulfonate
Inotropic properties of 2-amino-6-methylheptane
(+)-camphor-10-sulfonate were identiﬁed
[31] Trieb, G.;Nusser, E. 1974 Ordinal®retard
The medicament Ordinal® retard combining Octodrine,
3-octopamine and adenosine demonstrated pressure
effects in treatment of patients with hypotension
Nervous system
[30] Fellows, E.J. 1947 2-amino-6-methylheptane
2-amino-6-methylheptane demonstrated local
anaesthesia and elevation of local pain threshold in
experiments with animals (rabbits, cats, dogs)
Antimicrobial activity
[45]
Kim, K.;
Zilbermintz, L.;
Martchenko, M.
2015 Octodrine Octodrine demonstrated antifungal activity inexperiments with serum-grown C. albicans
[46] Niu, H.; Cui, P. 2015 Octodrine Octodrine demonstrated experimental activity againststationary phase E. coli
Reference to its multiple medicinal properties was found in ﬁve of these papers, which highlighted
its sympathomimetic and broncho-spasmolytic effects, with possible further actions as a stimulant,
anti-obesity and appetite suppressant agent. The molecule is cited also as an antimicrobial with speciﬁc
antifungal activity [45], as a nasal decongestant [47] and as an ingredient of dietary supplements [48].
Other scholarly papers (a total of seven) made passing or limited reference to Octodrine, covering the
chemical properties and analyses of several compounds including this one, or providing data on its
antimicrobial effects only [45,46]. These are other scattered examples of relevant documentation,
including an invention patent from 2012 [49]. However, the lack of experimental randomized
controlled trials (RCTs) and other interventional studies on humans has led to a complete absence of
systematic reviews and meta-analytic studies related to use of Octodrine as a medicinal agent or food
supplement. Two of the three papers found on PubMed were published in the Journal of Pharmacology
and Experimental Therapeutics in 1947 and 1951 respectively [27,30], while the third paper [29] was
published at the Archives internationales de pharmacodynamie et de thérapie. Since the 1950s, there
have been no other scholarly-published data speciﬁc for Octodrine in any peer-reviewed journal,
neither observational nor experimental could be found on the entire web, including medical and
paramedical databases, or unpublished literature. The substance remerged on the literature in 2017,
when Cohen et al. published a study conducted on six different supplements: Game Day, Infrared,
2-Aminoisoheptane, Simply Skinny Pollen, Cannibal Ferox AMPed and Triple X. All these products
disclosed on their label the words Octodrine, 2-amino-6-methylheptane and 6-methyl-2-heptanamine
or listed the stimulant as if it were an extract of Aconitum kusnezofﬁi plant. Results showed that
only one of them, Game Day, contained Octodrine, while the others contained different or banned
stimulants [50].
8
Brain Sci. 2018, 8, 34
3.1.1. Limited Data-Reporting in Scholarly Peer-Reviewed Papers and Invention Patents
There is limited mention of Octodrine in invention patents from 2012 in relation to a novel stable
anaesthetic for reducing skin reactions [49].Two papers, pertinent to the disciplines of toxicology and
chemical chromatography, examined Octodrine in terms of its physiochemical properties including
relative retention time (RTT) and its identiﬁcation in hair samples [51,52]. Furthermore, Niu et al. and
Kim et al. [45,47] discussed the broad-spectrum antimicrobial effect, antifungal effect, anti-persister
activity and application for the treatment of Candida albicans and uropathogenic strains of Escherichia
coli. These two papers also discussed Octodrine microbial resistance. Additionally, Kuo et al. (2004) [26]
and Schlessinger et al. (2011) [53], documented the sympathomimetic properties of Octodrine and
effects related to norepinephrine transporter (NET) and G-protein-coupled receptors (GPCRs), which
was in concordance with the results from 1947 and 1951 animal studies [27,30].
3.1.2. Google Trends
Google Trends provided valuable data in relation to the interest in Octodrine on the Web.
Four keywords provided good insight on the trend as far back as the year 2004. These keywords
are “Octodrine,” “2-aminoisoheptane,” “aminoisoheptane” and “DMHA.” There was an obvious
incremental increase of interest in Octodrine starting in the year 2012. This interest plateaued between
2013 and 2014 and was followed by a steep rise in 2014–2015, followed by a further escalation starting
in 2015 before peaking by the January of 2018 [54]. Comparing to other three keywords, DMHA has
demonstrated the greatest interest among Google users ranging between 9 searches in July 2008 and
100 searches in September 2017. The leading countries in terms of internet searches of Octodrine
(DMHA) were the USA, Canada and Australia. On the Russian-language Internet, users showed no
search activity for Octodrine, while intensively searching for DMAA. In June 2017, the quantity of
DMAA searches in Russian-language zone was 100. Since 2004 the trend has demonstrated stable
growth in this local online area [55]
3.1.3. Bodybuilding Website, (Bio)Chemistry, Pharmaceutical Websites, Blogs and Online Fora
Body building websites provided a major source of data, especially in relation to the analysis
of online trading platforms and fora discussing Octodrine and its effects. A multilingual approach
used in this part of the study facilitated the characterisation of regional and national features of
sport-stimulant markets.
No speciﬁc inclusion criteria were imposed upon the body-building websites, beyond
demonstrating a mention of DMHA or synonym. All such instances were included in the evaluation.
The English-language domain was investigated with relevant results. No results were produced
from searches in Arabic. Thousands of websites can be located using the Google search terms
“Octodrine” and its synonyms [56–59]. Popular brand names include: Olympus Labs CONQU3R
Unleashed, Total War, Simply Skinny Pollen, AdrenaCLENV2, Game Day, Cannibal Ferox Amped,
Giant Sports Giant Rush [57–66]. By January 2018, 68 English- and 6 German-language online
shops selling Octodrine were identiﬁed. The product is often advertised as the “next big thing”
in bodybuilding environments and described as the “new MDAA” whose effects are “just right” for
dietary supplement users and/or stimulant-enthusiasts as it can allegedly enhance focus, experience
and performance. Many of these sites also provide detailed information around usage and dosage,
alongside with warnings on risks and severe side effects of this emerging molecule [56–59]. Professional
scientiﬁc or pharmaceutical sites regarding the chemistry characterization of this compound can be
found on the web, as well as “amateur” websites, displaying more generic scientiﬁc information on
this potentially dangerous substance [67,68]. Online stores are predominantly American or Australian
domains that ship their products all over the world. Octodrine is presented as a DMAA-like stimulant
and predominantly sold as a fat-burner product or pre-workout formula. Some websites also
recommended it for intensive study sessions, positioning this molecule among the Nootropics;
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pharmaceuticals used to improve cognitive and executive function, memory and creativity in healthy
individuals. Claims such as “It boosts dopamine and noradrenaline uptake, while slowing down
reuptake just long enough for a solid workout or study session” are quite common [58].
Usually Octodrine is sold in powder (e.g., Cannibal Ferox AMPed, Olympus Labs CONQU3R
Unleashed, Game Day, Total War) as pre-workout or in capsules (Infrared, Simply Skinny Pollen) as
fat burner, with prices ranging from 1.75 to 3.75 dollars per serving.
German online trading platforms focus customers’ attention on Octodrine with detailed feedback
from the reviewers (estimation of taste, effects, “price-quality”) [68] or vague offers of “ﬁtness hardcore
pre-workout booster for pumps and focus” [69]. The trader for amazon.de mentions Octodrine as
additives “Oct” in “Arginine AKG, Beta-Alanine, Citrullin Malate complex” and omits a description of
its side-effects. Standard marketing technologies widely used by German traders are also employed,
such as discounts, world-wide express-delivery and even “halal” certiﬁcation.
In terms of the Russian-language results, the majority consisted of bodybuilding resources
linked to 73 online shops delivering Octodrine to the Russian Federation, the Ukraine and 4 Central
Asian countries. In contrast, fora did not indicate signiﬁcant popularity among local athletes and
were predominantly arranged within Russian social nets [70,71]. All identiﬁed Russian-language
websites run their activity legally on the surface web, a fact explained by the absence of any law
enforcement restrictions referring to DMHA and DMAA in Russia and Ukraine. The relative lesser
popularity of these particular stimulants is no doubt inﬂuenced by the availability of much cheaper
locally produced analogues. An imported stimulant complex with DMHA and DMAA (from the
USA) costs 1.27 ± 0.19 USD per unit compared to a local analogue for 0.49 ± 0.23 USD per unit.
The local online platforms offer more than 20 brands of Octodrine. The immense variety of trading
names of this substances is attributable to continuous rebranding as attempts to overcome counterfeit
production [72]. By offering athletic stimulant complexes, Russian online shops strive to advertise
DMHA and DMAA as the active components for the desirable results; less attention is paid to
other substances such as vitamins, tyrosine, taurine and DMAE [73,74]. Trading and producing
companies announced anti-inﬂammatory, anaesthetic, spasmolytic and anticonvulsant properties of
Octodrine offering the “ideal” substance for “hard-core” training [72]. The use of Octodrine as a
weight loss product is rarely advertised (e.g., only 9 Russian-language online shops were identiﬁed).
Fat burners containing Octodrine are typically sold at a higher price point: 1.3 USD per unit in
contrast to the 0.5 USD for the pre-training complex. Taking into account the legality of DMHA and
DMAA in Russian-language territories and the absence of relevant trading regulations, local online
shops did not notify their customers to possible side and toxic effects of the stimulants. Some shops
explicitly claim that Octodrine has no side effects and that is potential is the same as caffeine [75].
For example, berserktakticalfarma.blogspot.com underlined the safety and high effectiveness of
DMHA, emphasising that its potency is equal to 90% of DMAA [76]. Only one of 73 identiﬁed
online websites warned that Octodrine and DMAA can be detected and could possibly mislead
sport competition testing and thus advised users to cease Octodrine beforehand [74]. An additional
online shop mentioned contraindications generally for stimulant complexes without speciﬁcation on
Octodrine [77].
Discussions on fora include suggested dosages, combinations, duration of action, among others.
According to such anecdotal evidence, a “safe dose” is considered to be around 1mg/kg of bodyweight
up to 160 mg per day, while others recommend 100 mg of the synthetic DMHA isomer and 75 mg of
the natural one to reach the “sweet spot.” In the Russian-language internet zone, the recommended
dose of DMHA substantially differed between online shops (30 to 400 mg), as did the dosing schedule.
For instance, the online retailer hulkfood.ru advised to take Octodrine for 45 days without stopping to
gain signiﬁcant desired stimulating effects before sporting competition [78].
Users suggest an intake approximately 15–30 or 30–60 min prior to working out [79,80].
Alternatively, if used for its appetite suppressant properties, DMHA consumption was advised
between meals and never in the evening as it might affect sleeping. According to users, 25 mg
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twice a day are enough to “keep one’s mind off food” [81]. Experienced users shared their insights:
“If used predominantly for its appetite suppressant properties, DMHA can be used during the day
between meals. However, we recommend taking caution if using this ingredient late in the afternoon
or early evening, as it has the potential to hinder your ability to sleep.”
DMHA effects will occur ~15 to 60 min after consumption. The substance demonstrates potency
to heighten level of mental focus, increase energy and reduce appetite, as well as raise feelings of
wellbeing. Bloggers described a three-phase effect for pre-work-out complexes containing DMHA:
(1) stimulation, (2) post-stimulation side effect symptoms and (3) sleep disturbances. Octodrine is
frequently advised as a substance intensifying the ﬁrst two phases with no impact on sleep [82].
Because of its stimulants effects, Octodrine has also been used outside ﬁtness settings, including
working environments as non-prescribed medication [83,84]. To boost athletic performance, it is
sometimes ingested in combination with huperzine A, DMAE, n-acetyl tyrosine, alpha-gpc, noopept,
phenotropil and picamilon to gain maximal focusing on training. Phenibut and ladasten strengthen
the euphoric effects of Octodrine [82].
Side effects such as mood swings, tremor, concentration deﬁciency, over-stimulation, energy
crashes, anxiety, high blood pressure, dyspnoea, rapid heartbeat and heartburn have been reported
6–8 h after the initial onset of effects [85,86]. Some users also reported eyes twitching (blepharospasm),
pulsing sinus area (carotid sinus), mood ﬂuctuation, absent-mindedness; a rise in blood pressure,
piloroerection and hyperthermia following ingestion of Octodrine (e.g., Anabolicminds.com, 2016;
Project Bodybuilding, 2016; kandeleria.ru). There were only a limited number of indications for
professional athletes: some websites suggest avoiding consumption for ethical considerations, or
because it could be considered a violation of the WADA restrictions [72,86,87].
Some fora provide information on abuse potential and possibility of dependency on Octodrine.
Namely, users warned about withdrawal symptoms and growth of tolerance resulting from the short-
and long-term use of the stimulant [71,82]. Experienced athletes recommend alternating 3–4 stimulant
complexes each training day to overcome undesirable adaptation [77].
4. Discussion and Conclusions
To the best of the authors’ knowledge, this study is the ﬁrst to implement a systematic review
of the literature or undertake cross-sectional analysis of the content of the web in relation to the
diffusion and e-commerce of Octodrine. The authors also bring to the spotlight the noteworthiness of
subsequent studies on Octodrine, speciﬁcally chemical analysis and receptor-ligand binding assays,
with the aim is of reaching a full understanding of this widely used substance. The restrictions on
amphetamine-type stimulants (e.g., DMAA, DMAE) exacerbate demands on new formulas tailored to
the ambitions of bodybuilders and athletes. The sympathomimetic properties of Octodrine, inheriting
the potential of DMAA, meet the expectations of “new-generation boosting” and stimulate the growth
of global trading. Meanwhile discrepancies between practical experience and theoretical knowledge
were observed in our study. Very little is known about its pharmacodynamics and pharmacokinetics
proﬁles, or the chemical proﬁle of the commercially-available Octodrine-related products.
On the Internet, Octodrine is misleadingly advertised as a “safe and legal” analogue of banned
stimulants (e.g., DMAA and phenethylamine), making it potentially more attractive to new and
experienced users. Intensive marketing campaigns with unlimited worldwide delivery, discounting
programs and displays of “good” feedback from reviewers, have contributed to the re-emergence and
current spread of Octodrine in the drug market. According to anecdotal for a, reports and trading
information, motives of use go beyond athletics gyms: more often the drug is recommended as a
day-life stimulator.
The psychoactive effects of Octodrine were neither previously described in literature nor studied
despite its structural similarity to other drugs of abuse (DMAA, DMAE). Its metabolic pathway and
adverse reactions have not been studied in humans, making its use in ﬁtness settings extremely
hazardous. A limited number of open claims were found on the potential risk, side effects and
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complications of Octodrine use, while its properties as “hard-core” for advanced users are often
emphasized. Sites exploited fragmented and sporadic “scientiﬁc news” describing only favourable
effects of Octodrine, with research evidence being completely omitted. Only some English and German
sites warned about ceasing Octodrine use before sport competitions. Meanwhile, on Russian-language
trading platforms, DMHA was actively offered in combination with DMAA - attributable to the legal
status of both in this geographical zone (Russia, Belarus, Kazakhstan, Kyrgyzstan). Amphetamine-type
stimulants (such as DMAA) have showed more popularity, especially for the last two years.
The reported side effects of Octodrine suggest the strong need for further research. The desirable,
stimulatory effects of Octodrine are accompanied with a range of mental and somatic symptoms,
with frequent use of Octodrine being associated with tolerance, withdrawal symptoms and risks of
dependence syndrome. We reiterate here the importance of focusing and asking direct questions on
the pharmacological and toxicological properties of Octodrine. The addictive potential should be
promptly identiﬁed and assessed. Hence, attention should be paid to further investigation in the ﬁeld
and consider the incorporation of Octodrine within WADA and FDA prohibited substances lists.
There are some limitations to our study. Only ﬁve peer-reviewed papers were directly pertinent
to Octodrine and these were mainly published 6–7 decades ago. Other scholarly-published studies
addressed Octodrine in a marginal way. The paucity of the available literature, absence of review
articles, systematic reviews and meta-analytical studies clearly limit the extent of this present
review. Taking into consideration lack of publications on the chemical analysis of Octodrine,
a comprehensive chemical analysis is necessary for future research, with the aim of establishing
the detection and identiﬁcation of Octodrine, along with potential contaminants, excipients and other
active ingredients in the currently promoted powder-products under the name Octodrine or DMHA.
The sympathomimetic effect of Octodrine is well-understood. However, the central effects including
the psychostimulant and anti-obesity effects are not adequately explored and/or reported, with no
formally documented experimental studies nor case reports. Future studies should focus on the central
effect of Octodrine and its correlation with patterns of cerebral dominance and the lateralization of
brain function. Moreover, there is an inadequate body of data in relation to the geographic usage
of Octodrine, particularly for contrasting the developing world (including the Middle East, North
Africa and post-soviet regions) versus the developed world. In terms of multilingual analysis of
websites and drug fora, only publicity available information was considered for the study to uphold
observational status. Fora requesting registration were not included in the study. Self-reported
experiences are only partially reliable and it may be inappropriate to trust such anecdotal evidence
without independent veriﬁcation.
Author Contributions: V.C. carried out most of the scientiﬁc review and wrote the ﬁrst version of the paper. M.P.,
A.A.-I. and Y.E. contributed to the online searches in German, Russian and Arabic. S.M. revised the manuscript at
various stages and contributed to the assessment of the literature searches. R.C., G.M. and M.Z. provided inputs
on the research work at different stages and reviewed the manuscript before the submission. O.C. oversaw the
overall project. O.C. provided guidance and inputs at each stage of the work and reviewed the work before the
ﬁnal submission.
Conﬂicts of Interest: The authors report no conﬂicts of interest. The authors alone are responsible for the content
and writing of the article.
References
1. Corazza, O.; Assi, S. Promoting Innovation and excellence to face the rapid diffusion of Novel Psychoactive
Substances in the EU: The outcomes of the ReDNet project. Hum. Psychopharmacol. Clin. Exp. 2013, 28,
317–323. [CrossRef] [PubMed]
2. Martinotti, G.; Lupi, M. Novel psychoactive substances: Use and knowledge among adolescents and young
adults in urban and rural areas. Hum. Psychopharmacol. 2015, 30, 295–301. [CrossRef] [PubMed]
3. Martinotti, G.; Lupi, M. Novel psychoactive substances in young adults with and without psychiatric
comorbidities. Biomed. Res. Int. 2014, 2014, 815424. [CrossRef] [PubMed]
12
Brain Sci. 2018, 8, 34
4. Van Hout, M.C. Kitchen chemistry: A scoping review of the diversionary use of pharmaceuticals for
non-medicinal use and home production of drug solutions. Drug Test Anal. 2014, 6, 778–787. [CrossRef]
[PubMed]
5. Di Nicola, A.; Martini, E. FAKECARE: Developing expertise against the online trade of fake medicines by
producing and disseminating knowledge, counterstrategies and tools across the EU. In eCrime Research
Report; StampaLith Snc: Trento, Italy, 2015; Volume 2.
6. Corazza, O.; Roman-Urrestarazu, A. Novel Psychoactive Substances: Policy, Economics and Drug Regulations;
Springer: Berlin, Germany, 2017.
7. Rahman, S.Z.; Gupta, V. Lifestyle Drugs: Concept and Impact on Society. Indian J. Pharm. Sci. 2010, 72,
409–413. [CrossRef] [PubMed]
8. Mooney, R.; Simonato, P. The use of supplements and performance and image enhancing drugs in ﬁtness
settings: A exploratory cross-sectional investigation in the United Kingdom. Hum. Psychopharmacol. 2017, 32.
[CrossRef] [PubMed]
9. Corazza, O.; Parrott, A.C. Novel psychoactive substances: Shedding new lights on the ever-changing drug
scenario and the associated health risks. Hum. Psychopharmacol. 2017, 32. [CrossRef] [PubMed]
10. Lanni, C.; Lenzken, S.C. Cognition enhancers between treating and doping the mind. Pharmacol. Res. 2008,
57, 196–213. [CrossRef] [PubMed]
11. Franques, P.; Auriacombe, M. Sports, use of performance enhancing drugs and addiction. A conceptual and
epidemiological review. Ann. Med. Interne t (Paris) 2001, 152, 37–49.
12. Mazzoni, I.; Barroso, O. Anti-doping Challenges with Novel Psychoactive Substances in Sport. In Novel
Psychoactive Substances: Policy, Economics and Drug Regulations; Corazza, O., Urrestarazu, A., Eds.; Springer:
Berlin, Germany, 2017; pp. 43–56.
13. Van Hout, M.C. SMART: An Internet study of users experiences of synthetic tanning. Perform. Enhanc. Health
2014, 3, 3–14. [CrossRef]
14. Schifano, F.; D’Ofﬁzi, S.; Piccione, M.; Corazza, O.; Deluca, P.; Davey, Z.; Di Melchiorre, G.; Di Furia, L.;
Farré, M.; Flesland, L.; et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal
online reports in comparison with related gabapentin and clonazepam data. Psychother. Psychosom. 2011, 80,
118–122. [CrossRef] [PubMed]
15. European Drug Report 2017. Available online: http://www.emcdda.europa.eu/publications/edr/trends-
developments/2017 (accessed on 20 September 2017).
16. World Drug Report. Available online: http://www.unodc.org/wdr2017/ (accessed on 21 September 2017).
17. Corazza, O.; Bersani, F.S. The diffusion of performance and image-enhancing drugs (PIEDs) on the internet:
The abuse of the cognitive enhancer piracetam. Subst. Use Misuse 2014, 49, 1849–1856. [CrossRef] [PubMed]
18. Vandrey, R.; Johnson, M.W. Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace.
Adolesc. Psychiatry (Hilversum) 2013, 3, 123–134. [CrossRef] [PubMed]
19. The World Antidoping Code. International Standar. Available online: https://www.wada-ama.org/
sites/default/ﬁles/resources/ﬁles/2016-09-29_-_wada_prohibited_list_2017_eng_ﬁnal.pdf (accessed on
20 September 2017).
20. Australian Sports Anti-Doping Autority. Available online: https://www.asada.gov.au/sanctions/nathan-
tait (accessed on 21 September 2017).
21. NIST Chemestry WebBook, SRD 69. Available online: http://webbook.nist.gov/cgi/inchi?ID=C543828&
Mask=200 (accessed on 25 September 2017).
22. Eskay’s, O. Physicians Desk Reference 1949, 3rd ed.; Medical Economics Inc.: Rutherford, NJ, USA, 1949; p. 476.
23. Gode, J. The bronchospasmolytic effect of ambredin. Therapie der Gegenwart 1958, 97, 106. [PubMed]
24. Tschudin, M.L. Experiences with ambredin in the treatment of asthmoid states. Praxis 1960, 49, 920. [PubMed]
25. US Food and Drug Administration. Drugs approved 1938-present (including supplements) (Listed by
approval date). 1990; p. 1439.
26. Kuo, C.L.; Wang, R.B. G-protein coupled receptors: SAR analyses of neurotransmitters and antagonists.
J. Clin. Pharm. Ther. 2004, 29, 279–298. [CrossRef] [PubMed]
27. Marsh, D.F.; Herring, D.A. The comparative pharmacology of the hydroxy and methyl derivatives of
6-methyl-2-heptylamine. J. Pharm. Exp. Ther. 1951, 103, 178–186.
28. Charlier, R.; Philippot, E. Action of three aliphatic amines on the respiratory volume. Arch. Int. Pharmacodyn. Ther.
1950, 82, 243–246. [PubMed]
13
Brain Sci. 2018, 8, 34
29. Charlier, R. Pharmacology of 2-amino-6-methyl-heptane. Arch. Int. Pharmacodyn. Ther. 1951, 85, 144–151.
[PubMed]
30. Fellows, E.J. The pharmacology of 2-amino-6-methylheptane. J. Pharmacol. Exp. Ther. 1947, 90, 351–358.
[PubMed]
31. Trieb, G.; Nusser, E. Untersuchungen zur Kreislaufwirkung von Ordinal® retard bei Patienten mit hypotoner
(statisch labiler) Blutdruckregulationsstörung. Herz/Kreislauf 1974, 6, 681–688.
32. Petry, R.; Kolb, K.H. Studies on the intestinal absorption of sympathomimetic substances in man.
Arzneim-Forsch 1973, 23, 1535–1538.
33. Ota, Y. Pharmacological studies on alklaminoheptane deriavatives. IV. Blood pressor, antispasmodic and
capillary permeability inhibiting action of N-alkyl-1,5-dimethylhexylamine derivatives. Yakugaku Zasshi
1961, 81, 403–407. [CrossRef]
34. Oelkers, H.A. Pharmacology of 2-amino-6-methylheptane (+)-camphor-10-sulfonate. Arzneim-Forsch 1967,
17, 25–28.
35. Becker, K.H.; Doerner, J. Circulation studies with 2-amino-6-methylheptane (+)-camphor-10-sulfonate in
dogs. Arzneim-Forsch 1967, 17, 28–32.
36. Ademiluyi, A.O.; Ogunsuyi, O.B. Alkaloid extracts from Jimson weed (DaturastramoniumL.) modulate
purinergicenzymes in rat brain. Neuro Toxicol. 2016, 56, 107–117.
37. Wei, X.Y.; Xu, H.X. Analysis of essential oil of Forsythia suspense (Thunb.) Vahl. By GC-MS and its
antioxidant activities. Shaanxi Shifan Daxue Xuebao 2010, 38, 70–74.
38. Zhao, Y.Y.; Dai, Y. Chemical constituents of Aconitum kusnezofﬁi volatile oil. Zhongchengyao 2007, 29,
588–591.
39. Al-Wathnani, H.; Ara, I. Bioactivity of natural compounds isolated from cyanobacteria and green algae
against human pathogenic bacteria and yeast. J. Med. Plants Res. 2012, 6, 3425–3433. [CrossRef]
40. Sadasivan, S.L.; Nair, B.R. GC-MS analysis in two species of Biophytum DC. (Oxalidaceae). J. Pharm. Res.
2014, 8, 466–473.
41. Xu, Y.; Liu, Y. Determination of volatile compounds in turbot (Psetta maxima) during refrigerated storage by
head-space solid-phase microextraction and gas chromatography-mass spectrometry. J. Sci. Food Agric. 2014,
94, 2464–2471. [CrossRef] [PubMed]
42. Arkhipov, A.; Sirdaarta, J. Metabolomic proﬁling of Kigelia Africana Extracts with anti-cancer activity by
high resolution tandem mass spectroscopy. Pharmacog. Comm. 2014, 4, 10–32.
43. Xu, Y.X.; Liu, Y. Analysis of volatile compounds in turbot by SPME with different extraction ﬁbers.
Shipin Gongy Keji 2013, 34, 90–97.
44. Google Trends. Available online: https://www.google.com/trends/ (accessed on 10 September 2016).
45. Kim, K.; Zilbermintz, L.; Martchenko, M. Repurposing FDA approved drugs against the human fungal
pathogen, Candida albicans. Ann. Clin. Microbiol. Antimicrob. 2015, 14, 32. [CrossRef] [PubMed]
46. Niu, H.; Cui, P. Identiﬁcation of anti-persister activity against uropathogenic Escherichia coli from a clinical
drug library. Antibiotics Basel 2015, 4, 179–187. [CrossRef] [PubMed]
47. Lilly, E. NEW and nonofﬁcial remedies: Methylhexamine; forthane. J. Am. Med. Assoc. 1950, 143, 1156.
48. Yang, C. The New DMAA (DMHA/2-Aminoisoheptane/Octodrine). Available online: https://www.linkedin.
com/pulse/new-dmaa-dmha-2-aminoisoheptane-octodrine-cain-yang (accessed 10 September 2017).
49. Portal, T. New Stable Anaesthetic Composition for Reducing Skin Reactions. U.S. Patent Application US
14/693,361, 2015. Galderma Research & Development. Opio, FR.
50. Cohen, A.; Travis, J.C. Four experimental stimulants found in sports and weight loss supplements:
2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine
(1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA). Clin. Toxicol. 2017, 1–7. [CrossRef] [PubMed]
51. Dugal, R.; Massé, R. An integrated methodological approach to the computer-assisted gas chromatographic
screening of basic drugs in biological ﬂuids using nitrogen selective detection. J. Anal. Toxicol. 1980, 4, 1–12.
[CrossRef] [PubMed]
52. Broecker, S.; Herre, S. General unknown screening in hair by liquid chromatography-hybrid quadrupole
time-of-ﬂight mass spectrometry (LC-QTOF-MS). Forensic Sci. Int. 2012, 218, 68–81. [CrossRef] [PubMed]
53. Schlessinger, A.; Geier, E. Structure-based discovery of prescription drugs that interact with the
norepinephrine transporter, NET. Proc. Natl. Acad. Sci. USA 2011, 108, 15810–15815. [CrossRef] [PubMed]
14
Brain Sci. 2018, 8, 34
54. Google Trends. Available online: https://trends.google.com/trends/explore?date=all&q=octodrine,2-
aminoisoheptane,aminoisoheptane,DMHA (accessed on 10 January 2018).
55. Google Trends. Available online: https://trends.google.com/trends/explore?date=all&geo=RU&q=DMAA
(accessed on 10 January 2018).
56. DMHA (Octodrine). Available online: https://massivejoes.com/articles/supplements-simpliﬁed/dmha
(accessed on 28 August 2017).
57. Octodrine (DMHA). Available online: http://www.suppreviewers.com/ingredients/octodrine/ (accessed
on 28 August 2017).
58. DMHA/2-Aminoisoheptane/Octodrine: 2016’s Stimulant. Available online: https://blog.priceplow.com/
(accessed on 28 August 2017).
59. DMHA is Here. Available online: https://www.pinterest.com/pin/300544975113533041/ (accessed on
29 August 2017).
60. Cannibal Carnage Killer Bombsicle. Available online: https://www.chaosandpain.com/cannibal-carnage-
killer-bombsicle/ (accessed on 16 January 2018).
61. CONQU3R UNLEASHED. Available online: https://olympus-labs.com/conqu3r-unleashed/ (accessed on
29 August 2017).
62. REDCON1-TOTAL WAR. Available online: https://www.thesuppstop.com.au/shop/pre-workouts/
redcon1-total-war/ (accessed on 25 August 2017).
63. Simply Skinny Pollen. Available online: https://www.downtoearth-solutions.com/simply-skinny-pollen.
html (accessed on 16 January 2018).
64. Stealth Sports–AdrenaClen. Available online: https://www.vfsupplements.com.au/stealth-sports-
adrenaclen.html (accessed on 27 August 2017).
65. Game Day from MAN Sports: Review. Available online: http://muscles.zone/pre-workout/game-day-
man-sports-review (accessed on 12 January 2018).
66. Giant Sports Giant Rush. Available online: https://www.powermyself.com/giant-sports-giant-rush-60-
servings.html (accessed on 25 August 2017).
67. WEBMD. Available online: http://www.webmd.com/vitamins-supplements/ingredientmono-1538-
octodrine.aspx?activeingredientid=1538&activeingredientname=octodrine (accessed on 10 January 2018).
68. GANNIKUS.COM. Available online: https://www.gannikus.com/review-uebersicht/goldstar-triple-x-im-
test/ (accessed on 19 January 2018).
69. Amazon.de. Available online: Amazon.de/Pre-Workout-Preworkout-Supplement-Beta-Alanine-Citrullin
(accessed on 20 January 2018).
70. PVSport.ru. Available online: https://vk.com/pvsport (accessed on 29 January 2018).
71. Weekend Rambler. Available online: https://weekend.rambler.ru/items/36735347-zdes-vse-chto-nado-
znat-o-zhiroszhigatelyah-i-predtrenirovochnyh-kompleksah/ (accessed on 29 January 2018).
72. Fit Magazine. Available online: http://ﬁtmagazine.kandeleria.ru/?s=DMHA&post_type=product (accessed
on 29 January 2018).
73. Smart Nutrition. Available online: https://smartnutrition.kz/index.php?route=product/search&ﬁlter_
name=DMAA (accessed on 29 January 2018).
74. Big Blog. Available online: http://bigblog.com.ua/ (accessed on 29 January 2018).
75. BCAA.RU. Available online: http://ekb.bcaa.ru/category/predtreniki-i-energetiki/ (accessed on 29 January 2018).
76. Berserk. Available online: http://berserktakticalfarma.blogspot.com/search?q=DMHA (accessed on
29 January 2018).
77. DOM AMBALA. Available online: http://domambala.ru/search/?q=dmha (accessed on 29 January 2018).
78. HULKFOOD.RU. Available online: https://hulkfood.ru/energy/pre_workout/ (accessed on 29 January 2018).
79. MRSUPPLEMENT. Available online: https://www.mrsupplement.com.au/dmha-octodrine (accessed on
29 January 2018).
80. GORILLAZMARKET.RU. Available online: http://gorillazmarket.ru/search/?search=dmha (accessed on
29 January 2018).
81. PROHORMONEFORUM.COM. Available online: http://prohormoneforum.com (accessed on 20 September 2017).
82. DO4A.COM. Available online: https://do4a.com/search/30585319/?q=dmha&o=date (accessed on
29 January 2018).
15
Brain Sci. 2018, 8, 34
83. Geekzone. Available online: https://www.geekzone.co.nz/forums.asp?forumid=161&topicid=217945
(accessed on 29 January 2018).
84. PHPBB. Available online: http://www.chemport.ru/forum/viewtopic.php?f=16&t=121426 (accessed on
29 January 2018).
85. LeanBulking.com. Available online: https://leanbulking.com/dmha-2-aminoisoheptane-review (accessed
on 29 January 2018).
86. SpotrBaza. Available online: http://sportbaza52.ru/shop/valhalla-labs/berserk.html (accessed on
29 January 2018).
87. AnabolicMinds.com. Available online: http://anabolicminds.com (accessed on 29 January 2018).
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
16
brain
sciences
Review
The Effects of Cannabinoids on Executive
Functions: Evidence from Cannabis and Synthetic
Cannabinoids—A Systematic Review
Koby Cohen and Aviv Weinstein *
Department of Behavioral Science, Ariel University, Ariel 40700, Israel; kbbcohen@gmail.com
* Correspondence: avivweinstein@yahoo.com; Tel.: +972-39-076-555
Received: 22 January 2018; Accepted: 24 February 2018; Published: 27 February 2018
Abstract: Background—Cannabis is the most popular illicit drug in the Western world. Repeated
cannabis use has been associated with short and long-term range of adverse effects. Recently, new
types of designer-drugs containing synthetic cannabinoids have been widespread. These synthetic
cannabinoid drugs are associated with undesired adverse effects similar to those seen with cannabis
use, yet, in more severe and long-lasting forms. Method—A literature search was conducted
using electronic bibliographic databases up to 31 December 2017. Speciﬁc search strategies were
employed using multiple keywords (e.g., “synthetic cannabinoids AND cognition,” “cannabis AND
cognition” and “cannabinoids AND cognition”). Results—The search has yielded 160 eligible studies
including 37 preclinical studies (5 attention, 25 short-term memory, 7 cognitive ﬂexibility) and
44 human studies (16 attention, 15 working memory, 13 cognitive ﬂexibility). Both pre-clinical and
clinical studies demonstrated an association between synthetic cannabinoids and executive-function
impairment either after acute or repeated consumptions. These deﬁcits differ in severity depending
on several factors including the type of drug, dose of use, quantity, age of onset and duration of use.
Conclusions—Understanding the nature of the impaired executive function following consumption
of synthetic cannabinoids is crucial in view of the increasing use of these drugs.
Keywords: cannabis; synthetic cannabinoids; executive function
1. Introduction
The most popular illicit drug of the 21st century is cannabis, in its many forms and shapes [1–5].
According to the United Nation Ofﬁce on Drugs and Crime (UNODC), approximately 181 million
adults have used cannabis across the globe [2]. Moreover, in many countries more than 50% of young
adults have used cannabis at least once in their lifetime [3]. Recently, new types of drugs that contain
Synthetic Cannabinoids (SC) have become popular among drugs users worldwide [5–7]. SC drugs
are associated with severe adverse effects (Table 1), have greater harm potential and they are more
addictive than the traditional organic cannabis drugs [4,6–9]. Therefore, governments and health
institutions across the Western world make major efforts in order to prevent the spread of SC and to
improve the knowledge regarding SC and their potential risks [5,8]. One of the most notorious adverse
effects that is associated with cannabinoids consumption is impairment of cognitive function [4].
Both pre-clinical and human studies drew a link between consumption of cannabinoids and long-term
deﬁcits of cognitive functions, especially high-order cognitive functions [4,5,10–13]. The purpose of the
current review is to present and describe the acute and long-term effects of SC drugs in comparison with
organic cannabis on executive function (EF) based on current literature from both human and animal
research. A literature search was conducted using electronic bibliographic databases (PubMed®,
ScienceDirect ®and Google Scholar platforms) up to 31 December 2017. Database-speciﬁc search
strategies were employed using multiple keywords (e.g., “synthetic cannabinoids AND cognition,”
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“cannabis AND cognition” and “cannabinoids AND cognition”). The search has yielded 160 eligible
studies including 37 preclinical studies (5 attention, 25 short-term memory, 7 cognitive ﬂexibility)
(Table 2) and 44 human studies (16 attention, 15 working memory, 13 cognitive ﬂexibility). Studies
were included if they stated the following inclusion criteria: use of objective measurements of speciﬁc
executive function (working memory, attention and cognitive ﬂexibility) involving cannabinoid users
(regular and recreational users) or cannabinoid treatments and a control group. Exclusion criteria were:
studies that involved participants who had other neurological or psychiatric disorders or individuals
who met criteria for alcohol dependence or other substance use disorders (abuse or dependence)
different from cannabis and nicotine.
Table 1. Common clinical adverse effects induced after consuming synthetic cannabinoids.
Type of Effects Symptoms
Psychosis Recurrent psychosis episodes [9,14–16].
Agitation Last for several hours after intoxication of SC [16–18].
Affect disturbance Severe anxiety symptoms and panic attacks shortly after consuming SC [14,17–20].
Cognitive alterations Impairment in memory and attention deﬁcits [14,20–22]
Cardiovascular effects Both tachycardia, tachyarrhythmia and cardiotoxicity were reported after exposure to SC [14,23].
Gastrointestinal effects Nausea, vomiting and diarrhea after severe exposure to SC [14,24,25].
Table 2. Pre-clinical rodent studies of the effects of cannabinoid-agonists on executive function.
Animals CannabinoidsTested Main Findings Reference
Male Long–
Evans rats
WIN55,212-2 and
Δ9-THC
Dose-related attention impairments afteracute exposure to
cannabinoid CB1 receptor agonist. Impairments were reduced
after treatment with CB1 antagonist.
[26,27]
Male Sprague–
Dawley rats Δ9-THC
Decreased performance on a divided attention tasklasts for
2 weeks after chronic administration withcannabinoid CB1
receptor agonist.
[28]
Male Sprague–
Dawley rats AM-4054
Decreased sustained attention after acute treatmentwith a
cannabinoid CB1 receptor agonist.Impairments were associated
with task demands.
[14]
Male Sprague–
Dawley rats Δ9-THC
Impairments of visual attention on an operant signaldetection
task after acute treatment with cannabinoid CB1 receptor agonist.
[29]
Male Sprague–
Dawley rats WIN55,212-2
Deﬁcits of working memory after chronic treatmentwith a
cannabinoid CB1 receptor agonist.
[30]
Female Long–
Evans rats Δ9-THC
Repeated administration with cannabinoid CB1 receptoragonist in
adolescence induced persistent impairment of working memory. [31]
Male Sprague–
Dawley rats WIN55,212-2
Acute injection of cannabinoid CB1 receptor agonist in
late-adolescence period induced temporary impairment of
short-term memory. Chronic treatment with cannabinoid CB1
receptor agonist impair short-term memory for several weeks
after the last administration.
[32]
Male Sprague–
Dawley rats Δ9-THC
Acute exposure to a cannabinoid CB1 receptor agonistinduced
working memory impairments [33,34]
Male Sprague–
Dawley rats, Lister
rats and C57B16 mice
Δ9-THC Working memory impairments were induced afterchronictreatment with a cannabinoid CB1 receptor agonist.
[35,36]
Wild-type and
CB1 receptor
knockout mice
JWH-081
Acute treatment with cannabinoid CB1 receptor agonist induced
short-term memory deﬁcits in wild-type mice but not in
knockout mice.
[37]
Male Long–
Evans rats HU-210
Acute treatment with a cannabinoid CB1 receptor agonistinduced
working memory deﬁcits. [38,39]
Male C57B1/6 mice Δ9-THC Acute injection of Δ9-THC disrupted performance of the workingmemory task, impairments were reversed by SR1417161A. [40]
Male Wistar Rats Δ9-THC Acute administration induced set-shifting impairments24 hafter treatment. [41]
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Table 2. Cont.
Animals CannabinoidsTested Main Findings Reference
Male albino
Wistar rats Δ9-THC
Acute treatment with a cannabinoid CB1 receptor agonistinduced
short-term memory deﬁcits, impairments were attenuated after
treatment with cannabinoid CB1 antagonist.
[42]
Male ICR
(CD-1) mice
JWH-018,
JWH-018-Cl,
JWH-018-Br and
Δ9-THC
SCs dose-dependently impaired short- term memory. Their effects
resulted more potent respect to that evoked by Δ9-THC. [43]
Male Long–
Evans rats JWH-018
Chronic exposer to cannabinoid CB1 receptor agonist induced
spatial learning and short-term memory alterations well after the
drugs exposure period.
[44]
Male Lister Hooded
and Wistar rats CP55,940
Acute administration of cannabinoid CB1 receptor agonist
impaired short-term memory in both strains, yet, no long-term
effects were observed.
[45]
Male Long–
Evans rats Δ9-THC
Acute treatment with a cannabinoid CB1 receptor agonistinduced
reversal learning deﬁcits while set-shifting ability has maintained [46]
Male Long–
Evans rats HU-210
Administration of the cannabinoid CB1 receptor agonistelicited
dose-dependent disruptive effects on set-shiftingperformance.
Impairments were diminished afteradministration of the CB1
antagonist AM251.
[47]
Male Albino
Wistar rats
AB-PINACA or
AB-FUBINACA
compere with
Δ9-THC
Two weeks after repeated administration of cannabinoid-agonist
short-term memory impairments were observed, in SCs groups
the impairments were greater and last for longer time.
[48]
Female and Male
Sprague–Dawley rats WIN55,212-2
Self-administration of SCs in low dosages during adolescence
period improve or did not induce permanent memory
impairments, while treatments of high dosages of SCs in
adolescence period induced permanent short-term
memory impairments.
[49,50]
2. Pharmacology of Organic Cannabis
Cannabis is the generic name of the psychoactive drug that is derived from the female plant
Cannabis sativa [51]. There are more than 400 compounds including more than 60 cannabinoids,
which are aryl-substituted meroterpenes unique to Cannabis sativa [52,53]. The main psychoactive
ingredient in cannabis is Δ9-Tetrahydrocannabinol (Δ9-THC), which is the most potent cannabinoid
that is present in the organic form of cannabis [53]. Besides Δ9-THC, organic cannabis products
contain additional cannabinoids which do not induce psychoactive effects, such as Cannabidiol (CBD),
Δ8-Tetrahydrocannabinol and Cannabinol [54–56]. Furthermore, CBD is considered a non-psychoactive
cannabinoid that also moderates the psycho tropic effects of Δ9-THC [57–60].
The psychoactive effects of cannabis are dose-dependent [58,61,62] and there is evidence that
as the content of Δ9-THC increases, the psychoactive effects of cannabis drugs increase [59,62].
Cannabinoid agonists in general and speciﬁcally Δ9-THC, exert their effects by acting on at least
two types of endogenous cannabinoid receptors (CB1, CB2), which are widely distributed in numerous
regions within mammals’ brain [52,63,64]. Pacher and Kunos (2013) suggested that endocannabinoid
receptors, the two endocannabinoid ligands and their related enzymes are the components of
the Endo-Cannabinoid System (ECS), which is involved in a wide range of somatic and mental
functions [65].
3. Synthetic Cannabinoids, from Therapeutic Agents to a Global Disease
3.1. Old Origins, New Trends
Since the discovery of Δ9-THC and the involvement of the ECS in a wide range of health
conditions, cannabinoids have been synthesized for medical research purposes as promising research
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and therapeutic tools [23,24]. In contrast to organic cannabinoids such as Δ9-THC, SCs selectively
activate the endocannabinoid receptors [24,56,57].
In the beginning of the new millennium, a growing number of reports indicated that there
were new psychoactive products which included mostly SC ingredients mixed with other herbal
blends [6,66,67]. The production, distribution and use of SC drugs were initially neither controlled
nor illegal, therefore they are presented as “legal-highs” [67], by various generic names such as;
“Mr. Nice Guy,” “Spice Gold,” “Spice Diamond,” “Yucatan Fire” and most commonly as “K2” or
“Spice” [7,25]. These products were often sold without age restriction over multiple sources such
as the internet and convenience stores [4,7–9,25,67]. As the popularity of SC drugs increased, their
severe undesired adverse effects were observed; affective disorder, recurrent psychosis, tachycardia,
seizures and prolonged hospitalization were not rare outcomes of SC intoxication [4,5,7–9]. Some of
these adverse effects are related to the effect of additional psychoactive agents which these products
contain [6,8,68].
Despite the fact that SCs are labeled as “not for human consumption” and “for aroma therapy
use only,” the popularity of these drugs appears to be growing [5]. SCs induce more intense effects
than traditional cannabis, they are less expensive and they are undetectable in standardized drug
tests. These unique features contribute to the growing numbers of recreational drug users who have
used SCs [4,5].
3.2. The Psychoactive Ingredients of Synthetic Cannabinoid Products
Over than 140 products containing SC have been identiﬁed, although, the main psychoactive
components of these products are different types of SCs which are categorized into four major
groups including; (a) Aminoalkylindole or JWH series, (b) classical cannabinoids, (c) non-classical
cannabinoids and (d) fatty acid amides (e.g., oleamide) [21,22,69,70].
The ﬁrst generation of SC products mostly contain the series of 1-alkyl-3-(1-naphthoyl)
indoles known as JWH compounds or aminoalkylinodels. This SC series is named after John W.
Huffman who developed these ligands for medical research purposes [71] The JWH series advanced
from computational melding of the chemical structural structures of Δ9-THC with previously
developed aminoalkylinodels [71]. One of the ﬁrst SC from this series to be abused is JWH-18
(1-penthyl-3-(1-napthoyl) indole), which features as easy synthesizable and high potency contribute
to its popularity [9]. Compared to Δ9-THC, JWH-018 has 4 times the afﬁnity for CB1 receptors and
10 time the afﬁnity for the CB2 receptors [72]. JWH series represent the main psychoactive compounds
detected in SC products across many countries [9].
Additional components detected in SC products include analogues of Δ9-THC, so-called classical
cannabinoids such as HU-210 and HU-211. HU-210 developed in the middle of the 20th century at the
Hebrew University (HU) [73] and is a hundred times more potent than Δ9-THC binds both CB1 and
CB2 receptors [73,74] Similar to other SC, HU-210 acts as CB1 receptors full-agonists [73].
The cyclohexylphenol (CP) is a non-classical cannabinoids series synthesized by Pﬁzer labs in
the early 1970s; examples include CP 59,540, CP 47,497 and their n-alkyl homologues [71]. Similar to
JWH-018, CP-47,497 is included in large numbers within SC products e [67]. In addition, SCs from
the CP series act as CB1 receptors full agonists [67]. However, within any given SC products, various
types of SC are found in different concentrations [9,67] accompanied by additional psychoactive
compounds from synthetic opioids such as O-desmethyltramadol, harmine and harmaline, which are
inhibitors of the monoamine oxidase enzyme, to benzophenone (HM-40) and even caffeine [9,11,68].
There are several common features among different compounds of SC products which can highlight
the risk potential which these drugs have and their related adverse effects. Firstly, SCs act as full
agonists to CB1 receptors and some also bind to CB2 receptors [7]. Secondly, SCs are much more
potent, easily cross the blood-brain barrier and have more afﬁnity compared to organic psychoactive
cannabinoids like Δ9-THC [68,69]. In addition, SC drugs do not contain CBD, which has high potency
as an antagonist to CB1 and CB2 receptors and therefore it is able to revert the psychotic and anxiolytic
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adverse effects of cannabinoid-agonists. It is suggested that the lack of CBD in SC products ampliﬁes
their psychotropic effects [4,6,75]. Moreover, SC products hold a unique characteristic, which is its
ever-changing composition. The ﬁrst generation of SC products commonly contain JWH-018, JWH-073
and CP-47,49, since these SCs became regulated, there has been an emergence of new types of SCs like
JWH-081, JWH-210 and AM-2201, in an attempt to dodge regulations. Despite slight chemical structure
modiﬁcation, all of these SCs share the same main features and aim to mimic the psychoactive effects
of Δ9-THC and even to transcend it [4,6,66,67,75].
4. Executive Function (EF) and the Long-Term Effects of Cannabinoids
4.1. The Three Core Factors Model of Executive Function
Although preclinical and human studies demonstrate that endocannabinoids involve and affect
cognitive function in general and speciﬁcally high-order cognitive function [12,13,51,68], there is still a
debate regarding the effects of chronic consumption of cannabinoid products such as cannabis or SCs
on EF [12,13,46,70] (Table 1).
The term EF refers to “high-order” cognitive functions, which involve regulation, “lower-order”
cognitive process and goal-directed behaviors [76,77]. EF generally clusters various cognitive
abilities such as verbal reasoning, problem-solving, planning behaviors, sequencing, multi-tasking,
cognitive ﬂexibility, sustained attention, resistance to interferences and the ability to deal with novel
information [77–80]. Due to the wide range of functions which are considered as executive or
high-order, there is still an ongoing debate regarding the mechanisms which underlie executive
function, performances and regarding which cognitive functions should be marked as executive [76].
Diamond (2013) suggested that EF should be divided into two subgroups: core EF and higher
order EF [77]. Accordingly, the three cores EFs are (a) inhibition control or attention (b) Working
Memory (WM) and (c) cognitive ﬂexibility. The basic EFs are essential for the production of higher
order cognitive functions such as verbal reasoning, problem-solving, planning behaviors, sequencing
and multi-tasking. Accordingly, these functions do not involve much emotional arousal and they are
logic based [77].
4.2. Cannabinoids and Attention-Evidence from Preclinical Studies
The ability to evaluate and allocate priority to external stimuli or internal habits and to optimize
behavioral response requires attention [13,77]. These enable focus and selectively attend to desired
stimuli and to inhibit response to irrelevant stimuli [77]. Studies have suggested that numerous brain
regions facilitate attention performance, yet, it is mediated by the frontal lobes [81,82]. Additionally,
the Anterior Cingulate Cortex (ACC) is a crucial factor in the execution of this function [82,83].
Preclinical studies provide strong evidence regarding the effects of repeated treatment with
cannabinoid-agonists and impaired attention. The Lateralized Reaction Time task (LRT) of visuo-spatial
attention that has been previously used in rats, is considered as a valid model for attention in rodents.
In this paradigm, rodents need to attend to apparatus for the location of a visual stimulus over
numbers of trails [83]. Arguello and Jentsch (2004) reported that acute treatments with the SC agonist
WIN55212-2 (2.5 mg/kg) induced deﬁcits in attention measured on the LRT task. In addition, treatment
with SR141716A 1 mg/kg which is a CB1 antagonist reversed the WIN55212-2-induced attention
impairment, although, when administered alone, this compound did not produce any effects on
attention [26].
A further study by Verrico et al (2004) examined the effect of repeated treatments with Δ9-THC
on attention using the LRT task in rats. In their study, rats that were daily treated with Δ9-THC
20 mg/kg for 2 weeks, presented attention impairments which lasted 14 days after the last treatment
with Δ9-THC [28]. Later-on, Miller et al. (2013) treated rats with small doses of novel SC agonists
AM-4054 before performing a two-choice reaction time task, which measures sustained attention. They
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reported that AM-4054 induced attention impairments which were positively correlated with task
demands and harder trails were associated with poorer functions [14].
Some authors suggested that lesions of the medial prefrontal cortex or striatum can produce
attention deﬁcits similar to those presented after cannabinoid administration [84,85]. Chronic exposure
to cannabinoid-agonists led to alterations within meso-limbic dopaminergic neurons [86], thus,
cannabinoid-induced attention impairment might arise via continuous activation of CB1 receptors
across the striatum or prefrontal cortex [83].
4.3. Cannabinoids and Attention-Evidence from Clinical Studies
The disruptive acute effect of cannabis on attention is widely described in clinical studies [87–90]
and systematic reviews [11,70,87]. Yet, human studies failed to draw consistent evidence regarding the
effect of chronic consumption of cannabinoids and impaired attention. While some studies described
impairments of tasks which demand attention in chronic cannabis users [17,19,61,89,91], other studies
demonstrated no differences in behavioral performance between cannabis users and non-users [22,87].
Since neuronal and functional alterations of the ACC region were consistency observed among chronic
cannabis users [92] a recent review study suggested that the marginal effects that were observed in
these studies are probably an outcome of a compensation mechanism that was developed among
chronic users [87].
There are several tasks for measuring attention. In a paradigm such the Stroop task, a control
of interference from of a pre-potent response is required [93]. Incongruent conditions of the classical
Stroop color-word task contain color words written in another color. Subjects are required to ignore
the semantic meaning of the word and instead attend to and report the color. Since humans are trained
to read and to ignore other words’ features such as font style or color, people are slower and prone to
make more errors in the incongruent trials of the Stroop task [77].
On the Go/No-Go task, the participants do not inhibit natural response at the expense of another.
On this task, participants are required to respond when target stimulus is presented and should not
respond when a non-target stimulus appears [94]. Other tasks such as the Continuous Performance
Task (CPT) are being used for measuring sustained attention. In this paradigm, participants are
required to maintain attention over a continuous period in order to detect infrequent targets, thus
ensuring that the goals of the behavior are kept over time [20].
Eldreth and colleagues (2004) have examined the performance on a modiﬁed Stroop task in which
healthy individuals were compared with abstinent cannabis users. Although there were no behavioral
differences between the groups, cannabis users had greater activation in prefrontal brain regions than
non-users [95]. Similarly, Jager et al. (2006) observed moderate differences in brain activity between
cannabis users and healthy individuals while performing attention and WM tasks. They reported that
compared with healthy subjects, cannabis users presented hypo-activation in the left superior parietal
cortex while performing the attention task [96].
Recently, Hatchard and colleagues (2014) observed a similar pattern among young cannabis users.
Recreational cannabis users did not differ in performance on the modiﬁed Stroop task compared with
non-users, however, differences in neuronal activity of several brain regions including the ACC and
post-central gyrus were observed, suggesting that chronic consumption of cannabis affects neuronal
process even in an absence of behavioral expressions [97]. In another study, Hester et al (2009) reported
that alterations in attention correlated with neuronal hypo-activity of ACC in heavy cannabis users.
The attention deﬁcits expressed in performing more errors on the Go/No-go task, suggested that
attention depended on cannabis consumption history, including doses, frequency and age of onset [98].
The studies described so far examined the complex association between chronic consumption
of organic cannabis and impaired attention, yet, there is limited objective evidence for an association
between chronic consumption of SCs and impaired attention in humans [9]. Cohen et al (2017) showed
that SC users had more errors performing on the classic Stroop color-word task compared with
regular cannabis users and healthy subjects [11]. Furthermore, several case reports described SC users
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who experienced “thinking problems” which last from days to weeks following last consumption.
However, attention deﬁcits were less common and they were accompanied with additional symptoms
such as affective disturbances and cognitive dysfunction including severe alterations in short-term
memory [8,99,100].
4.4. Cannabinoids and Working Memory-Evidence from Preclinical Studies
Working Memory (WM) is deﬁned as a cognitive mechanism for the temporary storage and
manipulation of stored information [101], or simply, as a cognitive system which involves holding
information in mind and mentally working with it [77].
The function of WM has been associated with integration of a wide range of neural networks.
WM networks are associated with frontal-parietal regions including dorso-lateral pre-frontal cortex,
ventro-lateral prefrontal cortex, pre-motor cortex, lateral parietal cortex and the frontal lobe [102].
An additional brain region which is considered a major component in WM is the hippocampus, which
is essential for acquiring, encoding and consolidating new types of information. This information
is represented and manipulated by the WM system in the prefrontal cortex [103]. In rodent models,
changes in hippocampal morphology were observed following chronic treatments of various doses
with cannabinoid agonists like Δ9-THC and WIN55,212-2, these neuronal alterations correlated with
behavioral dysfunction [30–32].
Preclinical studies which used rodent as animal models, utilized both maze-based and
instrumental tasks for investigating the effect of cannabinoids on WM [31]. Maze-based tasks require
the rodent to use spatial cues correctly. These tasks are based on the navigational behaviors of rodent
for foraging or in order to escape from predators [104]. Several works have suggested that chronic
treatment of Δ9-THC induced WM impairments on in different types of maze-based tasks [33,34] and
in water maze tasks [35,36,38]. These impairments are dose-related, thus greater impairments were
observed after exposures to more potent cannabinoid-agonists [36,41]. Therefore, it is not surprising
that SC agonists such as JWH-081 and HU-210 induce similar disruptive effect on WM performances
in maze-based tasks [37,39]. In addition, similar impairment is induced with anti-cholinergic agents
like physostigmine, suggesting that cannabinoid-agonists induce WM impairments due to interaction
with acetylcholine system [105].
Instrumental WM tasks in rodents include the delayed matching to sample (DMTS) or delayed
non-matching to sample (DNMS) tasks. During these tasks, the animal is initially presented with a
stimulus and following delay period, both the original stimulus and a novel stimulus are presented.
The animal must indicate either the sample stimulus or the novel stimulus follow the task’s rule [31].
The effects of chronic treatment with cannabinoid agonists such as WIN55212-2 and Δ9-THC on WM
in DMTS or DNMS paradigms are widely observed, both in rodents [27,41,42,106] and in primate
models [107,108]. Again, most of the studies report that the disruptive effects of cannabinoid agonists
are dose-dependent [31].
Recently, Barbieri et al. (2016) reported that administration of a CB1 receptors antagonist AM251 to
mice as pre-treatment, fully prevented the disruptive effects of cannabinoid agonists including JWH-018
and Δ9-THC on WM, thus suggesting a CB1 receptor involvement in the effect of cannabinoids on
WM [43]. Other studies reported that repeated treatment with SC agonists JWH-018 and CP55,940
in the puberty period induced severe WM impairments that remained in adulthood [44,45]. These
ﬁndings are consistent with previous theories which suggested the involvement of ECS in brain
development and that consumption of cannabinoid agonists in adolescence alter the function of the
ECS [24,32,109,110].
Interestingly, some studies report contrary results where reduced impairments following repeated
treatment with cannabinoid agonists were presented [38], although, this might be a result of
tolerance [31]. In addition, further preclinical research is needed to examine the degree of persistence
of deﬁciencies induced by chronic treatments with cannabinoid agonists [31]. Yet, a growing number
of publications indicate that exposures to cannabinoids in early age are associated with greater and
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persistent WM deﬁcits, suggesting that the age of onset may be a mediating factor in the association
between cannabinoids and WM performance [32,106,111–113].
4.5. Cannabinoids and Working Memory- Evidence from Clinical Studies
The disrupted effect of acute cannabis intoxication on WM performance in humans is widely
documented [33,87]; however, there is a growing debate whether chronic cannabinoid consumption
induces long-term impairments of WM [87,114,115].
The most common paradigm for measuring WM performance is the n-back task. During this
task a sequence of constant stimuli in form of digits, shapes or numbers are presented to the subject,
who need to decide if the presented stimulus is identical to a previous stimulus from n steps earlier.
The load factor n reﬂects different WM loads; lower n represents an easier task [116]. Kanayama and
colleagues (2004) investigated WM in chronic cannabis users and used functional Magnetic Resonance
Imaging (fMRI) [117]. They reported that cannabis users did not show WM dysfunction; however,
increased activation of several brain regions including prefrontal-cortex, ACC and basal-ganglia
regions were observed. The authors suggested that chronic consumption of cannabis induced subtle
neurophysiological deﬁcits which are compensated by hyper-activation to meet the demands of the
task [117,118].
In addition, an fMRI study which focused on hippocampus activity during performance on the
n-back task, compared cannabis users with two control groups of healthy individuals and tobacco
smokers [119]. Poorer performance was observed in cannabis users compared with both control groups
on the task’s overall score. Furthermore, cannabis users presented less activity in the right hippocampus
across the task’s conditions contrary to both control groups [119]. In a further neuroimaging study,
Jager et al. (2007) examined the effects of cannabis use on neuronal activity in abstained cannabis users
and healthy control participants during performance on the n-back task consisting of encoding and
recall conditions [120]. Similar to previous studies [121], there were no differences between the groups
in terms of behavioral performance. Interestingly, cannabis users exhibited hypo-activation in the right
dorso-lateral pre-frontal cortex and in bilateral hippocampus regions. This reduced activity in WM
responsible areas were limited to the encoding phase and were not presented in the rest of the task
phases’ [120].
Smith and colleagues (2010) used fMRI to examine the neuronal brain activity of heavy cannabis
users and control non-users while performing different loads of the n-back task. The two groups
presented similar WM performance, however, in contrast to other studies, cannabis users demonstrated
hyper-activity in the right frontal gyrus, left middle inferior frontal gyrus and right superior temporal
gyrus [122]. In a recent systematic review, Bossong and colleagues (2014) suggested that most
functional neuroimaging studies present similar pattern of hyper neuronal brain activity in cannabis
users compared with control participants that were accompanied with normal WM function [123].
They support the view that increased activity reﬂects greater neural effort in order to maintain good
task performance [123]. On the other hand, a-3-year longitudinal neuroimaging study failed to ﬁnd
behavioral or functional differences between cannabis users and control participants, suggesting that
a moderate use of cannabis may not have substantial effects on WM neural network and behavioral
performance [124]. However, WM deﬁcits in chronic cannabis users are more likely to be elicited
in complex conditions [115]. Therefore, a lack of differences in WM performance between cannabis
users and control participants does not necessarily indicate a lack of association between chronic
consumption of cannabis and WM [123].
Convergent evidence from structural neuroimaging studies supports the last view indicating that
chronic consumption of cannabis is associated with neuronal alterations in several brain regions which
are involved in WM including reduction in size of the hippocampus and amygdala. In addition, these
alterations correlated with the amount of cannabis use and dependence [125]. Recently, Battistella
et al. (2014) reported similar data, where neuronal alterations in several brain regions including the
parahippocampal gyrus were observed in chronic cannabis users compared with occasional users.
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Furthermore, these alterations are associated with age of onset and frequency of cannabis use in the
last 3 months [126].
To our knowledge, there is a limited number of available laboratory human studies investigating
the association between persistence consumption of SC with WM performance. Yet, Castellanos
and Thornton (2011) reported that young adults who used SC drugs experienced alterations in
short-term memory; however, their main symptom was a severe psychotic episode [127]. Further
reports described similar clinical manifestations where SC users experienced symptoms including
alterations in short-term memory [128,129]. Cohen et al. (2017) demonstrated WM impairments
observed among SC users compared with non-users and recreational cannabis users [11]. These
reports are not surprising since CB1 receptors are highly distributed in the hippocampus and in
prefrontal cortical regions [130,131], which are associated with WM [102]. In addition, SC products
contain high-potency cannabinoid agonists, therefore it is reasonable that chronic consumption of SC
induces impairments in WM function in more salient forms than those which are induced by organic
cannabis [66,67].
4.6. Cannabinoids and Cognitive Flexibility- Evidence from Preclinical Studies
Cognitive ﬂexibility has been described as the cognitive ability to think about multiple concepts
simultaneously and to be able to switch between thinking about two different concepts [18]. Miyake et
al. (2000) identiﬁed cognitive ﬂexibility as the ability to shift one’s thinking and attention between
unrelated tasks, typically in response to a change in environmental demands [81]. Diamond (2013)
expanded the view of the term and suggested that an additional feature of cognitive ﬂexibility is being
able to change perspectives spatially or inter-personally. Accordingly, for changing perspectives, an
individual needs to inhibit the last perspective and to load a new perspective into WM [77]. In that
sense, cognitive ﬂexibility builds and depends on WM and inhibition control. Other aspects of cognitive
ﬂexibility involve changing the way of thinking in response to external demands and thinking “outside
the box” [77].
In rodents, variations of attention set-shifting paradigms are being used to assess behavioral flexibility.
During these tasks rats are required to change behavioral responses, by learning new stimulus-reward
associations through earlier learned response inhibition tendencies [13]. These paradigms differentiate
between two types of behavioral ﬂexibility; (a) for successful extra-dimensional shifts the rats need to
shift attention bias between different features of stimuli, (b) reversal-learning discriminations required
the rats to update relations between stimuli and rewards presentation, in this inter-dimensional
discrimination based on cue from a single modality [13,83]. This differentiation is important since
these two aspects of behavioral ﬂexibility are linked with different brain regions [13], while reversal
learning is associated with orbito-frontal cortex [132], extra-dimensional shifts are mediated by the
medial pre-frontal cortex [133,134].
Several preclinical studies investigated the effects of cannabinoid-agonists on cognitive ﬂexibility
and indicated inconsistent results. Egerton and colleagues (2005) reported that acute administration
of 5 mg/kg Δ9-THC induced impairments in reversal learning, whilst attention set shifting ability
was maintained [46]. Further primate research presented similar results using smaller doses and
demonstrated that an acute administration of 0.5 mg/kg Δ9-THC induced more errors in reversal
learning and it did not affect attention set shifting ability [135].
However, an additional rodent study has demonstrated different ﬁndings, whereby administration
of 0.2 mg/kg of the SC agonists HU-210 2 days before measuring set-shifting, induced dose-dependent
impairments in extra-dimensional set shifting ability [47]. These impairments were diminished after
administration of a CB1 antagonist AM251. In addition, cannabinoids did not affect inter-dimensional
reversal learning [47].
Further evidence regarding the effects of cannabinoids on cognitive ﬂexibility was demonstrated
by Varvel and Lichtman (2001). Knockout mice, which lack cannabinoid CB1 receptors presented
impaired reversal learning in inter-dimensional water maze reversal learning task [40]. Their ﬁndings
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support the view that the ECS are involved in execution of cognitive ﬂexibility [13]. Consistent with
earlier studies, Gomes and colleges (2015) recently indicated that rats which were repeatedly treated
with 1.2 mg/kg of a CB1 agonist WIN55,212-2 for 2 weeks in adolescence, showed deﬁcits in adulthood
in performance of set-shifting tasks and alterations in dopamine levels in the ventral tegmental area.
These alterations were present in adulthood and were similar to those which were shown in pre-clinical
models of schizophrenia [136].
The conﬂicting results demonstrated by previous studies, reﬂect the need for further studies on the
effect of cannabinoids on cognitive ﬂexibility. The available evidence demonstrates that cannabinoids
have indeed an effect on cognitive ﬂexibility [13], possibly via modulation of dopamine and glutamate
concentrations in several brain regions including the ACC and prefrontal cortex [13,83].
4.7. Cannabinoids and Cognitive Flexibility- Evidence from Clinical Studies
Recent studies using fMRI have found a variety of brain regions that were activated while
performing cognitive processes that demand ﬂexibility, including, the pre-frontal cortex, basal
ganglia, ACC and posterior parietal cortex [137]. Some of the regions which underlie cognitive
ﬂexibility are involved in WM and inhibition control and thus, the ﬁndings support the hypothesis
that cognitive ﬂexibility depends both on WM and inhibition control [81]. In addition, levels of
certain neurotransmitters such as monoamines in several brain regions are associated with cognitive
ﬂexibility [138].
Paradigms for investigating cognitive ﬂexibility include a wide array of task-switching and
set-shifting tasks. One of the oldest and most common task for measuring this performance is the
Wisconsin Card Sorting Task (WCST) [139]. In this task, a number of stimulus cards are sorted by color,
shape or number. The participant is required to conclude the correct sorting criterion on the basis of
feedback. Set-shifting ability is required when sorting criterion has been changed and perseverative
errors are the outcome of failure in set-shifting [77]. Additional tasks for measuring cognitive ﬂexibility
include verbal ﬂuency and semantic ﬂuency. In these tasks participants are required to demonstrate
unusual patterns of thinking by answering a serial of verbal questions (What is common between a ﬂy
and a tree?) in order to be successful [77].
Acute intoxication of cannabis has disruptive effects on cognitive ﬂexibility [62,105,140]. However,
the evidence on non-acute effects of cannabinoids on cognitive ﬂexibility have been inconsistent.
Bolla et al. (2002) reported dose-related effects of cannabis use on cognitive function. They have
examined several aspects of cognitive function including cognitive ﬂexibility in heavy cannabis users
compared with moderate and occasional users who abstained from cannabis for 28 days. Poorer
performance was positively correlated with increased frequency of cannabis consumption [61].
Later on, Pope et al. (2003) has reported similar effects, except that deﬁcits in performance
on the WCST were observed in heavy cannabis users who had started smoking cannabis during
adolescence [141]. In addition, there were no differences in ﬂexibility performance between cannabis
users who had started using cannabis in adulthood compared with non-users [141]. A further study
demonstrated that heavy cannabis users’ performance on the WCST resemble those of schizophrenic
patients; however, there was no association between frequency of cannabis use and errors on the
WCST [142]. Contrary to the last results, several studies indicated that while repeated consumption of
cannabis has disruptive effects on some cognitive functions, impairments in cognitive ﬂexibility were
not presented in heavy cannabis users even after controlling for demographic variables [143,144].
In a systematic meta-analysis, Grant and colleagues (2003) examined the non-acute effects of
cannabis on several aspects of cognitive function using strict inclusion criteria on a limited number of
studies. The authors failed to ﬁnd signiﬁcant non-acute effects of cannabis consumption on cognitive
ﬂexibility. However, it should be noted that cognitive ﬂexibility was referred as a component within
the factor of abstraction reasoning [145]. This methodological issue is critical since abstract reasoning
and cognitive ﬂexibility are different components of EF [77].
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The evidence so far points out to a lack of available evidence regarding the effects of SC
on cognitive ﬂexibility in humans. Altintas et al. (2016) examined several cognitive domains in
SC users who experienced psychotic episodes and compared their performance with hospitalized
schizophrenic patients. Interestingly, there were no differences between the groups in cognitive
ﬂexibility measurement [146]. Yet, their results cannot be interpreted as an outcome of SC use
exclusively since it cannot be differentiated from psychotic symptoms that were observed among
SC users as well. There are two additional aspects of the association between cannabinoid abuse
and cognitive ﬂexibility which should be noted. First, impairments in cognitive ﬂexibility have been
suggested to play a major role in continuous use of cannabinoids despite negative consequences [83].
Secondly, deﬁcits in cognitive ﬂexibility were associated with affective alterations [147]. Both greater
mood alterations and greater rates of abuse are commonly observed among SC users and heavy
cannabis users [9,148].
In summary, both pre-clinical and clinical ﬁndings suggest that the ECS are involved in cognitive
ﬂexibility [13]. Although, there are inconsistent ﬁndings in human studies, the non-acute disruptive
effect of cannabinoids on cognitive ﬂexibility is probably mediated by several factors including the age
of onset and the frequency of cannabinoid consumption [58,141], yet, further exploration of the last
relation is required.
5. Conclusions
Cannabinoid drugs, in both organic and synthetic forms became increasingly popular despite
the potential harms associated with their use [6,10,87]. While the main psychoactive ingredient of
cannabis is the CB1 receptor partial-agonist Δ9-THC [13,51–53], SC drugs contain varied types of
cannabinoid-agonists which are more potent than organic cannabinoids [65,149]. Although SC and
organic cannabinoids bind to the same CB receptors, the psychotropic effects of SC are more severe,
more rigid and much more unpredictable than those induced by organic cannabinoids [4,5,65,75].
Taking into account the above evidence that SC drugs do not contain CBD, their harm potential is
signiﬁcant [5,75,114].
Taking together the recent ﬁnding of both animal and human studies, repeated consumption of
cannabinoids is associated with EF impairments, yet, there is still a gap of knowledge regarding the
last of these impairments [11,114]. The available data from both animal and human studies suggest
that ECS involve and effect cognitive functions in general and EF speciﬁcally [9,10,12,13,83]. The ECS
has a major role in neurodevelopmental and maturational process, which are especially prevalent
during adolescence. Consumption of exogenous cannabinoids affect the functioning of the ECS,
it is plausible that chronic consumption during early adolescence alters the neurodevelopmental
maturational process during this period [5]. Consequently, it is not surprising that current evidence
suggests that exposure to cannabinoids during the adolescent period may induce severe long-lasting
cognitive impairments [5,78,96,108,147,148]. Furthermore, most of the current evidence indicates an
association between the amount of cannabinoid consumption with the degree of impairment; more
consumption, or consumption of drugs which contain more potent cannabinoids is associated with
greater impairments [5,83,87]. Accordingly, although there is a limited number of human studies
which examine both the acute and long-term effect of SCs on EF, it is reasonable to assume that SC
which contain extremely potent cannabinoid-agonists may induce long-term EF-impairments [5–8].
Yet, further research is needed to expend to knowledge of the last phenomena.
It is important to note some of the limitations of the current review. Most of the available evidence
regarding the effects of SCs on EF is based on pre-clinical studies. When interpreting these results, it is
important to take into account that the methodological limitations which animal studies naturally hold.
Firstly, while cannabis or SC users mostly use these drugs by smoking or inhaling [1,3,7], most of the
pre-clinical studies mentioned in this review treated animals by intraperitoneal (I.P) injection which in
contrast to inhaling induce greater effect in shorter time [9,32]. Furthermore, it is important to take
into account that most of the mentioned pre-clinical studies have used speciﬁc SCs or pure Δ9-THC
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for exploring their exclusive effect on a chosen factor [3,9,32]. In contrast to that, evidence from
epidemiological data or human studies present information regarding the effects of SC or cannabis
products which mostly contain a range of cannabinoids and in some cases additional psychoactive
compounds [1,3,7,9,32].
Understanding the effects of cannabinoids on EF has considerable practical utility in the clinical
setting. Executive function is essential to an individual’s multiple abilities in daily life [77]. It has been
suggested that due to impaired EF, patients may have difﬁculties in learning new coping behaviors and
accordingly increases the likelihood of treatment dropout and poor treatment outcomes [12]. Therefore,
the current review emphasizes the need of attention by the clinician regarding cognitive abilities of
patients who suffer from cannabinoid abuse. In case of cognitive impairments, an alternative unique
therapeutic method should be considered such as behavioral therapy [150] or introducing the patient
with cognitive rehabilitation strategies [12]. This may be crucial, especially in cases of patients who are
heavy cannabinoid users, or young patients who used cannabinoids in early age for persistent periods.
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Abstract:Many novel psychoactive substances (NPS) have entered the recreational drug scene in recent
years, yet the problems they cause are similar to those found with established drugs. This article will
debate the psychobiological effects of these newer and more traditional substances. It will show how
they disrupt the same core psychobiological functions, so damaging well-being in similar ways. Every
psychoactive drug causes mood states to fluctuate. Users feel better on-drug, then feel worse off-drug.
The strength of these mood fluctuations is closely related to their addiction potential. Cyclical changes
can occur with many other core psychobiological functions, such as information processing and
psychomotor speed. Hence the list of drug-related impairments can include: homeostatic imbalance,
HPA axis disruption, increased stress, altered sleep patterns, neurohormonal changes, modified brain
rhythms, neurocognitive impairments, and greater psychiatric vulnerability. Similar patterns of deficit
are found with older drugs such as cocaine, nicotine and cannabis, and newer substances such as
3,4-methylenedioxymethamphetamine (MDMA), mephedrone and spice. All psychoactive drugs
damage human well-being through similar basic neuropsychobiological mechanisms.
Keywords: amphetamine; cocaine; mephedrone; cannabis; spice; drug; mood; homeostasis
1. Mood State Fluctuations
Psychoactive drugs, by deﬁnition, cause mood states to change and ﬂuctuate. Hence an important
factor for drug-induced distress is mood instability. This is found with sedative drugs such as alcohol
or cannabis, and stimulant drugs such as cocaine or methamphetamine [1–6]. Indeed, the main reason
that psychoactive drugs are used recreationally is for their “positive” mood effects, such as feelings
of relaxation and pleasure [4]. Novel psychoactive substances (NPS) such as mephedrone and spice
cannabinoids are very similar in this regard [6–9]. Although one of the paradoxes of drug taking is that
many of the apparent mood gains represent the reversal of unpleasant abstinence feelings. Nicotine is
a prime example of this pattern [10–12], although it also occurs with other substances [4].
Psychoactive drugs can also produce undesirable mood state changes. For instance, recreational
cannabis, whether herbal or spice, can lead to feelings of tension and suspiciousness [2,13]. Stimulants
such as cocaine, methamphetamine and mephedrone can also lead to feelings of anxiety and
paranoia [1,14,15]. The acute mood effects of all psychoactive drugs can be highly variable and
may differ considerably between individuals. On alcohol some users become happy and jovial, while
others become moody and aggressive, especially after excess levels of consumption [5,16,17]. In a
similar way, Le Strat et al. [18] documented a wide range of responses to an acute dose of cannabis.
Furthermore, those with positive initial mood reactions were most likely to become regular cannabis
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users, whereas those with negative or neutral mood reactions to cannabis tended not to persevere with
its usage. Similar differences in mood response have also been empirically demonstrated with the
methamphetamine derivative MDMA (3,4-methylenedioxymethamphetamine or “Ecstasy”). This drug
is often described as the most euphoriant of all the recreational stimulants. Yet acute MDMA can
release a wide range of feelings and cognitions-both positive and negative. Liechti et al. [19] found that
an acute dose of MDMA in the laboratory led to signiﬁcant increases in feelings of both introversion
and extraversion, while feelings of happiness and depression were also signiﬁcantly intensiﬁed. In a
comprehensive review of the acute-dose MDMA mood literature, it was found that a wide range
of positive and negative psychological material could be released/intensiﬁed [20]. For instance,
psychotherapists who have incorporated MDMA into their therapy sessions have noted that the
emergent psychological material can be difﬁcult and stressful for the client to handle, although its
release may also be important for potential therapeutic gains [20–24]. In positive environmental
situations, the positive mood effects of MDMA predominate, whereas in neutral situations its mood
effects can be more variable and less positive [14,15]. These adverse mood abreactions to MDMA
can be more frequent than is commonly portrayed. In an article entitled: “Hug drug or thug drug”,
Reid et al. [25] noted that MDMA often generated feelings of anger and aggression. Rugani et al. [26]
noted that acute psychotic patients who had used MDMA for recreational purposes demonstrated
heightened levels of hostility, physical violence, and verbal aggression than non-users. The authors
noted that this ﬁnding “surely runs counter to the expected entactogenic effects of Ecstasy” (for further
debate, see [27]).
In a large Internet study of mephedrone and MDMA users, the acute mood effects of each drug
were broadly similar, although some intriguing differences in pharmacodynamic tolerance were
apparent [9]. A mixture of positive and negative mood changes is also found with established
recreational stimulants such as cocaine [28], and laboratory doses of methamphetamine [14,15].
The effects of high doses of amphetamine and cocaine can be very strong, with reports of a physical
rush or hit. These high doses can lead to intensely negative moods, with very severe feelings of
suspiciousness, or clinical paranoia. Spice cannabinoids can also have far stronger effects that herbal
cannabis, in both positive and negative ways [29]. The more extreme mood reactions of the more
powerful drugs can lead to changeable and unpredictable patterns of behavior. However, these
abreactions can occur with any psychoactive drug, irrespective of whether they are established
or novel.
1.1. Drug Withdrawal and Repetitive Mood Vacillation
One of the main problems with every psychoactive drug is that the brief period of on-drug mood
gains is followed by a period of neurochemical depletion afterwards, when the opposite mood states
develop. These rebound moods are typically negative and aversive, and are readily reversed by taking
the drug again. Hence every mood-altering drug has addiction potential. Indeed, the essence of
addiction is these repetitive mood vacillations [4,30]. This pattern can be illustrated by legal stimulants
such as nicotine, illicit drugs such as cocaine, or novel substances such as MDMA or mephedrone.
The former two drugs have been extensively studied, with nicotine showing many pharmacokinetic
and pharmacodynamic similarities to cocaine [31]. Both drugs are powerful Central Nervous System
(CNS) stimulants, with the ﬁrst cigarette of the day increasing heart rate substantially [32,33], which is
one of the reasons tobacco smokers develop hypertension. In mood terms, tobacco smokers feel more
alert after the ﬁrst cigarette of the day, but soon this activation is lost, and after 20–60 min the regular
smoker needs yet another cigarette. This mood ﬂuctuation repeats over the rest of the day and recurs
every day for the rest of their lives—until they quit or prematurely die [10,11,34].
Similar patterns of mood ﬂuctuation occur with cocaine, since nasal snorting leads to a rapid
hit, followed by a low-mood comedown, and the urgent need for another drug hit. Cocaine therefore
displays high addiction potential, with crack cocaine being even more troublesome and addictive, due
its extreme rapidity of action [4,35,36]. Khat leaf chewing occurs in many countries around the Horn of
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Africa [37,38], with cathinone being slowly released into the systemic circulation. Cathinone displays
weaker stimulant properties than cocaine. Yet Khat chewers also report acute mood gains, followed
by negative moods on withdrawal, in a pattern identical to that found with other stimulants [37].
This is also evident with MDMA, although over a longer time period. Hence the acute moods peak
after a couple of hours, while the recovery period can last for several days [28,39–42]. This long
pharmacodynamic proﬁle explains why Ecstasy/MDMA is only taken intermittently and displays
lower addiction potential than most other stimulants [43,44].
Cannabis may be a sedative drug, but it shows a similar pattern of mood vacillation to the
stimulant drug nicotine. Vandrey et al. [45] compared the mood changes found during withdrawal
from cannabis and tobacco, and concluded that they were very similar. For instance, the unpleasant
mood effects of cannabis withdrawal could include feelings of irritability, anger, and depression
(i.e., very similar to tobacco), along with other problems such as impaired sleep, altered circadian
rhythms, changed appetite, and drug cravings [45,46]. These symptoms of cannabis withdrawal
have been formalized in standardized questionnaires such as the Cannabis Withdrawal Discomfort
Scale [47], and the Marijuana Craving Questionnaire [48]. The high addictiveness of cannabis does
make it difﬁcult to understand current movements to make its usage legal [49].
1.2. Related Psychobiological Problems
Many other psychological skills and abilities may also ﬂuctuate during drug stimulation and drug
withdrawal. For instance, tobacco smokers display worse memories than non-smokers [50]. The reason
for this is that new information is being laid down in memory and is being stored under a constantly
changing background of nicotine levels. Hence memory storage and retrieval are both adversely
affected by nicotine addiction [12]. Sleep is also adversely affected by nicotine addiction, while it
improves to normal following smoking cessation [12]. The many psychobiological problems found in
recreational stimulant users have been described in numerous comprehensive reviews [1,3,36,51,52].
Similarly, the addictiveness of herbal cannabis was noted earlier, while the stronger skunk varieties
of herbal cannabis display greater potential [53]. Artiﬁcial spice cannabinoids are even stronger, and
hence more damaging. Some of the artiﬁcial spices are full agonists for the cannabinoid receptor,
whereas herbal cannabis is a weak partial agonist [54]. Hence spice displays far greater addictiveness,
with some users committing suicide when they cannot access their normal drug supplies [6,29,55–58].
The practical consequences of cannabis dependency can be severe [49]. In the USA around 300,000
individuals approach professional drug addiction services for cannabis dependency every year [59].
Clinically disabling dependency occurs in around 10% of those who have ever tried the drug [60],
while 65% of cannabis ever-users report some aspects of drug dependency [61], with young initiates
the most vulnerable [62]. In summary, the core problems related to drug dependency are similar for
stimulants and depressant drugs, and for older and newer psychoactive substances.
2. Homeostasis
One fundamental index of psychological balance and health is homeostasis. When the organism
is well adapted to its environment, its daily rhythms of behavioral and physiological activity occur
smoothly and efﬁciently. Selye [63] noted that disruption to homeostasis led to psychological imbalance,
increased bio-physiological stress, and led to excessive energy expenditure. Furthermore, the
repeated experience of acute stress led to cumulative chronic stress and this caused physical and
psychological ill-health. Selye [63] showed that the Hypothalamic-Pituitary-Adrenal (HPA) axis was
crucial for psychophysiological stability, with cortisol being the key neurohormone for maintaining
homeostatic balance [64]. Healthy individuals showed regular circadian rhythms of cortisol secretion,
and this master hormone helped to maintain the optimal secretion patterns for other important
neurohormones [63,65,66].
Many psychoactive drugs affect neurohormonal secretions acutely, and when these drugs are
taken repeatedly, they can lead to chronic stress. This may be illustrated with the recreational stimulant
38
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MDMA [65,66]. In placebo-controlled laboratory trials, an acute dose of MDMA can generate a cortisol
increase of around 150% [67]. Recreational Ecstasy/MDMA users show peak cortisol increases of around
800%, probably due to the combined effects of taking a stimulant drug in a stimulating environment [42,68].
The Cortisol Awakening Response can also be affected in recreational Ecstasy/MDMA users [69],
with around 70% of recreational users complaining of disrupted sleep, even when drug-free [70].
Body temperatures can also change, with MDMA showing well-documented patterns of thermal
change [71–73]. Synthetic cannabinoids such as AKB48 can induce hypothermia [74], while synthetic
cathinones such as mephedrone can also affect thermal reactivity [75]. Returning to chronic stress, regular
MDMA users show strong longer-term neurohormonal changes. When cortisol was measured in 3-month
hair samples, the regular Ecstasy/MDMA users displayed 400% higher cortisol levels than non-user
controls, while the light Ecstasy/MDMA users showed intermediate cortisol values [76]. MDMA is
not the only recreational drug which can affect cortisol. Raganathan et al. [77] showed that acute
tetrahydrocannabinol (THC) led to a significant increase in cortisol secretion. King et al. [78] found that
chronic cannabis users had significantly higher salivary cortisol levels than non-user controls. Currently
there is a paucity of empirical evidence on the neurohormonal effects of Novel Psychoactive Substances,
and empirical studies in this area are therefore needed.
Psychiatric Aspects
All psychiatric disorders are dimensional, with symptoms ranging on a continuum from low to
high. This core notion may seem rather obvious, but it needs to be stated since it can help explain how
psychoactive drugs contribute to mental distress. The core processes described earlier, of mood state
vacillation and homeostatic imbalance, can each contribute to mental instability, while those individuals
with a predisposition to mental distress may be particularly vulnerable to the destabilizing effects
of psychoactive drugs. For an example of this interactive psychiatric model applied to recreational
MDMA, see Parrott [79].
The ﬁrst written report of psychiatric problems being caused by any psychoactive drug were
present in the world’s oldest pharmacopoeia, attributed to Emperor Shen Nung in bronze-age China.
This noted that when cannabis was taken in excess, it could produce “visions of devils” [80]. Modern
research has conﬁrmed that cannabis may cause a form of psychosis, with many similarities to classic
schizophrenia [13]. Hence an acute dose of cannabis can induce bizarre thoughts and cognitions [81].
D’Souza and colleagues [82] administered THC and placebo to recreational cannabis users without
any prior psychiatric history. The active cannabis condition led to signiﬁcant increases in scores on
the Positive and Negative Symptom Scale (PANSS), the standard rating scale for clinical symptoms
of schizophrenia. Individual subjective experiences under the acute inﬂuence of THC included the
following: “I thought I could see into the future” . . . “I thought you were trying to program me”
. . . “I thought you could read my mind” . . . “I thought I was god”. These delusional thoughts as
measured by raised PANSS positive symptom scores, can also correlate with changed patterns of brain
activity [83].
When used regularly, cannabis can lead to both clinical psychosis, and other forms of psychiatric
disorder [84]. The Swedish Conscript study was the ﬁrst prospective investigation to demonstrate
an association between cannabis and schizophrenia [85]. This ﬁnding has been replicated in further
prospective studies, where regular cannabis use led to an increased risk of psychotic breakdown in
later years. Le Bec et al. [86] undertook a comprehensive review and concluded that every published
study showed a signiﬁcant link between recreational cannabis and the later emergence of psychosis.
One crucial factor is that the drug needs to be taken repeatedly and regularly. In one prospective study,
Henquet et al. [87] found that occasional cannabis users showed no increase in risk, weekly-users
showed a slightly increased risk, while daily-cannabis users showed a highly signiﬁcant increase in
later psychosis. Regular cannabis use is also associated with an increased risk for other mental health
problems, such as depression and mania [88,89].
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Recreational CNS stimulants can also cause greater psychiatric distress. Feyissa and Kelly [90]
noted that Khat chewing could lead to a range of mental health problems including depression and
hypomania; hence even weaker drugs such as cathinone can lead to psychiatric problems, while regular
users of stronger stimulants such as amphetamine, cocaine or methamphetamine can experience
a wide range of problems, including psychosis, depression, paranoia, psychomotor tics/tremors,
eating disorders, and aggression [1,3,4,35,51,91]. Recreational MDMA is also associated with a
wide range of adverse psychiatric consequences, such as clinical depression, aggression, problems
with weight control, eating/food intake, and some of these issues may endure for years after drug
cessation [26,76,92–99].
3. Neurocognitive Deﬁcits
Cognitive skills are an important focus for most areas of applied psychology, and
psychopharmacology is no exception. The extensive empirical literature demonstrates both acute and
chronic drug inﬂuences. By deﬁnition, any drug which is psychoactive will affect not only mood states
(see Section 1), but many other psychological functions including neurocognition. CNS stimulants such
as cocaine or mephedrone will speed information processing, but also increase errors through increased
carelessness and impulsivity. CNS depressants will generally lengthen reaction times but may increase
errors through reduced alertness and vigilance/attention. When combined with drug-induced feelings
of conﬁdence, these changes can make any psychoactive drug dangerous for practical skills such as car
driving [4,55,100]. Their chronic use can also be damaging. In an extensive review, Cruickshank and
Dyer [1] noted that methamphetamine led to impairments in executive functioning, learning, memory,
and motor skills. Other reviews have generated similar lists of neurocognitive impairments following
other stimulants such as cocaine [52,101], or Ecstasy/MDMA [27,44,102–108]. Cannabis can lead to
acute deﬁcits in memory, learning, sustained attention, and higher cognitive skills, while its chronic
use can lead to a wide range of cognitive deﬁcits, even including a decline in general intelligence, with
reduced IQ test scores [109–114]. Neuroimaging studies of regular cannabis users indicate deﬁcits in
various brain regions, such as the hippocampus and amygdala [114], with white matter degeneration
and de-myelination [115].
4. Final Overview
Psychoactive drugs can damage human well-being simply by being psychoactive! In acute terms
they may boost activity for a short period, but this is soon followed by a period of neurochemical
recovery, when the opposite psychological states develop. These psychological ﬂuctuations are readily
seen in mood state changes of daily tobacco smokers (see Figure 1 in Parrott, [10]). However, moods and
feelings provide just one index for other more general changes in psychological status. Many different
psychological functions can be affected—in different ways by different drugs. They also affect many
different neurotransmitter systems. Yet despite the multitude and variety of their neurotransmitter
actions, in psychobiological terms these drugs all display the same underlying pattern of disrupted
balance and equilibrium [4,11,30,38]. These core biological factors also explain why every psychoactive
drug displays addiction potential. Regular users suffer from negative states off-drug, and feel better
when on-drug, hence the “need” to take the drug repeatedly [10]. As novice users, the more they
succumb to their new habit, the stronger their drug dependency becomes.
Psychoactive drugs also affect the HPA axis, causing hormonal dysregulation, and increasing
the susceptibility for stress [4,66]. The healthy human organism displays a natural balance between
sympathetic and parasympathetic nervous system activity. So, when humans take recreational drugs,
they disturb this natural balance, and this leads to adverse consequences [4]. Proponents for drug use
typically only talk about the short-term drug gains, and with this narrow focus, any psychoactive drug
can be miss-described as beneﬁcial. It is only by covering all aspects of their acute and chronic usage
that a more complete picture of their damaging effects can emerge.
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Abstract: The Internet has played a major role in the distribution of New Psychoactive Substances
(NPS), and crypto markets are increasingly used for the anonymous sale of drugs, including NPS.
This study explores the availability of individual NPS and vendors on the crypto markets and
considers whether crypto markets are a reliable platform for the sale of NPS. Data was collected
from 22 crypto markets that were accessed through the hidden web using the Onion Router (Tor).
Data collection took place bimonthly from October 2015 to October 2016 as part of the CASSANDRA
(Computer Assisted Solutions for Studying the Availability aNd DistRibution of novel psychoActive
substances) project. In seven snapshots over 12 months, 808 unique vendors were found selling
256 unique NPS. The total number of individual NPS and vendors increased across the data collection
period (increase of 93.6% and 71.6%, respectively). Only 24% (n = 61) of the total number of NPS and
4% (n = 31) of vendors appeared in every snapshot over the 12 months, whereas 21% (n = 54) of NPS
and 45% (n = 365) of vendors only appeared once throughout the data collection. The individual
NPS and vendors did not remain the same over the 12 months. However, the availability of
NPS and vendors selling NPS grew. NPS consistently available on crypto markets could indicate
popular substances.
Keywords: new psychoactive substances; legal highs; darknet; hidden web; crypto market
1. Introduction
New psychoactive substances (NPS) are an emerging phenomenon, and their representation on
the hidden web (also known as the darknet) is under-researched. The Internet has played a major role
in the distribution of NPS, and drug marketplaces (also known as crypto markets) on the hidden web
are increasingly used for the anonymous sale of drugs, including NPS [1–3].
The European Union (EU) Early Warning System currently monitors over 650 substances [4].
However, not all substances are a cause of concern, and NPS rise and fall in popularity. Only a few
have had sizable prevalence or media attention [5], and research has shown that the legal status
of a substance is one of the factors determining why some NPS become popular and others do
not [6]. Various legislations have been created to tackle NPS diffusion across Europe and the world.
For example, the UK introduced the Psychoactive Substances Act in May 2016, which prohibited
the import, export, and supply of psychoactive substances (with some exemptions) but permitted
possession [7]. The Act achieved a reduction in UK-based online stores and ofﬂine retail stores [8].
As more countries seek to restrict access to NPS, the legal markets could be displaced by alternative
routes such as street-level drug dealing or crypto markets [3]. However, movement to the illicit market
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is dependent on its popularity, and therefore only those NPS with sufﬁcient demand will transition
into it [9].
On the hidden web, drugs can be sold and purchased anonymously through crypto markets
that use an “eBay”-style system where buyers can publicly review the sellers and therefore build
their reputation, attracting future transactions [10–14]. Conversely, negative reviews can discourage
buyers and shun unworthy vendors from the crypto markets [11,15]. It is argued that this feedback
mechanism and creation of a reputation are vital to the continuing function of the market and also
represent an explanation for a vendor’s lifespan [15,16]. To date, the majority of crypto market research
has been conducted on the Silk Road [13,17–21], which was closed by law enforcement in 2013 [22].
Christin [20] found that most sellers disappeared before three months, and most items sold for less than
three weeks. Christin [20] proposed the theory that short vendor lifespans could be due to lack of stock
or to vendors using the “stealth mode”. The stealth mode consists in vendors removing their listings
or only selling their listings to a speciﬁc customer base [13]. Potentially, the turnover of vendors is a
product of the instability of the crypto markets; individual crypto markets are said to be unpredictable
and have a frequent turnover, causing instability in the community [23]. Law enforcements have
succeeded in closing crypto markets in the past [14,22,24]. However, all successful operations have not
stopped the online trade of drugs [25], and the number of vendors has increased [3]. Previous research
on crypto markets have shown a small yet deﬁnite presence of NPS. Barratt, Ferris, and Winstock [18]
examined the use of Silk Road in a sample from the UK, US, and Australia and found that out of the
top 20 substances that were purchased, four of these were NPS. In addition, Van Buskirk et al. [3]
explored crypto markets in 2015 and concluded that around one-ﬁfth of vendors offered NPS.
Crypto markets are increasingly being used for the sale and purchase of drugs, regardless of the
instability both the markets and the vendors show. To date, research has not focussed speciﬁcally on
the lifespan of vendors selling NPS, substances whose popularity and availability are unpredictable.
This paper, therefore, aims to explore the lifespan of individual NPS sold on the crypto markets,
explore the lifespan of individual vendors selling NPS on the crypto markets, and consider whether
crypto markets are a reliable platform for the sale of NPS.
2. Methods
The study was part of the CASSANDRA (Computer Assisted Solutions for Studying the
Availability aNd DistRibution of novel psychoActive substances) project [26]. The crypto markets on
the hidden web were accessed through Tor (torproject.org, 501(c)(3), The Tor Project, Inc., Cambridge,
MA, USA), and the data were collected bimonthly over 12 months in October, December (2015),
February, April, June, August, and October (2016). The data were collected over two days in each of
the seven snapshots. The crypto markets that were included sold NPS, were conducted in English,
and had an open registration at the time of collection. The crypto markets present over the 12 months
of data collection ﬂuctuated because of crypto markets opening, adding NPS to their sales, or closing
following exit scams or law enforcement. A table of the crypto markets included in this study can be
found elsewhere [27].
Data were collected on each crypto market for NPS being sold that was visible to the researchers.
The data collectedwere: name of theNPS (not including conventional illicit drugs, steroids, or prescription
drugs), name of the vendor selling NPS, and name of the crypto market used by the vendor. Some NPS
were sold under various aliases; these were categorised by their most common name. Furthermore,
branded NPS that were commonly found on the visible Internet were categorised according to their
contents. All analyses were performed using Microsoft Excel 2016 (Microsoft Ofﬁce 2016, Microsoft,
Redmond, WA, United States), unless otherwise speciﬁed.
All users on crypto markets were anonymous. The research was purely observational and did not
involve interaction with either buyers or sellers. The study was approved by King’s College London
PNM Research Ethics reference number: LRS-15/16-3084 as part of the CASSANDRA project.
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3. Results
The total number of individual NPS and vendors increased across the seven snapshots in the data
collection period (increase of 93.6% and 71.6%, respectively) (Figure 1). Over 12 months, a total of
808 individual vendors were found selling 256 individual NPS.
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Figure 1. Number of NPS and vendors in each month of data collection (seven snapshots in 12 months).
NPS: New Psychoactive Substances.
A total corresponding to 21% (n = 54) of the NPS reported over the 12-month period only appeared
in one snapshot (Figure 2). Fourteen percent (n = 36) of the total number of NPS appeared in two of the
seven snapshots. Ten percent (n = 26) appeared in three of the seven snapshots, 7% (n = 18) appeared
in four of the seven snapshots, 11% (n = 29) appeared in ﬁve of the seven snapshots, and 13% (n = 32)
appeared in six of the seven snapshots. In addition, 24% (n = 61) of the total number of NPS appeared
in each of the seven snapshots over the 12-month period (Table 1).
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Figure 2. The number of NPS available across the seven snapshots (12 months) of data collection. NPS:
New Psychoactive Substances.
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Almost half of all vendors (45%, n = 365) appeared only once over the 12-month period (Figure 3).
Twenty-three percent (n = 184) of the total number of vendors appeared in two snapshots over the
12-month period, 13% (n = 103) appeared in three snapshots, 8% (n = 63) appeared in four snapshots,
4% (n = 30) appeared in ﬁve snapshots, 4% (n = 32) appeared in six snapshots, and only 4% (n = 31) of
the total number of vendors appeared in all seven snapshots.
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Figure 3. The number of vendors available across the seven snapshots (12 months) of data collection.
4. Discussion
The total number of individual NPS and vendors increased over the 12-month duration of the
study. Almost half of the total number of vendors had a lifespan of only a few months, and the NPS
advertised ﬂuctuated over the study. One-ﬁfth of NPS were available for the entirety of the study,
whereas just under one-quarter were only available for a few months before disappearing. From the
results of this study, the contents of the NPS market on the crypto markets varied, but a market was
consistently available.
Research has shown that the use of crypto markets and the availability of substances including
NPS have increased in recent years [3,20,24]. The results from this study complement these ﬁndings as
the availability of NPS increased over the data collection period. The increased availability of NPS on
the crypto markets suggests that NPS are being purchased via this method and that crypto markets
are seen as a viable platform for the sale of NPS. This is necessary to observe because of the changing
legislations surrounding these substances in countries around the globe, such as the ban in the UK that
was implemented during this study [7]. Legal markets will look to migrate to other platforms.
This study found that 256 different NPS were available for purchase over the 12 months of the
study, and nearly one-quarter of NPS remained available on the crypto markets, suggesting that
these substances could be the most popular NPS. The majority of the NPS that were available in
every snapshot were cathinones and phenethylamines (categorised according to [5]). However, there
was frequent turnover throughout the study, whereby some NPS were available for purchase for
a few months and then disappeared from availability. This pattern may have mirrored changes in
popularity within the overall NPS market, ﬂuctuating because of legality, ease of access, or similarities
to traditional drugs [4,9]. It is possible that certain NPS were removed from the market because limited
stocks were available to the vendors or because the demand of a speciﬁc NPS did not match up to its
availability. Another possibility is that the feedback from the customers about the NPS was negative,
and the stock was removed [15].
52
Brain Sci. 2018, 8, 46
Almost half of the vendors were only captured in one snapshot over the course of the data
collection, and the number of vendors who appeared in the data reduced as the snapshots increased
(Figure 3). These ﬁndings show that the lifespan of the vendors was relatively short, and just under half
of the vendors were available for under four months, mirroring what was found in the literature [20,28].
There are potential reasons for a short lifespan; research has suggested that vendors could only be
selling their limited stock, or that vendors move into stealth mode after they have gathered a sufﬁcient
client base [13,20]. Furthermore, the crypto market system is built on trust and reputation; if vendors
do not build an adequate reputation, they may remove themselves from the market either indeﬁnitely
or only apparently by setting up new accounts [15,28]. Only 4% of vendors remained available in every
snapshot over the 12 months of this study. Perhaps, these consistent vendors were highly reputable
vendors or vendors with a loyal customer base [28].
This study has several limitations. As this study was exploratory and lacked contact with the
vendors, we were unable to verify whether the substances advertised were the same substances being
purchased and received by the customers. Because of anonymity, another limitation is that studies like
the present one are unable to capture how many vendor proﬁles are controlled by one person or if the
number of vendors that are only available for a few months before disappearing are, in fact, opening
and closing various accounts [29].
5. Conclusions
Online sales hold a predominant portion of the NPS market, and crypto markets are an emerging
source of sale. NPS sold on crypto markets should be monitored to track the popularity and availability
of speciﬁc substances. Our study found that vendors selling NPS had short lifespans, with half of the
vendors only appearing once in the data collection. Individual NPS had longer lifespans, however
not all NPS were available over the study period; only a quarter of the total NPS were available in
all snapshots over the year. Regardless of the ﬂuctuation of the vendors in the NPS market on the
crypto markets, the number of NPS and vendors selling NPS increased over the year. The NPS that
consistently appeared across the 12 months of data collection may suggest what substances are popular
with the consumers. Crypto markets are therefore to be monitored for the sale of NPS, especially in
light of the tightening regulations being applied in various countries.
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Abstract: Hallucinogen Persisting Perception Disorder (HPPD) is a rare, and therefore, poorly
understood condition linked to hallucinogenic drugs consumption. The prevalence of this disorder is
low; the condition is more often diagnosed in individuals with a history of previous psychological
issues or substance misuse, but it can arise in anyone, even after a single exposure to triggering drugs.
The aims of the present study are to review all the original studies about HPPD in order to evaluate
the following: (1) the possible suggested etiologies; (2) the possible hallucinogens involved in HPPD
induction; (3) the clinical features of both HPPD I and II; (4) the possible psychiatric comorbidities;
and (5) the available and potential therapeutic strategies. We searched PubMed to identify original
studies about psychedelics and Hallucinogen Persisting Perception Disorder (HPPD). Our research
yielded a total of 45 papers, which have been analyzed and tabled to provide readers with the
most updated and comprehensive literature review about the clinical features and treatment options
for HPPD.
Keywords: Hallucinogen Persisting Perception Disorder; ﬂashbacks; hallucinogenic substances; LSD;
psychedelics; visual disturbances; perceptual disturbances
1. Introduction
Hallucinogens represent an enormous group of natural and synthetic agents [1,2]. The core
features of hallucinogens include their being empathogenic and being able to induce alterations of
consciousness, cognition, emotions, and perception. Their main characteristic is to profoundly affect a
person’s inner processes and the perception of the surrounding world. The perceptual distortions are
mainly visual, as in the vast majority of induced psychoses [3–5]. The hallucinogenic properties of
many natural products were known for thousands of years: popular healers, “brujos”, and shamans
used these substances in ancient times for medical, religious, spiritual, ritual, divination, and magical
purposes. Nevertheless, the attention of western culture was drawn to psychedelics only at the
beginning of the 20th century, but the turning point is considered to be 1938, the year in which
the lysergic acid diethylamide, better known as LSD, was synthesized by Albert Hofmann. In the
1950s and 1960s, LSD was considered to have a therapeutic potential in the psychiatric ﬁeld, allowing
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patients to access unconscious material in therapeutic settings. This has been recently re-evaluated with
uncertain results. After a mass diffusion of hallucinogens in the 1960s and 1970s, current prevalence
data [6] from the United States highlight that more than 180,000 Americans report a recent use of LSD,
and 32,000 a recent use of phencyclidine. Nowadays, the intake of hallucinogens is associated with
shamanic ceremonies, workshops of underground therapy and self-experiences. In these frameworks,
hallucinogenic substances are most commonly used alone, while in rave parties and social events
they are often part of a heavy polyvalent use that frequently includes Novel Psychoactive Substances.
These compounds, easily available on the Internet without any cultural barrier and sometimes without
any advice from the group of peers, have profoundly changed the drug scenario [7–10]. Their use is
becoming widespread, also due to their low cost and appealing market strategies [11,12]. However,
signiﬁcant medical and psychiatric problems have been reported for subjects using these drugs [13],
regardless of previous psychiatric antecedents [14].
This paper will focus on a rare, and therefore, poorly understood aspect of hallucinogen
consumption: the total or partial recurrence of perceptual disturbances that appeared during previous
hallucinogenic “trips” or intoxications and re-emerged without recent use [4,5]. These returning
syndromes are deﬁned “benign ﬂashbacks”, or pervasive Hallucinogen Persisting Perception Disorder
(HPPD). LSD is the model and prototype of the classical synthetic hallucinogen, and it is certainly
the most explored and investigated substance associated with the etiology of this unique and
captivating state [15]. HPPDs do not have a notable prevalence [16], and, therefore, they are frequently
unrecognized [17,18].
Classiﬁcations used to delineate and outline persisting perceptual disorders are now clearer than
in the past [18]. Two major subtypes of hallucinogenic substance-use related recurring perceptual
disturbances have been identiﬁed and reported [18]: (1) HPPD I, also described and named as benign
Flashback and Flashback Type; and (2) HPPD II, also named HPPD Type II [17,18]. HPPD I has a
short-term, reversible and benign course. Although visual images may provoke unpleasant feelings,
re-experiencing the ﬁrst hallucinogen intoxication may not lead to signiﬁcant concern, distress, and
impairment in individual, familial, social, occupational, or other important areas of functioning [17,18].
The impairment is mild and the prognosis is usually good. Some of the patients do not report being
annoyed by these phenomena: they may indeed consider them as “free trips” resembling psychedelic
experiences without consuming a psychoactive substance. Contrarily and conversely, HPPD II has a
long-term, irreversible or slowly reversible and pervasive course [17,19]. The impairment of HPPD II
is severe and the prognosis is worse. Some of the patients fail to adapt and live with these long-lasting
recurrent “trips”, and a consistent fraction needs to be constantly treated [19,20]. It has to be considered
that the distinction between HPPD type I and HPPD type II has not yet been made in the Diagnostic
and Statistical Manual of Mental Disorder, ﬁfth edition (DSM-5) and it is still debated. HPPD type I
is consistent with the diagnostic deﬁnition expressed by the International Classiﬁcation of Disease,
10th (ICD-10), while HPPD type II better matches the DMS-5 criteria.
A vast list of psychoactive substances has been identiﬁed and linked with the development of
this condition, including Magic Mushrooms (psilocybin) [21] and muscimol (Amanita muscaria (L.)
Lam.) [22]; San Pedro cactus and Peyote (mescaline) [16,23]; ketamine [24]; dextromethorphan [25];
MDMA and MDA [26]; and cannabis and synthetic cannabinoids [27–33]. This condition has also been
associated with the consumption of Ayahuasca, Datura stramonium L., Salvia divinorum Epling & Játiva,
and Tabernanthe iboga (L.) Nutt., which contains ibogaine [17,18]. It is, therefore, clear that HPPD is not
strictly associated with psychedelic consumption, but a number of hallucinogen-inducing substances
may be correlated with its arising.
The aim of the present study is to review all the original studies about HPPD in order to evaluate
(1) the possible suggested etiologies; (2) the possible hallucinogens involved in HPPD induction; (3) the
clinical features of both HPPD I and II; (4) the possible psychiatric comorbidities; and (5) the available
and potential therapeutic strategies.
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2. Materials and Methods
We searched PubMed to identify original studies about psychedelics and Hallucinogen Persisting
Perception Disorder (HPPD). The following search terms were used: “Hallucinogen Persisting
Perception Disorder” OR “Hallucinogen Persisting Perceptual Disorder”. The search was conducted
on 15 September 2017 and yielded 46 records. We included all original articles (open-label or
double-blind trials, prospective or retrospective observational studies, and case reports) written
in English. We included all studies describing perceptual distortions in patients with a previous
history of substance consumption. Reviews, commentaries, letters to the editor, and studies enrolling
adolescents were excluded. All the authors agreed on the inclusion and exclusion criteria. We excluded
17 records by reading the titles and abstracts. By reading the full texts of the 29 remaining articles,
we found 25 papers meeting our inclusion/exclusion criteria, and we, therefore, included them in the
qualitative synthesis (Figure 1).
Abstractsȱidentifiedȱthrough
PubMedȱsearchingȱ(n =ȱ46)
FullȬtextȱarticlesȱassessedȱforȱ
eligibilityȱ(n =ȱ29)ȱ
FullȬtextȱarticlesȱexcluded,ȱwithȱreasonsȱ(n =ȱ4):
Ȭ FullȬtextȱunavailableȱ(n =ȱ2)
Ȭ Inȱvitroȱ(n =ȱ1)
Ȭ Othersȱ(n =ȱ1)
FullȬtextȱarticlesȱincludedȱinȱ
qualitativeȱsynthesisȱ(n =ȱ25)
Abstractsȱexcludedȱ(n =ȱ17):
Ȭ ReviewȱandȱExpertȱOpinionȱ(nȱ=ȱ10)
Ȭ LettersȱtoȱEditorȱ(n =ȱ3)
Ȭ Adolescentsȱ(n =ȱ1)
Ȭ Languageȱ(notȱinȱEnglish)ȱ(n =ȱ3)
Figure 1. Flow-chart describing the data collection process.
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3. Results
3.1. Suggested Etiologies
HPPDs are poorly understood due to the enormous range and variability of recurrent sensory
disturbances, and the multiple distinct subtypes [17,18].
The main neurobiological hypothesis is that LSD consumers might develop chronic disinhibition
of visual processors and dysfunction in the function of the central nervous system (CNS) [4,34–36].
This disinhibition may be linked to an LSD-generated intense current [37] that may determine the
destruction or dysfunction [18] of cortical serotonergic inhibitory interneurons with gamma-Aminobutyric
acid (GABAergic) outputs, implicated in sensory filtering mechanisms of unnecessary stimuli [34–36,38].
The efficacy of some treatment options in a subject withHPPD, such as pre-synapticα2 adrenergic agonists,
selective serotonin reuptake inhibitor (SSRIs), benzodiazepines, and mood stabilizers would confirm this
neurobiological hypothesis (see Section 3.2). Reverse tolerance or sensitization that emerges after LSD
exposure may explain recurrent occurrences after the stimulus has been withdrawn [39]. Nonetheless,
HPPD-like experiences, such as flashbacks, moments of derealization, and hyper-intense perceptions are
reported in healthy populations and non-LSD exposed subjects [40]. Moving from biochemical receptor
interactions towards macroscopic areas, a temporary or permanent impairment in the Lateral Geniculate
Nucleus (LGN) has been hypothesized [4,41–43]. The LGN, which is located in the thalamus, is associated
with visual perception pathways [41–43]. Recent research highlighted a brain dysfunction in patients with
visual snow, located mainly in the right lingual gyrus [44], perhaps implying LSD involvement. Halpern
et al. [40] suggested that HPPD can be due to a subtle over-activation of predominantly neural visual
pathways that worsens anxiety in predisposed subjects after ingestion of arousal-altering drugs, including
non-hallucinogenic substances. According to Holland and Passie, environmental triggering by specific
situations or stimuli or other elements related to the original experience may be involved in flashback
experiences [45].
3.2. Substances That Induce HPPD
Different substances have been associated with visual and perceptual disturbances (Table 1).
Table 1. Substances that induce Hallucinogen Persisting Perception Disorder (HPPD).
Authors Cases (n) Substances InducingPerceptual Disturbances Trigger Cues
Zobor, 2015 [29] 1 Cannabis
Gaillard, 2003 [46] 2 Cannabis
Lerner, 2014 [47] 2 Cannabis (Synthetic)
Anderson, 2017 [48] 1 Cannabis and MDMA Stress
Brodrick, 2016 [49] 1 Cannabis and LSD
Coppola, 2017 [50] 1 Cannabis (Synthetic, JWH-122) Cannabis consumption
Lerner, 2003 [51] 16 LSD
Lerner, 2002 [20] 1 LSD
Lerner, 2000 [52] 8 LSD
Gaillard, 2003 [46] 1 LSD Alcohol intake
Lev-Ran, 2017 [53] 40 LSD Sexual intercourse or Intentional
Hermle, 2012 [54] 1 LSD Stress
Lerner, 2014 [19] 2 LSD
Abraham, 2001 [35] 38 LSD Dark environment
Litjens, 2014 [26] 31 LSD
Lerner, 2015 [55] 1 LSD
Baggott, 2011 [56] 104 LSD
Lev-Ran, 2015 [57] 37 LSD
Lev-Ran, 2014 [58] 12 LSD Situation and mental states
Lerner, 1997 [59] 2 LSD
Abraham, 1996 [34] 3 LSD
Espiard, 2005 [21] 1 PCP Cannabis consumption
Lauterbach, 2000 [60] 1 Risperidone
MDMA: 3,4-methylenedioxy-N-methylamphetamine; LSD: lysergic acid diethylamide; JWH-122: 4-methyl-1-
(naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone.
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According to the literature, we found that the majority of HPPD cases have been induced by LSD
or phencyclidine (PCP) (14 studies, 294 patients) [17,19,21,26,35,46,51–53,55–59].
The use of cannabis has been associated with the development of perceptual distortions in seven
patients [29,46,48,49,61]. In one case, it was associated with 3,4-Methylenedioxymethamphetamine
(MDMA) and in another case with PCP [48,49]. In two patients, visual distortion followed the
consumption of synthetic cannabinoids [61].
Lauterbach et al. reported the unique case of HPPD induced by the atypical antipsychotic
Risperidone [60].
3.3. Clinical Features
According to DSM-5, Hallucinogen Persisting Perception Disorder is the recurrence of perceptive
disturbances that ﬁrstly develop during intoxication. The contents of the perception and visual
imagery range extensively [17,19]. DSM-5 and previous DSM editions report a list of the most common
symptoms experienced by HPPD patients, but only a few symptoms have been described in the
professional literature. The main group of symptoms reported by Criterion A of the DSM-5 are
visual disturbances. In fact, as in the vast majority of induced psychoses, visual hallucinations are
notably more common than auditory [3]. Regardless, every perceptual symptom that was experienced
during intoxication may re-occur following hallucinogen withdrawal. We report a list of the main
literature-reported visual disturbances in Table 2.
A latent period may antecede the onset of returning visual occurrences. This latent period may
last from minutes, hours, or days up to years, and re-emerge as either HPPD I or II with or without any
recognized or perceived precipitator [17,19]. Episodes of HPPD I and II may appear spontaneously or
they may be triggered by identiﬁed and non-identiﬁed precipitators [18]. Episodes may be continuous,
intermittent, or sudden. With regards to this point, neither HPPD I nor HPPD II can really be considered
as persisting in a narrow sense of the word. Additionally, their differential diagnosis can only be
proposed in terms of prognosis rather than clinical presentation.
However, HPPD I usually onsets with warning “auras”, minor feelings of self-detachment, mild
bewilderment, and mild depersonalization and derealization [17,18]. Conversely, the onset of HPPD II
might be unexpected and abruptly detonate with bursting “auras”, deep feelings of self-detachment,
acute depersonalization-derealization [19].
The frequency of recurrence of perceptual distortions is lower for HPPD I than HPPD II [18].
Prior substance users can voluntarily elicit or produce visual disturbances with or without known
triggers [4,17,18]. After HPPD II onset, hallucinogenic events tend to occur more frequently, and their
duration and intensity increase. Subjects might perceive a partial or total loss of control.
Table 2. A representative, but not exhaustive, list of reported visual disturbances.
Symptom Description
Symptom Reported by Diagnostic and Statistical Manual of Mental Disorder, ﬁfth edition (DSM-5)
Visual hallucinations Perceptions in the absence of the objects. False perceived objects are often geometricﬁgures.
Altered motion perception False perceptions of movement in the peripheral visual ﬁelds
Flashes of color
Color enhancement Perception of intensiﬁed colors
Trails or tracers
Lines, stripes or bands that could be observed after animate and inanimate objects
have already moved from their previous location. According to DSM-5, images left
suspended in the path of a moving object as seen in stroboscopic photography
Palinopsia Positive afterimages that continue to appear in one’s vision after the exposure to theoriginal image has ceased.
Halos Colored light around a light source or an object
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Table 2. Cont.
Symptom Description
Micropsia Misperception of images as too small
Macropsia Misperception of images as too large
Common Symptoms Not Reported by DSM-5
Floaters Spots that seem to drift in front of the eye
Visualizations Dots, points, particles, mottles or specks emerging in an obscure room
Fractals Self-similarity perception or small parts that are seen having an equal and identicalshape or form as the whole
Repetitions Recurrence of inanimate or moving patterns or motives
Keenness Undimmed color contrasts
Pareidolia An image within an image like the imagery of objects or faces in a foggyarrangement
Superimpositions Superimposed or overlapped geometric patterns
Distorted Perception of Distance Objects were seen slightly closer or distant
Monochromatic Vision The visual perception of distinct colors as one unique color with different tinges andtonalities
Intense fragmentation The sense of disintegration of still or moving objects
Recurrent Synesthesia Stimulation of one sensory pathway leads to automatic, involuntary reactions orexperiences in a second sensory pathway
Geometric Phosphenes Seeing light without light penetrating the eye.
Imagistic Phosphenes
Casual and unplanned formed images like non-humans (zoopsia) and human faces
without geometric patterns or ﬁgures provoked by closing an eye and pressing it
with a ﬁnger
Acquired Dyslexia Difﬁculty with reading notwithstanding normal intelligence
Aeropsia or Visual Snow Virtually seeing particles of air
3.4. Mental Illnesses Comorbid with HPPD
Recent observations reported a co-occurrence with depressive [20] and anxiety traits [51]
and severe mental illnesses such as Major Depressive Disorder [23], Bipolar Disorder [23,62], and
Schizophrenia Spectrum Disorders [17,58]. However, HPPD I and HPPD II onsets are not necessarily
accompanied by any prominent additional psychiatric disorder, thus representing an independent
condition [17,18]. In particular, the onset of HPPD II is often linked to a clear negative mood and
affect. Anxiety and depressive features might aggravate new episodes. Anxiety might also evolve
into a panic attack. Anticipatory anxiety may antecede future visual aberration events, and avoidant
behavior may limit and restrict regular normal functioning [17,18]. Recently, in a study carried out by
Halpern, a comprehensive survey of 20 subjects reporting Type-2 HPPD-like symptoms was presented
and evaluated. The dissociative symptoms were consistently associated with HPPD, suggesting that
HPPD is in most cases due to a subtle over-activation of predominantly neural visual pathways
that worsens anxiety in predisposed subjects after the ingestion of arousal-altering drugs, including
non-hallucinogenic substances. The authors report that many perceptual symptoms reported were
not ﬁrst experienced while intoxicated, and are partially associated with pre-existing psychiatric
comorbidity, tempering the direct role of hallucinogens in the etiopathology of the disorder [40].
Only two observational studies and one case report evaluated psychotic patients with comorbid
HPPD [57,58,60] (Table 3). Two observational, cross-sectional studies compared schizophrenic patients
with prior use of LSD who developed HPPD (SCZ+HPPD, 49 patients) with those who did not (SCZ,
57 patients), for a total of 106 patients [57,58]. No differences between the two groups have been
found with respect to demographic characteristics, age of psychotic onset, age of drug use onset,
and type of substances abused [57,58]. As expected, SCZ+HPPD patients reported more distressing
and horriﬁc LSD experience (“bad trips”) (p < 0.05) [57]. Interestingly, the positive subscale of the
Positive and Negative Syndrome Scale (PANSS) did not differ between the two groups. On the
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contrary, SCZ+HPPD patients showed lower scores in the PANSS negative subscale, the PANSS
General Psychopathology Subscale, and the PANSS total scores (p < 0.05) [57]. Moreover, 67% of the
schizophrenic patients comorbid with HPPD were able to distinguish between perceptual distortion
and psychotic hallucinations [58], and 9 out of 12 patients could identify precursory cues for perceptual
distortion (substance-induced cues, situational cues, and mental cues) [58]. Lauterbach et al. [60]
reported a case of HPPD comorbid with psychosis, in which visual distortions were induced by
antipsychotic treatment. Interestingly, the patient did not report any history of previous substance
abuse [60]. The patient was treated with Risperidone, Clonazepam and Trazodone, and she reported
visual disturbances resembling HPPD, in particular, illusions, after three subsequent Risperidone
dosage increases [60].
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3.5. First-Line Medications
Pre-synaptic α2 adrenergic agonists are a treatment with a low side-effect proﬁle for patients with
a previous history of substance-related disorders. Symptoms alleviation has been reported in some
patients treated with these drugs [17,18,52,63]. The effectiveness may be based on the evidence that
clonidine may elevate plasma GABA levels in humans, having a benzodiazepine-like effect. Clonidine
may also decrease locus coeruleus activity, leading to a reduction of adrenergic activity [64], which can
be effective in the management of PTSD [65]. Therefore, as in PTSD-related recurring ﬂashbacks, some
visual disturbances could be associated with excessive sympathetic nervous activity. Thus, these visual
distortions could be ameliorated by Clonidine [52,63].
A dosage of 0.75 mg/die of Clonidine has been evaluated as a treatment option for nine HPPD
patients [51,59] (Table 4). The total remission has been reported in a single patient with ﬂashbacks and
anxiety treated with 0.25 mg of Clonidine three times a day for two months [59]. In the 2 months open
study on eight HPPD patients, the Clinical Global Impression (CGI) and Patient’s Severity Perception
signiﬁcantly decreased between entry and endpoint scores [51], although two patients dropped out at
week 3 and week 5, respectively [52]. Lofexidine (0.2–0.8 mg/day) is a sympatholytic centrally acting
α2 presynaptic adrenergic agonist that showed similar efﬁcacy in some cases [23,65,66].
Benzodiazepines may be useful and effective in eliminating benign HPPD I and ameliorating, but not
completely eradicating, pervasive HPPD II symptoms [18,67]. The effectiveness of Benzodiazepines may be
related to their activity on the cortical serotonergic-inhibitory inter-neurons with GABAergic outputs [2,4].
Alprazolam (0.25–0.75 mg/day) has been prescribed with some success and Clonazepam (0.5–1.5 mg/day)
appears to be the most reliable and effective benzodiazepine even at low doses [17,18,51,67]. Higher doses
(4 mg/day) have also been used with good outcomes [68]. Clonazepam may act on serotonergic systems,
improving, enhancing, and augmenting transmission [17,18,51,67], thus promoting alleviation and a
marked improvement [51,67]. Clonazepam has been evaluated in three case reports and one open-label
trial by Lerner [19,50,51]. In the clinical trial, 16 HPPD patients were treated with a Clonazepam dosage of
2 mg/day [51]. Their symptoms improved significantly after treatment initiation and the improvement
persisted during a 6-month follow-up after treatment discontinuation [51]. The same author reported two
cases of cannabis-induced visual disturbances and correlated anxiety features. In both cases, Clonazepam
(2 mg/day) was effective in improving symptoms, but focal visual disturbances without anxiety (trailing
phenomena in one case, and black moving spots in the second case) persisted during and after therapy [19].
More recently, Clonazepam (6 mg/day) has been proved to be effective in improving cannabis-induced
HPPD symptoms [50]. On the other hand, the intrinsic abuse potential of benzodiazepines might be
inconvenient in certain individuals with a past history of substance use [17,18]. Given the benign nature of
HPPD I, the use of benzodiazepines should be proposed only for severe cases, in the acute phase, and for
the short term.
HPPD patients appear to be sensitive to ﬁrst-generation antipsychotics at low doses, requiring
monitoring of extrapyramidal side effects. Haloperidol [69] and Triﬂuoperazine [70] were reported to
be helpful. Perphenazine (4–8 mg/day) [17,23], Sulpiride (50–100 mg/day) [23], and Zuclopenthixol
(2–10 mg/day) [17,23], at very low doses, are well tolerated and may be an effective treatment. Some of
the long-acting ﬁrst-generation antipsychotics may still be useful in co-occurring Psychotic Spectrum
Disorders and HPPD II [58]. In one study, haloperidol was noted to reduce hallucinations, but an
exacerbation of ﬂashbacks in the early phases of treatment was highlighted as well [1,69].
The use of second-generation antipsychotics in HPPD patients without comorbid psychotic
disorders is debated. Anderson recently reported the case of a young woman presenting prolonged
and distressing multimodal pseudo-hallucinations, depressive symptoms, and anxiety, who was
treated with Risperidone for three months without any signiﬁcant improvement [48]. At the same time,
conﬂicting evidence exists on the antipsychotics effects in psychotic HPPD patients. One study did
not report differences in antipsychotic treatment response between SCZ and SCZ+HPPD patients [58].
On the other hand, a more recent study has shown the ineffectiveness of antipsychotic medications in
an SCZ+HPPD population [57].
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Risperidone was usually prescribed due to its proven efﬁciency in the treatment of perceptual
disturbances in Psychotic Spectrum Disorders, mainly in Schizophrenic Disorders. LSD seems to work
as a partial agonist of postsynaptic serotonin receptors. Therefore, Risperidone, which is a strong
antagonist of both postsynaptic 5-HT2 and D2 receptors, was expected to be convenient. In contrast
with this supposition, Risperidone at recommended [71] and lower doses [72] worsens visual
disturbances and accompanying anxiety, or does not show any effect [54]. This was presumably due to
Risperidone’s α2 presynaptic antagonism and noradrenaline release [34]. In addition, Risperidone was
associated to the re-experiencing of visual disturbances in some patients suffering from schizophrenia
with a past history of LSD use [73]. One psychotic patient treated with Risperidone, Clonazepam,
and Trazodone reported visual disturbances resembling HPPD after three subsequent Risperidone
dosage increases [60]. At the same time, Risperidone has been shown to be effective in improving
PCP-induced HPPD with anxiety in one patient, while in the same patient Olanzapine produced
symptoms exacerbation [21].
Evidence not included in our systematic review suggested that low dosages of atypical
antipsychotics may be useful, speciﬁcally Aripiprazole (5–10 mg/day) [23], also because of its efﬁcacy
in substance and alcohol use disorders [74].
Visual oddities and disturbances with sudden paroxysmal onset have been interpreted as visual
seizures and prompted the use of antiepileptic drugs in HPPD. This consideration helped to explicate
the efﬁcacy of benzodiazepines and led to the prescription of Phenytoin [75,76]. Today, Phenytoin is
not used for HPPD treatment due to its troubled side effect proﬁle. Medications such as Valproic Acid
(200–600 mg/day), Carbamazepine (200–600 mg/day), Oxcarbamazepine (300 mg/day), Gabapentin
(300–900 mg/day), Topiramate (25–100 mg/day), and Lamotrigine (50–100) may be useful [23],
also because of their efﬁcacy in substance and alcohol use disorders [77–79]. In a single case of HPPD
symptoms and electroencephalographic (EEG) abnormalities, compatible with toxic encephalopathy,
the visual hallucinations that recurred at any alcohol ingestion improved, but did not disappear
with the use of Valproic Acid (1500 mg/day) [46]. Levetiracetam has shown to reduce some visual
symptoms as well as HPPD related-depersonalization and derealization [80]. Lamotrigine has shown
to be efﬁcacious in a recent severe case of HPPD with some EEG abnormalities (Anderson et al., 2018).
These medications may also be helpful when visual disturbances are accompanied by co-occurring
mood swings and mood disorders.
Antidepressant medications could help in the management of co-occurring HPPD II with anxiety
and depressive disorders [17,18,20,51,67]. HPPD II alone does not appear to be an appropriate
target. There are questionable and controversial results regarding Sertraline, which has been
reported to worsen [81] as well as to improve visual disturbances. Amelioration following long-term
administration of SSRIs was attributed to the down-regulation of 5-HT2 receptors, providing more
evidence to corroborate the serotonergic mechanisms underlying this condition. Other prescribed
SSRIs did not show any beneﬁts. Norepinephrine reuptake inhibitors (NRIs) such as Reboxetine have
been tried with some success in LSD-induced HPPD symptoms comorbid with Major Depressive
Disorder [20]. Agomelatine, given its peculiar function on neurotrophic factors [74], could have some
beneﬁts on the syndrome, although no data are available until now.
3.6. Second Line Medications
Naltrexone has been usually used, alone or with other medications, in chronic patients with
continuous visual imagery that previously did not respond to other medications [17,18].
Calcium Channel Blockers and Beta Blockers may be helpful in patients with co-occurring HPPD
II and anxiety disorders [18]. Propanolol at low (20–60 mg/day) and high doses (240 mg/day),
as well as Atenolol 25–50 mg/day, have been used to diminish accompanying anxiety of visual
imagery [18,23]. Investigations of HPPD patients with EEG mapping showed that HPPD is represented
by disinhibition [35] in the cerebral cortex [34]. The rationale behind this interesting and novel
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approach is that improving sensory gating by dopaminergic enhancers may cause an inhibition of
catechol-O-methyl transferase (COMT), that may improve HPPD symptomatology.
3.7. Brain Stimulation Treatments
Currently, brain stimulation treatments have been proposed as a possible therapeutic option to
enhance the recovery of refractory symptoms in several disorders [82,83]. Repetitive Transcranial
Magnetic Stimulation (rTMS) is a non-invasive brain stimulation approach that acts by modulating
speciﬁc brain circuits. While high-frequency (>5 Hz) stimulation determines a depolarization of nerve
cells, with long-term potentiation (LTP) effects, low-frequency stimulation protocols (1 Hz) determine
the long-term depression (LTD) of the targeted area, with the possibility to induce the localized
inhibition of speciﬁc disordered networks. According to the cortical hyperexcitability hypothesis about
its pathogenesis, several case reports propose that rTMS could be a promising therapeutic method for
refractory visual hallucinations in schizophrenia [84,85].
To date, no studies have investigated the potential use of rTMS in HPPD. Interestingly, Kilpatrick
and Ermentrout (2012) [86] studied the spatiotemporal dynamics of neuronal networks in HPPD, with
spike frequency adaptation. This study reported that altering parameters controlling the strength of
synaptic connections in the network can lead to spatially structured activity suggestive of symptoms
of HPPD. Future research is necessary to test the possible effectiveness of the rTMS neuromodulatory
effect on HPPD. Putative targets of stimulation could be hypothesized to be located in the visual cortical
areas, as well as in the occipitotemporal sulcus [87]. Functional neuroimaging may be beneﬁcial in
localizing a speciﬁc target for stimulation and may prevent wasting time and money on targets which
are not as likely to be involved in the pathogenesis.
4. Discussion
It has to be highlighted that a limitation of the study might be represented by the search method:
in fact, we decided to limit the literature search to the DSM terminology in order to exclude simple
“ﬂashback phenomena” that are commonly reported in psychopathology, and that may not follow the
use of hallucinogens. This could have narrowed the results, preventing the inclusion of other studies
using the ICD terminology, which is less “technical” about the issue.
The main consideration that has to be done with respect to HPPD is its rare and unpredictable
nature [16]: current prevalence estimates are unknown, but DSM-5 suggests 4.2% [88]. The condition
is more often diagnosed in individuals with a history of previous psychological issues or substance
misuse [56], but it can arise in anyone, even after a single exposure (mostly to LSD, but it has also been
reported after use of other psychedelics) [89]. In many cases, HPPD may also be explained in terms
of a heightened awareness of and concern about ordinary visual phenomena, which is supported by
the high rates of anxiety, obsessive-compulsive disorder, hypochondria, and paranoia seen in many
patients [90].
The crucial movement towards a comprehensive clinical understanding of Hallucinogen
Persisting Perception Spectrum Disorders (HPPSD) [23] is the establishment of an accepted operative
nomenclature. This wide spectrum of disorders encompasses different subtypes, ranging from HPPD I
to HPPD II, according to our hypothetical distinction. Among the innumerable triggers able to
precipitate HPPD, prospectively, the use of natural and synthetic cannabinoids appears to be the most
frequent. This is consistent with the rapid and vast diffusion of these novel psychoactive compounds,
nowadays easily available without speciﬁc cultural ﬁlters and references [91,92]. Distinct substances,
with completely different mechanisms of action, might lead or precipitate the genesis of HPPD,
therefore suggesting a multifaceted etiology. Thus, it is accordingly conceivable that different
medications could be useful and helpful in the treatment of different subtypes of HPPD. Tracers
and trailing phenomena appear to be the most resistant symptoms. Concomitant coexisting psychiatric
disorders can represent a further clinical challenge, with the clinical construct of the lysergic psychoma
as a possible heuristic model. According to this theory, the presence of induced psychopathological
68
Brain Sci. 2018, 8, 47
phenomena (the Psychoma) may trigger a speciﬁc reaction excepted by the not-affected part of the
mind, trying to counteract the psychoma, which is perceived as a “foreign body in the mind”. Of course,
when the psychoma is strong and repeated in its nature, the possibility to determine a full-blown
psychosis may become more concrete [93,94].
Regarding treatment options, a combination of medications may be needed according to the
preceding or subsequent psychopathology. Given the limited literature about HPPD, a possible
hypothesis about the pharmacotherapy of choice in relation to different etiologies has not been
considered. However, the presence of psychiatric and neurological comorbidities could represent
a valid criterion to address the choice. Clinical experience and an extensive and comprehensive
knowledge of these phenomena are vital for successful treatment outcomes.
Controlled clinical investigations are mostly needed in order to better understand the etiology,
mechanisms of action, clinical issues, and pharmacological treatment options for Hallucinogen
Persisting Perception Spectrum Disorders (HPPSD).
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Abstract: Substance misuse services need to meet the growing demand and needs of individuals
using new psychoactive substances (NPS). A review of the literature identiﬁed a paucity of
research regarding NPS use by these individuals and UK guidelines outline the need for locally
tailored strategies. The purpose of this qualitative study was to identify and explore key themes
in relation to the use of NPS by individuals receiving community treatment for their substance
use. Electronic records identiﬁed demographics and semi-structured interviews were undertaken.
A thematic analysis of transcripts identiﬁed a variety of substance use histories; 50% were prescribed
opiate substitutes and 25% used NPS as a primary substance. All were males, age range 26–59 years
(SD = 9), who predominantly smoked cannabinoids and snorted/injected stimulant NPS. The type
of NPS used was determined by affordability, availability, side-effect proﬁle and desired effects
(physical and psychological: 25% reported weight loss as motivation for their use). Poly-pharmacy,
supplementation and displacement of other drugs were prevalent. In conclusion, NPS use and
associated experiences vary widely among people receiving substance use treatment. Development of
effective recovery pathways should be tailored to individuals, and include harm reduction strategies,
psychosocial interventions, and effective signposting. Services should be vigilant for NPS use,
“on top” use and diversion of prescriptions.
Keywords: new psychoactive substances; substance use; cannabinoids; stimulants; substance misuse
services; substance use treatment; psychosocial interventions; harm reduction
1. Introduction
“New Psychoactive Substances” (NPS) is “a generic term for . . . substances produced to mimic the
effects of traditional illicit drugs” [1]. Formerly known as “legal highs”, NPS have dramatically changed
the UK drug scene and introduced a new challenge for healthcare professionals (HCPs) [2]. The internet
and the media may have had a signiﬁcant impact on the proliferation of this market. A study by Bright
et al. (2013) showed that the media played a signiﬁcant role in increasing the public’s awareness of new
NPS, which sparked curiosity and increased use. This, in turn, created a media “moral panic”, resulting
in legislative reactions, which led to the emergence of more harmful substances [3]. At a global level,
NPS are unregulated products with unpredictable effects and clandestine chemists continuously
and rapidly produce newly modiﬁed compounds [4]. The analysis of NPS products have found
controlled substances, mixtures of active substances and different constituents even from the same
supplier and using the same “brand” name [1,4,5]. People who use NPS present with unpredictable
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adverse effects, creating a dilemma for HCPs [6]. Previously, NPS were often labelled as “not for
human consumption”, so that under the Medicines Act 1968, manufacturers of NPS were not legally
required to list their ingredients or determine their safety [1,4,7,8]. The UK Government subsequently
introduced the Psychoactive Substances Act (UK PSA) in May 2016, to prohibit NPS sale, supply,
production, possession with intention to supply or possession in a custodial institution, with an aim to
reduce use [9,10].
Owing to their continuous emergence and sheer numbers (increased from 166 substances in 2009
to over 740 in 2016) [11], NPS are categorized based on their chemical class [12], legal status [13] or
chemical structure [14]. However, in clinical practice, NPS aremore commonly considered in the context
of their pharmacological effects and the substances they have been designed to replicate. Public Health
England (PHE) [15] therefore categorizes NPS as: sedating, stimulating, hallucinogenic, cannabinoids,
dissociative and “other” (not otherwise speciﬁed). Consequently, these PHE categories [15] are
used by substance misuse services (SMSs) to record information on the National Drug Treatment
Monitoring System (NDTMS) [16], which enables the monitoring of people receiving treatment and
national comparisons.
There are a variety of guidelines available to support HCPs working in mental health and SMSs,
such as those produced by the Department of Health [17] and the Novel Psychoactive Treatment UK
Network (NEPTUNE) [4]; however, none cover speciﬁc details for all NPS categories. Due to their
“novelty”, there is a lack of clinical data to support an evidence-based approach to the management of
individuals who use NPS [1]. Recent studies have shown that HCP baseline knowledge of NPS is poor
and that they are less conﬁdent in managing acute toxicities related to the use of NPS compared with
traditional illicit drugs [18,19]. Reports by both the Care Quality Commission and the HM Inspectorate
of Probation showed that SMSs did not offer NPS-speciﬁc interventions and that people who use
NPS poorly engaged [20]. Similarly, in Europe, HCPs in Italy within addiction, psychiatry, pediatrics
and A&E services also reported a lack of knowledge and conﬁdence with regards to NPS. They also
afﬁrmed that no questions are asked when taking drug histories during admission [2].
To understand the motivation for using NPS by individuals registered within SMSs, a detailed
electronic search of NHS evidence was undertaken using the Allied and Complementary Medicine
(AMED), Excerpta Medica Database (EMBASE), Health Management Information Consortium (HMIC),
British Nursing Index (BNI), Cumulative Index to Nursing and Allied Health Literature (CINAHL),
Medline, PsycInfo and Health Business Elite databases. This identiﬁed that the rapid proliferation
of NPS use may be changing drug taking habits (by displacing or supplementing pre-existing drug
repertoires), and may be affected by availability, price, purity and legal status [1,7,21,22]. In Ireland, in
depth interviews found people switching from illicit substances to “legal” NPS, due to perceptions
regarding improved effects, safety proﬁle and overall higher quality for a lower price; however, the
individuals were aged 18–33 years [23] and adult SMSs frequently treat people who are older than this.
Another group of Irish interviewees were found to transition from nasal administration to injecting and
binged excessively for long durations on stimulant NPS, but after they became controlled substances,
their use reduced following headshop closures, increased prices and concerns about contamination [24].
Qualitative case reports of people using stimulant NPS in the UK, prior to the introduction of the
UK PSA 2016, suggested their euphoric effects may lead to “more persistent patterns of drug use”
due to their perceived legal status and poor quality of their illicit equivalents [21]. The analysis of
cryptomarkets such as Alpha Bay, Valhalla, Agora and Evolution Market Place has also allowed the
exploration of views and perspectives of vendors and customers on a large scale [25–28]. A study by
Van Hout and Hearne (2017) has identiﬁed that cryptomarket customers prefer the sequential and
concurrent use of psychedelics as well as NPSs, in particular, GABA (γ-aminobutyric acid)-activating
NPSs [29]. The study showed that research of these market place forums can provide an insight on
novel trends of NPS use. Similarly, in their study, Bright et al. (2013) utilized Google Trends as a data
collection tool of NPS-speciﬁc news and employed it to generate media links related to “Kronic”—a
Canadian brand known to contain cannabis. Interviewees stated that they are mainly motivated by the
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poor detectability of this substance at workplaces, which outweigh the unknown harms associated
with this substance [3].
In contrast, a ﬁeld study of people attending “gay dance clubs” in London, who may be considered
early adopters of new substances, found they were not deterred by changes in legislation and that
stimulant NPS were more popular than any other substance [30]. The same survey found their addition
to existing drug repertoires to supplement more established “club drugs” (e.g., ecstasy and cocaine),
rather than replacing or displacing them [30]; however, use was affected by availability and purity [22].
A survey of experienced users in Holland also found that people who preferred stimulant NPS were
undeterred by legal status and did not displace other illicit substances [31].
Perhaps the reasons for these conflicting findings is that individuals may not always be open or
honest about their substance use behaviors when questioned, and NPS packaging may not always contain
the expected substance [1,5,32]. Therefore, some novel approaches have been utilized, such as surveying
websites and online forums such as Facebook and Twitter [29,33]. The former study found that NPS were
used for pleasure, out of curiosity, alongside or as an alternative to other substances [33], whereas, the
latter highlighted the diverted use of prescription medicines and poly-drug use due to “high level of
social media engagement” [29]; however this methodology requires individuals to have internet access,
which may not always be possible for or desired by people who have problems with substances, for
example, if they are leading particularly chaotic lives or are homeless. Analyzing samples in isolation
also does not allow for exploration of confounding factors or perhaps more importantly, discussion with
individuals regarding their reasons for use, experiences with them or any treatment needs.
Historically, SMSs have focused on provision of services for people using crack-cocaine
and opiates because these substances previously dominated the UK drug market [15]. Currently,
people using NPS are increasingly presenting to SMSs with physical and psychological problems,
including dependency [4,8,21]. Researchers working at the Camden and Islington NHS Foundation
Trust studied 442 people who were engaging in substance use admitted to a mental health unit. The
sample comprised 58 people who use NPS among which, 32 initially presented to A&E, 29 involved
the police, 30 were sectioned under the Mental Health Act, and 46 presented with violence before and
during admission; most of them were poly-substance users [34]. SMSs therefore need to adapt and
change to meet the growing demand from people using NPS [8,35]. Once engaged, limited treatment
data suggests that individuals often respond well, with high rates of successful treatment completion
when compared to other substances [15]; however, concerns about poor engagement of high-risk
people who engage in risky NPS use (e.g., MSM (men who have sex with men)) with SMSs remain [36].
They may present elsewhere such as sexual health services; therefore, this data may not be captured
by NDTMS [37]. On general adult inpatient wards of a Scottish psychiatric hospital, NPS use was
found to be prevalent among 22% of young male inpatients, in particular those with drug-induced
psychosis and often used with other drugs including cannabis and prescribed opiate substitutes [38].
In Hungary, a study by Kapitány-Fövény et al. (2017) also outlined stimulant NPS prevalence among
individuals receiving opiate substitution therapy. The main reasons for NPS use were curiosity and
practical reasons (including availability) rather than psychopharmacological preferences [39].
Further research is required into the use of NPS by those attending SMSs as highlighted in the
2014 Home Ofﬁce review [1]. For example, a large Hungarian needle exchange program study found
that high risk drug users switched from injecting predominantly illicit amphetamine to NPS and the
study recommended further exploration of purity, price and availability [40]. In depth interviews of
eleven Irish high-risk stimulant NPS injectors recommended further investigation into their adverse
health effects and displacement of other drugs [24]. Some people in SMSs use non-stimulant NPS and
do not always inject, so further research is required, which should include all NPS types used via
different routes of administration. UK research is particularly lacking, and more is required because
SMSs, legislation and illicit drug supply chains can be very different to other countries.
As described above, published research, which deﬁnitively outlines the use of NPS by individuals,
who engage with specialist adult SMSs in the UK was lacking. Due to the paucity of research, this study
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will consequently have national and international resonance, contributing to existing knowledge of how
NPS may be changing drug taking habits and consequently positively impact upon current practice.
The aim of the study was to explore NPS use by individuals receiving treatment for substance use
by exploring their type and pattern of NPS use and associated positive and negative experiences.
2. Materials and Methods
In the South West Peninsula of England, the charities RISE (Recovery and Integration Service)
in Devon (excluding Plymouth and Torbay) and Addaction in Cornwall have been commissioned to
provide integrated specialist SMSs (where RISE is a subsidiary of Addaction, a national organization).
RISE and Addaction work with people regardless of which substance(s) they have a problem with.
They cover predominantly rural areas, where national data suggests that NPS use may be more
common [1,15], although the reasons for this are poorly understood. The use of NPS by the population
who engage with these services has not been investigated. This is required because, in accordance
with PHE guidance [15], an improved, local understanding of NPS use is important to enable the
development of an effective recovery pathway, which appropriately supports the needs of those
requiring treatment. There is limited information on international, national or local recovery pathways,
to which these SMSs can refer. Ethics approval was obtained from Aston University’s Life and Health
Sciences Ethics Committee on the 20 January 2015 (Project Identiﬁcation Code No. 726). The study
was reviewed and approved by Addaction/RISE internal governance processes on 13 February 2015.
Time was then taken to undertake the study and to seek approval for its publication.
2.1. Study Design: Methodological Orientation and Theory
This was an explorative, qualitative study using thematic analysis [41–44]. Purposive sampling [41,42],
where all eligible individuals (as outlined by the inclusion and exclusion criteria below) were identified
by their Recovery Co-ordinators (RC) and invited to participate in face-to-face in depth semi-structured
interviews [41,42], enabled a range of relevant views to be obtained. This methodology was chosen because
it is suited to exploring knowledge in poorly understood areas such as an individual’s use of NPS [41–44].
Such methodology has been shown to be successful in obtaining detailed information from individuals
regarding their NPS use [42–44]. This study has been reviewed and approved by Addaction’s internal
governance processes and Aston University’s Life and Health Sciences Research Ethics Committee.
Anonymizing results to protect conﬁdentiality and the use of the same researcher, who has no
prior knowledge of the interviewees (or ability to routinely impact on their care such as changes to
their prescribed treatment) should have increased the likelihood of individuals sharing their personal
views and experiences [42–44]. The interviews were conducted by a qualiﬁed pharmacist with many
years of experience of working in mental health and substance misuse services.
2.2. Study Design: Participant Selection and Setting
Potential participants were contacted by their RC (who identified that the person had experience
of NPS) and individuals were provided with an information sheet and consent form which provided a
full explanation of the study. The person’s ability to provide informed consent [45,46] and eligibility to
participate was confirmed immediately prior to the interview. The interviews took place at one of the
SMSs or established partner agency sites, where the individual usually attends for their treatment reviews.
The presence of non-participants such as the person’s RC was permitted if requested by the individual.
Inclusion criteria: Previous experience of using NPS and receiving community treatment
(pharmacological/psychosocial) for substance use with the charities RISE in Devon or Addaction
in Cornwall.
Exclusion criteria: In receipt of in-patient or prison services; known in a clinical capacity by the
Researcher; presented with signiﬁcant risk issues (after assessment by their RC); additional needs
could not be met (for example if they required an interpreter because their ﬁrst language was not
English and the SMS was unable to facilitate) or lacked capacity to consent: particular care was taken
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if the person was thought to have a disability, mental health problem or thought to be under the
inﬂuence of substances [47,48].
2.3. Study Design: Data Collection
Halo is the electronic record system utilized by SMSs in the South-West Peninsula of England.
Quantitative data was collated from the Halo system to identify key characteristics including the
participants age, sex, employment, housing status and primary substances they use (such as opiates,
cannabis, stimulants and alcohol), which the system classiﬁes in accordance with PHE [15] for the
NDTMS [16].
The interview guide (Supplementary Information 1 (SI1)) was piloted to ensure it was suitable
for use, and open questions were used to avoid leading the person’s responses. The piloting process
involved local SMS managers and experienced HCPs reviewing the questions. The interviews were
digitally recorded and fully transcribed verbatim [41]. The intention was to undertake approximately
twenty interviews to achieve a degree of data saturation, where no new or relevant information is
elicited; however, research suggests that as few as eleven or twelve may be required [49], and this was
found to be the case in this study.
2.4. Data Analysis
During the transcription process any potentially identifying information was deleted and only
Halo identification codes used to identify participants. Thematic analysis, which has been specifically
designed for applied qualitative research that commences deductively from specified aims and
objectives, was used to organize and make sense of the data using a framework approach [41–44].
Initially, a framework was developed from existing literature; this was then updated based on the new
data obtained from the interviews using a stepwise approach: (a) interviews were audio-recorded and
transcribed verbatim; (b) familiarization: initial recurrent themes were identified following immersion
in the transcripts; (c) coding: researcher applied line-by-line codes to describe key issues, concepts and
themes by which the data was examined and referenced; (d) developing an analytical framework: after
coding the initial transcripts, the researcher in consultation with supervisor, developed a set of codes that
could be applied to all subsequent transcripts. Codes were then grouped into categories; (e) applying
the analytical framework: data was attached to the framework of codes and categories; (f) developing a
framework matrix: to manage and summarize the data, it was put on to the framework to which the
data related. At this stage all transcripts were actively searched for results, which contradicted the key
conclusions; (g) data interpretation: the framework matrix was used to define concepts and discover
associations between the themes to provide explanations for the results; and (h) the end result was a
matrix of themes from each source.
3. Results
Twelve individuals participated in this study between July and September 2015 and their
demographic particulars are summarized in Table 1. All participants were in receipt of psychological
interventions, with an age range of 26–59 years (SD = 9; mean 37). Three people (all within Addaction
Cornwall) were known to the Criminal Justice Team as they were subject to Court Treatment Orders
(CTOs) for their substance use.
During the interviews, one participant (P9) was accompanied by his RC following his request.
Interviews had a mean duration of 11 min 23 s (with a range of 4 min 45 s to 24 min 57 s). No individuals
had additional needs, which required support during the interviews. The data was collated and
manually analyzed by the same researcher. When transcripts were independently reviewed for themes,
the findings were discussed, and no differences were identified.
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Using thematic analysis [41–44], data from the interview transcriptswere assigned to four core categories:
1. Substance use history;
2. Type and pattern of NPS use;
3. Positive experiences associated with NPS use;
4. Negative experiences associated with NPS use.
Thematic analysis [42–44] enabled further explorations of the data and identiﬁed sub-themes
which are evidenced in Tables 1–4, including participants’ quotations. A summary of the frequencies
of the sub-themes is presented in supplementary information (SI2).
1. Substance use history
Individuals described a wide range of substance use histories and were at different stages in their
recovery journeys; some described more complex histories and most used a variety of substances.
There were varying perceptions of the severity of their substance use and some described ongoing
entrenched behaviors:
“I’d been in accidents and the doctors had had me on codeine and dihydrocodeine and slow release morphine and stuff . . . I
just gradually got used to it over the years and years and years and because I didn’t have a regular doctor, I was seeing a
different doctor each time who just kept giving me scripts . . . My body got used to it and I just started taking more and
more . . . I’d just split up with my wife, and sort of going through a bit of a dodgy patch” P1
“I’m a recovering alcoholic . . . Anything that would go up my nose was going” P2
“Fertiliser–from off the farm . . . I inject heroin . . . tried every drug in the alphabet . . . got a crack addiction . . . started
having counselling . . . gotta get my life sorted . . . going to rehab . . . Childhood–stepdad beat me up . . . ” P3
“I fell in with the wrong crowd . . . I lost both my parents in a car crash so sort of went downhill and then sort of started
using heroin” P4
“Started taking mind altering substances when I was 16 . . . these 20 years . . . changing my mental state on a daily basis
. . . good help from a drug worker . . . got a job . . . more stable . . . My childhood trauma is what they think kind of led to
my habitual use of drugs” P5
“I can’t put drugs away . . . just work my way through them to the bitter end” P6
“I don’t really know why I take them anymore. I think it’s just a habit” P7
“I used to do it [speed-balling] quite a lot . . . since I was a kid . . . once a month or so, I might have a drink but nothing to
excess . . . never more than a bottle of whiskey” P11
2. Type and pattern of NPS use
Table 2. Type and pattern of NPS use. A list of all the themes and sub-themes, with respective quotes
by participants.
Participant Quote Theme Sub-Theme
P1
Plant food . . . Snorting it . . . Just a couple of times . . . it
wasn’t really something I got into heavily or used a lot . . .
just a couple of times . . . A mate of mine had it at his house
NPS type “Other” (not otherwisespeciﬁed) only
Source Friend only
Frequency Occasional
Route of administration Nasal only
P2
Sparkle . . . exodus . . . I’m injecting [i/v] . . . back of my
hands, my arms . . . I’m now snorting instead . . . I’m
surprised they [veins] haven’t collapsed yet to be fair . . . I
was taught by the best . . . Sat down for an afternoon . . .
talked process and cleanliness [injecting technique] . . .
About three or four [times a day] it used to be ﬁve or six . . .
I’m using another to come down on [synthetic cannabinoid]
. . . a couple of tokes . . . at the end of the session, however
many days that is-3 or 4 . . . I tend to get my money at the
beginning of the fortnight and I’ll plan out for it. I’m a
typical user . . . [from a headshop] It’s easier than buying,
chasing a dealer
NPS type Stimulating and Cannabinoid
Source Headshop only
Frequency
Daily (several times)
Binging
Route of administration Nasal and Intra-venous injection
Concomitant use Cannabinoid NPS to end stimulantNPS use
Preference
Accessibility
Avoid dealers
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Table 2. Cont.
Participant Quote Theme Sub-Theme
Harm reduction
Changed route of administration
Safer injecting training
Affordability Budgeting
P3
Mephedrone . . . Cherry Bomb [cannabis type] . . . speedy
. . . Gocaine . . . smoke . . . snort powder . . . banging up . . .
It was cheap . . . shops and online . . . you can buy it . . . in
a kilo and sell it off in ten bags . . . made a lot of money . . .
dealt loads
NPS type Stimulating and Cannabinoid
Source Headshop and Online
Route of administration Nasal, Smoking and Intra-venousInjection
Affordability
Cheap
Dealing
P4
Pink Panthers and Eisenberg . . . represent speed . . . uppers
. . . Black Mamba . . . I smoked them but I have been known
to inject a Pink Panther . . . I dibbled and dabbled . . . it
wasn’t an everyday thing, only you know once every 3 or 4
weeks . . . and then when I would come home, I would do a
bit of heroin to go to sleep . . . [head] shop
NPS type Stimulating & Cannabinoid
Source Headshop only
Frequency Occasional
Route of administration Smoking and Intra-venous Injection
Concomitant use Opiates to end stimulant NPS use
P5
[Speedy ones] the names they had for them were things like
Gogaine, or Posh . . . Stimulants were either taken orally or
snorted . . . if I was smoking synthetic cannabis, I would be
using tobacco with it . . . constantly . . . either be becoming
high on synthetic stimulants or coming down off that and
using synthetic cannabis . . . if I’d just been paid . . . in one
hit and then top up throughout the week . . . I go in there for
one thing, the temptation to buy something else . . . My
willpower was helped by a change of circumstances and that
change of circumstances in that the shop’s no longer
selling it
NPS type Stimulating and Cannabinoid
Source Headshop only
Frequency Daily (several times)
Route of administration Oral, Nasal and Smoking
Concomitant use
Cannabinoids with tobacco
Cannabinoid NPS to end stimulant
NPS use
Preference Accessibility
Affordability Budgeting
P6
The pot ones . . . Spice . . . Scorpion . . . Clockwork Orange
. . . Pandora’s Box . . . Toxic Waste . . . Smoking it neat in a
pipe . . . in a rolled cigarette . . . I found that the dosage is
important . . . I’d do very small amounts . . . I was writing
it down, how much I was doing, taking tiny puffs . . . I was
on methadone at the time . . . I substituted it [with NPS]
. . . At the newsagent, you were able to buy them pre-rolled
and my friend who smokes pot . . . headshop . . . online from
some dodgy retailer . . . Couldn’t get any marijuana
NPS type Stimulating and Cannabinoid
Source Headshop, Friend, Online andOther (newsagent)
Route of administration Smoking only
Concomitant use
Displacement (prescribed opiates)
Cannabinoids with tobacco
Preference Accessibility
Harm reduction Changed dose
P7
Diamond Dust, Lush, Sparkle [speedy types] . . . Crystal
. . . IV . . . In my arms . . . Since I’ve been doing legal highs
I haven’t touched it [heroin] . . . legal high shop
NPS type Stimulating only
Source Headshop only
Route of administration Intra-venous injection only
Concomitant use Displacement (illicit opiates)
P8
Low Rider, Cotton Candy, Strawberry Cough . . . cannabis
types . . . Smoking them, putting them into joints or into a
pipe . . . just this and tobacco . . . Every 20 min . . . buy it
in bulk of tens . . . headshop
NPS type Cannabinoid only
Source Headshop only
Frequency Daily (several times)
Route of administration Smoking only
Concomitant use Cannabinoids with tobacco
Affordability Bulk-buying
P9
Mephedrone . . . Devil’s Dust . . . an upper, a stimulant . . .
synthetic cannabinoids . . . IV [groin] . . . smoking
[cannabinoids] . . . No more often than once a day
[cannabinoids] . . . About every quarter of an hour
[stimulants] . . . obviously there were sleep breaks but it was
about a 6-month period . . . I didn’t withdraw from opiates
. . . it took me away from heroin . . . Group of friends and
from a chap
NPS type Stimulating and Cannabinoid
Source “Street dealer” and Friend
Frequency
Daily (several times)
Binging
Route of administration Smoking and Intra-venous Injection
Concomitant use Displacement (illicit opiates)
P10
The powders and the puff . . . Smoking it. Injecting it . . .
snorting everything . . . Stopped me drinking . . . no
withdrawals . . . Legal high shop . . . Dealers as well
NPS type Stimulating and Cannabinoid
Source “Street dealer” and Headshop
Route of administration Nasal, Smoking & Intra-venousInjection
Concomitant use Displacement (alcohol)
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Table 2. Cont.
Participant Quote Theme Sub-Theme
P11
Mephedrone . . . Methalone. A couple of hallucinogenic
ones. And the pills that they did . . . Hawaiian Woodrose
. . . They’re a seed basically and they’ve got an LSA in them
which is like a precursor to LSD . . . smoking . . . Usually I
would just have a couple of Valium [to help come down from
NPS] . . . Internet . . . It was just a sort of weekend thing
. . . Not very regularly.
NPS type Stimulating, Dissociative andHallucinogenic
Source Online only
Frequency Occasional
Route of administration Smoking only
Concomitant use Benzodiazepines to end NPS use
P12
Crystal, Boom Dust . . . Diamond Dust mephedrone . . .
smoke the cannabinoids . . . Lotus . . . The speedy ones . . .
Crystal Meth ones–the uppers . . . opiates from Italy . . . I
snort them . . . dabble them . . . Put it in your mouth, let it
dissolve . . . smoking if they’re the cannabinoid ones . . .
Putting it in with baccy, it makes it last longer . . . If you
mix them together, you hallucinate . . . It’s opportunist . . .
just down the road...just go to the shop and don’t get ripped
off by the drug dealers . . . every day.
NPS type Stimulating, Cannabinoid andSedating
Source Headshop only
Frequency Daily (several times)
Route of administration Oral, Nasal and Smoking
Concomitant use
Potentiating effects
Cannabinoids with tobacco
Preference
Accessibility
Avoid dealers
Affordability Cannabinoids with tobacco
3. Positive experiences associated with NPS use
Table 3. Positive experiences associated with NPS use. A list of all the themes and sub-themes, with
respective quotes by participants.
Participant Quote Theme Sub-Theme
P1
I wasn’t thinking about the ex-wife . . . The buzz . . . like
being drunk without the drink . . . fuzzy, happy, chilled out
sort of feeling
Psychological effects
Escapism
Relaxation
Happiness
Euphoria
P2
It allows me not to be me . . . Without them, I’m a totally
different person, I would never talk you right now without it
. . . allows me to be conﬁdent . . . Part of it was to lose
weight . . . I was 17 stone when I started out on it . . . just
10 times better than the drink . . . It’s stronger than street
Psychological effects
Escapism
Conﬁdence
Physical effects Weight loss
Preference
Strength
Quality
P3
They keep me awake when I was out clubbing . . . Was I
allowed to sell them? I thought I was cos it was legal
Psychological effects Alertness/Energy
Preference Legal status
P4
It was about a ﬁver whereas you go out and buy a gram of
coke and its 60 quid Preference Affordability
P5
Wanting to escape from reality any way, or change that
reality . . . [stimulants] a heightened sense . . . very
energetic . . . happy . . . [cannabinoids] lethargic, very
drowsy . . . most of the time dozing on the sofa in front of
the TV-that is what I wanted . . . It’s hundreds of times
stronger . . . would last for ages . . . I got bored . . . I was
drawn to try them . . . It’s cheaper [than marijuana] . . .
13.5 stone down to about 9.
Psychological effects
Escapism
Relaxation
Happiness
Alertness/Energy
Physical effects Weight loss
Preference
Strength
Affordability
Curiosity
Boredom
Duration
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Table 3. Cont.
Participant Quote Theme Sub-Theme
P6
More involved in the music, ﬁlm . . . my playing sounded
great . . . [it] wasn’t very great . . . they didn’t have any
downside at all . . . they didn’t relax you or send you to
sleep–quite the opposite . . . I went back because of the power
it had over me. It scared me and I wanted it to . . . I wanted
to tame it . . . I wanted to be able to do it without freaking
out . . . it would last for ages because it’s so strong
Psychological effects
Alertness/Energy
Improved subjective experiences
Overcome and control previous
negative experiences
Preference
Strength
Duration
P7
You just get more for your money worth [than “street”
amphetamine] Preference
Quality
Affordability
P8
I like the relaxing, calming numb feeling . . . The effect, it’s
quicker than marijuana. You get higher quicker . . . faster
Psychological effects Relaxation
Preference Onset of action
P9
It was quite stimulating . . . had an overriding desire to
argue with Christians . . . improved my darts. It deepened
my appreciation of Johnny Cash . . . You legalise [it] and I’ll
be back on it . . .
Psychological effects
Alertness/Energy
Improved subjective experiences
Preference Legal status
P10
Make myself happy . . . made me stronger . . . gives me
conﬁdence . . . I eat every day [resulting in weight gain
when previously underweight]
Psychological effects
Happiness
Conﬁdence
Physical effects Weight gain
P11
Totally a good feeling basically, made me feel quite happy
and cheerful . . . I tried most of them really to see what they
were like I stuck to the illegal ones cos they work better . . . I
thought, yeah I’ll try that–see what happens
Psychological effects Happiness
Preference
Quality
Curiosity
P12
[Stimulant NPS] gives me more energy . . . [cannabinoid
NPS] calms me down . . . It enhances–changes your
perspective on stuff . . . Helps me listen to music . . . I’ve
lost a lot of weight doing them. I was 18 and a half stone
before I started doing them . . . I like to keep the weight off
. . . I’ve got a bad leg and it takes that pain away
Psychological effects
Relaxation
Alertness/Energy
Improved subjective experiences
Physical effects
Weight loss
Analgesia
4. Negative experiences associated with NPS use
Table 4. Negative experiences associated with NPS use. A list of all the themes and sub-themes, with
respective quotes by participants.
Participant Quote Theme Sub-Theme
P1
My lip and my front teeth just went numb . . . it makes your eyes
water . . . and your nose burnt sometimes. The nostrils would burn
[when snorting NPS]
Physical effects Administration site
P2
A little bit dearer [than “street drugs”] . . . It has turned me into a
more devious person as well, although I’ve never stolen . . . I am the
nastiest person on it . . . I don’t like the shakes . . . it makes me itch a
bit . . . eczema . . . it’s a really dangerous sweat, it’s pretty
embarrassing
Psychological effects Personality changes
Physical effects
Tremor
Eczema
Sweating
Itching
Preference Affordability
P3
I’ve had thoughts of . . . killing myself . . . not wanting to be here
. . . I didn’t like the effects . . . it’ll kill you . . . the heartbeat on the
high ones . . . you feel like, I’ve just injected here and my heart’s
going. It feels like I’m dying . . . That’s a vein there and it’s just left
a massive lump . . . It’s too powerful
Psychological effects Suicidal ideation
Physical effects
Administration site
Cardiac
Preference Strength
P4
I couldn’t go out, struggled concentrating . . . They don’t make you
feel good; all they do is make your heart feel like you’re having a
heart attack . . . heart ﬂuttering, palpitations . . . Too strong,
over-powering
Psychological effects
Concentration
Impaired activity of daily living
Physical effects Cardiac
Preference Strength
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Table 4. Cont.
Participant Quote Theme Sub-Theme
P5
I stopped cleaning my ﬂat . . . go for about 4 days without eating . . . lost interest in my
home. I wasn’t paying my bills . . . washing up not done for months . . . got sacked . . .
all I wanted to do was get money and buy legal highs. That was my whole life . . .
crawling around my carpet on my hands and knees . . . try and get enough for another
rollie . . . that’s how addictive they were . . . Eventually the police turned up and I
basically got detained under the Mental Health Act for 24 h, until the effect of the drugs
wore off . . . I started ﬁtting in the street and I just couldn’t control my body . . . it no
longer had that kind of kick to it . . . I stopped buying it . . . you get a variation . . . the
illegal high stuff is more consistent in its strength
Legal Detained (Mental Health Act)
Psychological effects
Impaired activity of daily living
Self-neglect
Loss of control
Dependency/Addiction
Physical effects Seizures
Preference
Strength
Quality
P6
Too potent . . . I hate the fact that this is controlling me . . . I don’t have control . . .
Couldn’t remember what I was doing . . . completely confused . . . Gave me panic attacks
. . . Wouldn’t have been in any ﬁt state to go out . . . It seemed to speed my heart up to a
frightening degree . . . I really thought I was gonna have a heart attack . . . my heart was
thumping away madly . . . Hundreds of times stronger . . . it’s easy to go over-board . . .
the intensity of it was just on another level . . . I think they’re more dangerous because
they are just so intense . . . It could be a little bit hit and miss . . . it wouldn’t have the
same sort of effect
Psychological effects
Impaired activity of daily living
Confusion
Impaired memory
Panic attacks
Loss of control
Physical effects Cardiac
Preference
Strength
Quality
P7
It was pretty strong and I thought I was gonna collapse and die . . . It was the strength
of it Preference Strength
P8
I want to keep to that high all the time . . . sleep [to stop] . . . It might make you cough
. . . sweats
Psychological effects Dependency/Addiction
Physical effects
Coughing
Sweating
P9 Abscesses Physical effects Administration site
P10 You get more addicted. You wanna another bag, another bag and another Psychological effects
Dependency/Addiction
Cravings
P11 I stuck to the illegal ones cos they work better Preference Quality
P12
I need them, cos I’ve been doing them for 6–7 years . . . I don’t like having to wake up
when I haven’t got the money for them. Then I have to try to get the money for them. I
don’t like that part of it . . . they’re quite addictive . . . done some quite reckless stuff to
get them . . . trouble with the police . . . Makes me shake a lot . . . all the time
Psychological effects Dependency/Addiction
Physical effects Tremor
Legal Police involvement
4. Discussion
This study contributes to existing knowledge of how NPS are used by individuals, who engage
with specialist adult SMSs. Seven (58%) reported opiates (illicit heroin/morphine) as their primary
substance of use; this is in keeping with the ﬁnding that ﬁve (42%) of participants were in receipt
of opiate substitution prescriptions. For a quarter of individuals, NPS was their primary substance
of use in accordance with PHE classiﬁcation [15], suggesting that while not as common as opiates
(which SMSs are more familiar with treating [15]), NPS use is prevalent among individuals accessing
treatment services, as previously suggested by both national and international ﬁndings [7,8,39].
The interviews allowed individuals to describe their experiences with all types and routes of
administration of NPS; therefore, adding to the existing evidence base, particularly since previous
studies [24,40] have largely focused on stimulant NPS, which were injected. Audio recordings allowed
for more complete data and detailed transcriptions than relying on memory or notes alone and piloting
should have increased the likelihood of individuals sharing their personal views and experiences [42–44].
Harm reduction measures aim to reduce the harm that someone may experience because of
their ongoing substance use [45,46]. These include but are not limited to avoiding poly-pharmacy,
administering by routes associated with less risk (such as smoking rather than injecting), not sharing
drug paraphernalia and using smaller amounts. This study, as with other research, found that
individuals did not usually know exactly which chemical they were taking [19,50]. Amount of
experience with NPS and frequency of use varied greatly, from very occasional up to every 20 min.
Frequent use was mainly observed with synthetic cannabinoid receptor agonists (SCRAs) and stimulant
NPSs. Due the wide chemical diversity of SCRAs, little is known on their pharmacokinetics [51].
However, stimulants such as mephedrone may have a short duration of action warranting repeated
dosing [52]. Overall substance use patterns ﬂuctuated over time (with varying self-perceptions), which
may be explained by individuals being at different stages in their recovery journeys. Participant ages
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ranged from 26 to 59 (SD = 9); other studies have found and that most people using NPS are under
30 years old [1]. The difference may be because this study unlike national data reﬂects the age of those
requiring treatment. Our results therefore show that SMSs need to manage individuals with a range of
ages presenting with NPS use.
Previous studies and national reports have outlined a complex relationship between NPS and
other substances, and the need for further investigation. Factors affecting use include substance
availability, effects, safety proﬁle, quality, price, purity and legal status [1,16,21–23,38]. This study
equally found that NPS were favored over other substances for their perceived legal status, improved
price, availability and higher quality, including quicker onset and duration of action, therefore adding
to the existing knowledge base.
The large proportion (n = 9; 75%) of participants who stated they had experience with SCRAs
is perhaps to be expected (SI2), given that cannabis, the traditional illicit substance, which these
substances are attempting to mimic, has the highest prevalence rate of all illicit substances [53].
Preference for NPS type appeared to be dependent upon the required effect (usually stimulating
or sedating). Some wanted to gain conﬁdence, energy and alertness; others wanted to “escape
reality”, experience euphoria, feel happy, relaxed or were potentially self-medicating for underlying
psychological trauma (and in one case (P12) for leg pain). This has been found in other studies [30,54],
where stimulating effects were particularly popular [21,31,54]. One study found that psychedelic effects
were commonly favored [30]; although this could be due to the differing study environments (such as
dance venues and festivals). Individuals also reported using NPS to alleviate feelings of boredom
and out of curiosity, which has also been found previously [1,21,55] and similarly for traditional illicit
substance use [1].
NPS were often mixed with other substances [34,50] and administered by a variety of routes,
although snorting/injecting stimulant NPS and smoking SCRAs, the latter in combination with
tobacco (n = 4; 33%) predominated (SI2). Stimulant and SCRA NPS were also used sequentially to
balance the effects of each other. Excessive binging for long durations on stimulant NPS, followed by
substances with sedating and relaxing effects to “come down” supports the results of another study [24].
Poly-pharmacy is associated with an increased risk of drug interactions and side-effects including
overdose and death [7,45], so harm reduction advice, which SMSs offer, should include: overdose
awareness, how to reduce frequency, avoid “binges”, minimize polysubstance use, manage altered
tolerance levels as well as the provision of take home naloxone [24,56].
The amount participants spent on their NPS varied widely and was affected by how much
money they had access to, the source of NPS supply and pattern of use. To reduce costs NPS were
bought in bulk or smoked with tobacco and one person (P3) also described dealing NPS to fund
his habit. NPS were described as comparatively cheap to traditional illicit drugs which has been
similarly suggested by the Home Ofﬁce [1]. A Dutch study has found them to be similar in price to the
substances they are attempting to mimic [30] and this may be accounted for by differences between
England and Holland drug markets.
Strength of NPS was perceived as both a positive and negative. Some found them to be too strong,
leading to unwanted effects and overdoses; others preferred them for their strength, considering them
to be more cost-effective and of higher quality. Overall, NPS use reduced if strength and quality
was variable, and the NPS was viewed as inferior rather than superior to traditional illicit drugs;
this may be highly dependent on the local drug markets and has been similarly identiﬁed by the Home
Ofﬁce [1].
Our ﬁndings support other research, which identiﬁed that the rapid proliferation of NPS use
may be changing drug taking habits [22]. Several individuals reported NPS alleviating withdrawal
symptoms including cravings, from other substances and in some cases completely substituted with
NPS. SMSs should therefore provide individuals with advice on how to manage withdrawals (from all
substances). Using NPS in addition to traditional illicit drugs or prescribed substitute medication to
potentiate effects was also reported, particularly when then the person was presenting as more chaotic
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as found in similar studies [24]. This is unsurprising since individuals in the early stages of recovery
commonly present with more complex and riskier patterns of substance use.
Participants reported obtaining NPS from various sources; the majority had experience of using
headshops (n = 9; 75%) (SI2) in contrast to a qualitative study that found that NPS were usually obtained
from friends or online [30]. Headshops were often preferred for their convenience (particularly if they
could avoid “dealers”), with usage reducing when they could no longer be legally sold. However,
legal status did not always deter use, supporting Home Ofﬁce ﬁndings, which suggest this may be due
to the impact of legal status upon the quality of NPS [1,3]. Previous studies have equally conﬂicted in
their ﬁndings on the effect of legal status on the decision to use NPS [24,30]. Purchasing them from
high street vendors may add to the perception of this being “normal” behavior and the risk of them
being considered as “safe” and “legal” and consequently increase NPS use. For example, one person
(P3) felt it was permissible to sell them because they did not consider them to be “drugs” in the same
way as traditional illicit substances. Recent studies showed that there is an underlying competition
between cryptomarkets and street networking, which may drive high quality of illicit substances as
well as NPS [25–28]. However, an international drug testing service that was offered to cryptomarket
users suggested that this may not be the case [25].
Participants described a wide range of physical and psychological problems including symptoms
of NPS dependency reﬂecting national and international ﬁndings [4,8,57,58]. Similar to the ﬁndings of
other studies [31,57,58], reported physical health effects included tremor, coughing, itching, seizures,
eczema and sweating, and problems associated with speciﬁc routes of administration such as venous
abscesses. Like other studies, cardiac effects were reported (n = 3; 25%) (SI2), usually following
stimulant NPS use and sometimes lasting a few days [31,57,58]. While individuals described some of
these effects as sometimes being prolonged, the long-term effects remain unknown. Individuals were
not speciﬁcally asked about their experiences of acute compared to chronic effects or to distinguish
between side-effects and withdrawal symptoms. This suggests further study development and
provides additional support for the need for longitudinal research [1]. Unpleasant psychological
effects, included feelings of loss of control, difﬁculties concentrating, impaired memory, confusion,
personality changes, panic attacks and cravings; sometimes leading to crime, impaired activities of
daily living and self-neglect. Suicidal ideation and in one case (P5), being sectioned under the Mental
Health Act following prolonged NPS use was reported. Individuals with pre-existing mental health
conditions (“dual diagnosis”) may be particularly at risk of psychological problems and local integrated
pathways should outline how to obtain the required support quickly and effectively, especially in
acute situations such as the person disclosing suicidal ideation.
High risk administration practices and side-effects such as vein damage as a direct result of the
route of administration were described, although not as signiﬁcant as identiﬁed by a similar Irish
study, perhaps because it only included NPS mainly administered by injection [24]. To ameliorate
this, individuals actively undertook harm reduction approaches such as switching from injecting to
snorting and using less [45]. It is important that SMSs appropriately signpost to additional sources of
help and support, for example tissue bioavailability services.
4.1. Limitations of the Study
Repeat interviews and member-checking was not implemented due to difficulties in re-establishing
contact with the participants, time constraints and geographical problems. The purposive
sampling [42–44] approach enabled suitable participants to be identified. Although small, tentative
data saturation was achieved, as has been found to occur in other research [24,42–44,49]. A larger
sample size may have enabled more generalizability; however, this smaller sample size allowed for
more in-depth analysis.
Interviews require people to discuss their experiences in an artiﬁcial environment, which may
lead to problems with reliability. However, this approach of using semi-structured interviews to
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obtain detailed information from individuals regarding their NPS use has been successfully used
previously [23,24,30].
Data was collected in a predominantly rural environment and further research should be
conducted in more urban areas. The Devon RISE and Addaction Cornwall SMSs were almost equally
represented (7:5 respectively). Men dominate SMSs and reﬂecting this, all our participants were
men [1,7]. With a larger sample size, women may have been included, providing the opportunity
for comparison.
Data was collected in 2015, when many NPS were sold openly in headshops and NPS markets
have since changed. Currently, under the UK NPS Act 2016, headshops can no longer legally sell NPS
and a clear shift from the surface to the dark net was observed [59] and motivation for NPS use may
have consequently evolved. Implications of the new legislation include intentional poor disclosure of
NPS use to HCPs and NPS emerging on the illicit market, often sold as the traditional illicit drug the
NPS mimics, to increase proﬁt margins [55]. The delayed reporting of this study is due to the time
needed for the necessary approval for publication
4.2. Implications for HCPs and Policy-Makers
The way that the participants described NPS, easily made them identiﬁable in accordance with
PHE categories used by NDTMS, therefore providing support for this approach in clinical practice [15].
However, there were signiﬁcant discrepancies between NPS use recorded on Halo for the purposes of
NDTMS [16] and disclosures made by individuals during the interviews. Therefore, all individuals
presenting to SMSs should be asked about their use of NPS, the name of the substance, and reassessed
regularly, because they may not routinely present or perceive this as an issue, especially if other
substances dominate their pattern of substance use or if it changes over time. Additionally, this study
highlights that individuals should be asked about NPS regardless of their age. With the increasing
emergence of NPS (from approximately 478 in 2015 when this data was collected [14] to 740 in
2016 [11]), increasing chemical diversity, potency, and changing degree of purity [14,25], it is important
that HCPs reassess regularly the use of novel or existing NPS and tailor harm reduction approaches
to individuals. The importance of offering harm reduction interventions was demonstrated by the
positive impact that they had on individuals; however, the reports of managing withdrawal symptoms
by diverting prescribed medication or otherwise using polypharmacy must not be underestimated in
clinical practice. HCPs must check that prescribed doses are optimized to reduce cravings and “on
top” use. Additionally, adherence to medication regimens must be checked and community pharmacy
teams must promptly notify prescribing services of missed doses.
Consequently, treatment needs may also ﬂuctuate over time, so SMSs need to be able to
accommodate this and regularly review the person’s progress. These ﬁndings also provide support for
using interviews to elicit more accurate data regarding people’s NPS use and highlights that reviewing
NDTMS data in isolation to assess the extent of NPS use is inadequate. This may be for a variety
of reasons, including lack of staff vigilance when completing the required data set and suggests a
potential training need.
Because of their overall experiences, some strongly felt that they would never use NPS again,
while others continued to use despite their negative consequences. These ﬁndings corroborated
with previous research on SCRAs, where users reported that these substances completely “hijacked
their personalities” [60]. These negative effects may have a signiﬁcant impact upon the person,
including their employment, housing status and criminal record, and the wider community. SMSs are
traditionally skilled in providing support with such problems but promoting awareness among staff
about how best to identify individuals requiring more intensive support, or those whose needs may
need to be prioritized, such as individuals with pre-existing conditions, those who are homeless or
subject to CTOs, may enable this to be provided more promptly.
There was evidence that the SMSs were raising awareness of harm reduction by advising on
alternative routes of administration, such as switching from injecting to snorting and offered safer
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injecting technique sessions. Risks may be further reduced if the substance could be tested to conﬁrm
its content prior to administration and harm reduction advice [5,61] was provided at the time of
purchase. Currently, neither is currently permissible in UK SMSs, therefore adding further weight to
reviewing existing legislation.
SMSs need to understand the motivation for using NPS: when individuals disclosed their
substance use histories, they were highly variable. In one case, iatrogenic dependency (P1) was
described, though reasons for use were frequently associated with traumatic life events, often from
childhood. This has been found to occur in other NPS studies [21] and SMSs should therefore
be sensitive to the needs of these individuals and tailor psychological interventions accordingly.
When more signiﬁcant disclosures are made, other services such as bereavement counselling and
mental health teams should be signposted so that any unresolved issues can be managed effectively.
Some described improved abilities and experiences with NPS, often acknowledging this was
perceived because of the mind-altering effects of the substance, such as having energy while on a
night out and enjoyment of activities such as playing music. Such information may be of interest
to policy-makers, where psychoactivity of newly emerging NPS has not yet been demonstrated.
One individual (P6), reported a desire to use NPS to overcome their previous negative experiences with
these substances, alongside entrenched addictive behaviors and boredom due to a lack of meaningful
daytime activities. This highlights the need for SMSs to promote a variety of psychosocial interventions
to help occupy an individual’s time in substance-free environments, which are tailored to the person’s
needs to enable them to progress with their recovery. Supporting people to develop skills which
will enable them to ﬁnd work is important because the number of participants in employment was
comparatively low and boredom was cited as a reason for NPS use, which may be compounded by
rural locations. Some may require more intensive RC support and there should be adequate provision
for this.
The main positive physical health effects reported were upon weight: three (25%) stated that using
predominantly stimulant NPS to keep their weight down was one of their main motivators for use.
This may be a particular problem once the person stabilizes their NPS use and weight gain is observed,
which may result in the occurrence of other eating disorder symptoms. In contrast, one individual
(P10) reported appetite stimulating effects which they found to be beneﬁcial as they were otherwise
losing weight due to self-neglect because of their chaotic drug use. However, it cannot be assumed that
the food they were selecting to eat included “healthy options”. In these situations, individuals should
be offered supportive explanations that if their substance use stabilizes their weight will usually return
without the need for stimulants. Malnutrition may be common in people in substance use treatment,
which is one of many reasons why SMSs supporting activities such as “breakfast clubs” and the
provision of “life-skills” courses which incorporate cooking techniques and general nutritional advice,
should be actively encouraged. Everyone involved in the care of people with substance use problems
(including GPs and community pharmacists in addition to specialist SMSs) should be vigilant for
eating disorder behaviors and provide the required support or signpost as required: there may be
training needs.
Three participants were subject to CTOs because of their substance use and would therefore
require regular drug testing for SMSs to report on their progress. Since NPS may not always be
detectable in routine drug screens and can produce false positives [5,55,61], SMSs could consider more
specialist NPS-speciﬁc tests. These may be expensive (and not always possible due to the novelty of
the substances), but if used sparingly and appropriately, they may be a useful tool. However, this
is not without risk, since it may also perpetuate the demand for “new” NPS that are not detectable.
Half of the participants were in receipt of a prescription for oral opiate substitution treatment and
using NPS as a replacement for such medication was reported. The diversion of prescribed medication
is highly likely in such situations. Therefore NPS-speciﬁc tests may also be useful for supporting
decisions around continued prescribing in circumstances where there is evidence of “on top” use or
diversion is suspected. Staff should receive appropriate training so that they are vigilant for “on-top”
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use, diversion and substitution of the person’s prescribed intervention with NPS, particularly if the
individual is under a CTO.
NPS treatment systems are complex and require structured partnerships between
multidisciplinary teams with a broad range of competencies. This includes: A&E departments,
sexual, social care and mental health services, prison, probation staff and Young Offender teams,
community adult and young people SMSs, youth services and organizations such as the police [6].
This is required to manage the myriad of health, social and criminal problems associated with NPS
use and to address the diverse needs of individuals including young people, MSM, prisoners, and
the homeless population. This approach should also involve people who use NPS and their carers.
Drug detection is key to support diagnosis and treatment planning, adherence and outcomes [5,6,55,61].
Proactive, engaging and competent SMSs are needed to respond appropriately to meet the needs
associated with NPS use. Regular education and training is of paramount importance to inform about
types and degrees of harm, new patterns and trends of recreational drug use and changes to the drug
scene [6]. NPS use should be considered in clinical assessments and management plans should be
devised accordingly [20].
5. Conclusions
This study found that NPS are used by individuals across a range of ages, presenting to SMSs
in Devon and Cornwall, but is highly variable. NPS may be favored over other substances for their
perceived legal status, price, strength, availability and better quality, including quicker onset and
duration of action and improved side-effect proﬁle. Consequently, NPS use may be dependent on
local drug markets and reduce if perceived to be variable in strength and quality in comparison to
traditional illicit drugs. SCRAs and stimulant NPS are most frequently used and preference for NPS
type is often dependent upon the required effect. Using poly-pharmacy (including NPS, traditional
illicit substances and prescribed medication) to potentiate effects, manage side-effects and withdrawal
symptoms occurs, sometimes resulting in displacement of substances. Therefore, SMS must remain
vigilant and consider the use of NPS-speciﬁc tests, especially when substitute medication is prescribed.
NPS are frequently administered by a variety of routes, including high risk injecting practices, though
individuals can respond well to harm reduction interventions, which should be routinely provided
and include the management of withdrawals. Results showed that a wide range of problematic
physical and mental health effects may occur, including symptoms of dependency, which may lead
to criminal activity, impaired activities of daily living and self-neglect. People’s perception of the
severity of their use, frequency and amount used varies widely and may change depending on their
recovery journey, consequently ﬂuctuating for individuals over time. People use NPS for a variety
of reasons, including stimulant types taken for the intention of losing weight. As malnourishment is
often an issue for individuals accessing SMS, the multidisciplinary team must be attentive, frequently
revisit the current pattern of substance use and any associated issues, promptly refer to other services
accordingly and may require further training. Local integrated pathways for individuals presenting
with more complex issues and particular needs such as dual diagnosis and tissue bioavailability
should be established to enable prompt access. SMSs should engage individuals with psychosocial
interventions and meaningful daily activities, especially in more rural areas. It is important that current
approaches to existing treatment strategies are adapted and recovery plans tailored to an individual’s
needs. Education and training is needed for HCPs working within various services where people
who use NPS are encountered. Multidisciplinary and multiagency approaches should be nationally
adopted to capture changing trends of NPS use.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3425/8/4/58/
s1. Supplementary Information 1 (SI1): Semi-structured Interview Guide; Supplementary Information 2 (SI2):
Summary of Themes and Sub-themes
Acknowledgments: No funding or grants were provided to conduct this study. Addaction and RISE had no
roles in study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the
89
Brain Sci. 2018, 8, 58
decision to submit the paper for publication. The views expressed here reﬂect only the authors’ views. The authors
would like to acknowledge the help of Julie Bonning-Snook for assisting with transcription processes and the
Addaction/RISE staff and clients without whom the data collection would not have been possible. Photo of NPS
packaging in the graphical abstract (taken by RG) is reproduced with permission from Addaction, UK.
Author Contributions: R.G. conceived the project and undertook the data collection, supervised by I.M. A.G.
conceived the paper and led on writing. F.S. advised on paper as a whole; R.G., A.G., F.S. and I.M. reviewed the
paper. All authors contributed to the writing of the paper.
Conﬂicts of Interest: No conﬂicts of interest are declared here that may have inﬂuenced the interpretation of
present data. Please note the following: R.G. is a credentialed member of the College of Mental Health Pharmacy
(CMHP) and a Council member of the CMHP. F.S. is one of the editors of this special issue of Brain Science, a
full member of the UK Advisory Council on the Use of Drugs (ACMD) and a member of the ACMD’s NPS and
Technical Committees. The views expressed here are solely those of the authors and do not necessarily reﬂect
those of the CMHP, Home Ofﬁce or the ACMD.
References
1. Stephenson, G.; Richardson, A. New Psychoactive Substances in England: A Review of the Evidence; Crime and
Policing Analysis Unit, Home Ofﬁce Science; Home Ofﬁce: London, UK, 2014.
2. Simonato, P.; Corazza, O.; Santonastaso, P.; Corkery, J.; Deluca, P.; Davey, Z.; Blaszko, U.; Schifano, F.
Novel psychoactive substances as a novel challenge for health professionals: Results from an Italian survey.
Hum. Psychopharmacol. 2013, 28, 324–331. [CrossRef] [PubMed]
3. Bright, S.J.; Bishop, B.; Kane, R.; Marsh, A.; Barratt, M.J. Kronic hysteria: Exploring the intersection between
Australian synthetic Cannabis legislation, the media, and drug-related harm. Int. J. Drug Policy 2013,
24, 231–237. [CrossRef] [PubMed]
4. Abdulrahim, D.; Bowden-Jones, O. Guidance on the Clinical Management of Acute and Chronic Harms of
Club Drugs and Novel Psychoactive Substances; Novel Psychoactive Treatment UK Network (NEPTUNE):
London, UK, 2015.
5. Guirguis, A.; Girotto, S.; Berti, B.; Stair, J.L. Identiﬁcation of new psychoactive substances (NPS) using
handheld Raman Spectroscopy employing both 785 and 1064 nm laser sources. J. Forensic Sci. Int. 2017,
273, 113–123. [CrossRef] [PubMed]
6. Independent Expert Working Group. Drug Use and Dependence. UK Guidelines on Clinical Management; Crown:
London, UK, 2017.
7. UNODC. World Drug Report. United Nations Ofﬁce on Drugs and Crime: Vienna, Austria, 2014. Available
online: https://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf (accessed on
21 March 2018).
8. Royal College of Psychiatrists (RCPsych). One New Drug a Week. Why Novel Psychoactive Substances and Club
Drugs Need a Different Response from UK Treatment Providers (FR/AP/02); Faculty Report; Faculty of Addictions
Psychiatry, Royal College of Psychiatrists: London, UK, 2014.
9. Psychoactive Substances Act 2016. The Stationery Ofﬁce Limited, 2016. Available online: http://services.
parliament.uk/bills/2015-16/psychoactivesubstances.html (accessed on 21 September 2015).
10. Drug Watch. A Simple (ish) Guide to the Psychoactive Substances Act (PSA), version 1.5; Linnell Communications:
Prestwich, UK, 2016.
11. United Nations Ofﬁce on Drugs and Crime (UNODC). Global Synthetic Drugs Assessment. Amphetamine-Type
Stimulants and New Psychoactive Substances; United Nations Ofﬁce on Drugs and Crime: Vienna, Austria, 2018.
12. United Nations Ofﬁce on Drugs and Crime (UNODC). The Challenge of New Psychoactive Substances.
Global SMART Programme; United Nations Ofﬁce on Drugs and Crime: Vienna, Austria, 2013.
13. Adley, M. The Drug Wheel. 2017. Available online: http://www.thedrugswheel.com/downloads/
TheDrugsWheel_2_0_2_colour.pdf (accessed on 2 February 2017).
14. Zloh, M.; Samaras, E.G.; Calvo-Castro, J.; Guirguis, A.; Stair, J.L.; Kirton, S.B. Drowning in diversity?
A systematic way of clustering and selecting a representative set of new psychoactive substances. RSC Adv.
2017, 7, 53181–53191. [CrossRef]
15. Public Health England (PHE). New Psychoactive Substances: A Toolkit for Substance Use Commissioners; Public
Health England: London, UK, 2014.
16. Public Health England (PHE). Healthcare Professionals and Partners; National Drug Treatment Monitoring
System (NDTMS): Manchester, UK, 2016.
90
Brain Sci. 2018, 8, 58
17. Department of Health (England) and Devolved Administrations. Drug Misuse and Dependence, UK Guidelines
on Clinical Management; Department of Health (England); Scottish Government; Welsh Assembly Government
and Northern Ireland Executive: London/Edinburgh, UK, 2007.
18. Guirguis, A.; Corkery, J.M.; Stair, J.L.; Kirton, S.B.; Zloh, M.; Goodair, C.; Schifano, F.; Davidson, C. Survey of
knowledge of legal highs (novel psychoactive substances) amongst London pharmacists. Drugs Alcohol Today
2015, 15, 93–99. [CrossRef]
19. Wood, D.M.; Ceronie, B.; Dargan, P.I. Healthcare professionals are less conﬁdent in managing acute
toxicity related to the use of new psychoactive substances (NPS) compared with classical recreational
drugs. QJM 2016, 109, 527–529. [CrossRef] [PubMed]
20. Badachha, S.New Psychoactive Substances: The Response by Probation and Substance Use Services in the Community
in England. A Joint Inspection by HM Inspectorate of Probation and the Care Quality Commission; Crown: London,
UK, 2017.
21. Sweet, A.D. Free return trajectories or enmeshment? Some psychodynamic factors and thoughts on the role
of social capital in the use of substituted cathinones (M-cats). Drugs Alcohol Today 2014, 14, 2–9. [CrossRef]
22. Moore, K.; Dargan, P.I.; Wood, D.M.; Measham, F. Do novel psychoactive substances displace established
club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy
and cocaine. Eur. Addict. Res. 2013, 19, 276–282. [CrossRef] [PubMed]
23. Van Hout, M.; Brennan, R. ‘Heads Held High’: An Exploratory Study of Legal Highs in Pre-Legislation
Ireland. J. Ethn. Subst. Abuse 2011, 10, 256–272. [CrossRef] [PubMed]
24. VanHout,M.C.; Bingham, T. “ACostly TurnOn”: Patterns of use and perceived consequences ofmephedrone
based head shop products amongst Irish injectors. Int. J. Drug Policy 2012, 23, 188–197. [CrossRef] [PubMed]
25. Caudevilla, F.; Ventura, M.; Fornís, I.; Barratt, M.J.; Vidal, C.; Quintana, P.; Calzada, N. Results of an
international drug testing service for cryptomarket users. Int. J. Drug Policy 2016, 35, 38–41. [CrossRef]
[PubMed]
26. Van Buskirk, J.; Naicker, S.; Roxburgh, A.; Bruno, R.; Burns, L. Who sells what? Country speciﬁc differences
in substance availability on the Agora cryptomarket. Int. J. Drug Policy 2016, 35, 16–23. [CrossRef] [PubMed]
27. Van Hout, M.C.; Hearne, E. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study
of characteristics of forum activity between NPS buyers and vendors. Int. J. Drug Policy 2017, 40, 102–110.
[CrossRef] [PubMed]
28. Wadsworth, E.; Drummond, C.; Deluca, P. The Dynamic Environment of Crypto Markets: The Lifespan of
New Psychoactive Substances (NPS) and Vendors Selling NPS. Brain Sci. 2018, 8, 46. [CrossRef] [PubMed]
29. Norman, J.; Grace, S.; Lloyd, C. Legal high groups on the Internet—The creation of new organized deviant
groups? Drugs Edu. Prev. Policy 2014, 21, 14–23. [CrossRef]
30. Van Amsterdam, J.G.C.; Nabben, T.; Keiman, D.; Haanschoten, G.; Korf, D. Exploring the Attractiveness of
New Psychoactive Substances (NPS) among Experienced Drug Users. J. Psychoact. Drugs 2015, 47, 177–181.
[CrossRef] [PubMed]
31. Measham, F.; Wood, D.; Dargan, P.I.; Moore, K. The rise in legal highs: Prevalence and patterns in the use of
illegal drugs and ﬁrst- and second-generation “legal highs” in South London gay dance clubs. J. Subst. Use
2011, 16, 263–272. [CrossRef]
32. Archer, J.; Dargan, P.; Rintoul-Hoad, S.; Hudson, S.; Wood, D. Nightclub urinals—A novel and reliable way
of knowing what drugs are being used in nightclubs. Br. J. Clin. Pharmacol. 2012, 73, 985.
33. Kalyanam, J.; Katsuki, T.; Lanckriet, G.R.G.; Mackey, T.M. Exploring trends of non-medical use of prescription
drugs and polydrug abuse in the Twittersphere using unsupervised machine learning. Addict. Behav. 2017,
65, 289–295. [CrossRef] [PubMed]
34. Shaﬁ, A.; Gallagher, P.; Stewart, N.; Martinotti, G.; Corazza, O. The risk of violence associated with novel
psychoactive substance use in patients presenting to acute mental health services. Hum. Psychopharmacol.
2017, 32, E2606. [CrossRef] [PubMed]
35. Pirona, A.; Bo, A.; Hedrich, D.; Ferri, M.; van Gelder, N.; Giraudon, I.; Montanari, L.; Simon, R.; Mounteney, J.
New psychoactive substances: Current health-related practices and challenges in responding to use and
harms in Europe. Int. J. Drug Policy 2017, 40, 84–92. [CrossRef] [PubMed]
36. Abdulrahim, D.; Whiteley, C.; Moncrieff, M.; Bowden-Jones, O. Club Drug Use among Lesbian, Gay, Bisexual
and Trans (LGBT) People; Novel Psychoactive Treatment UK Network (NEPTUNE): London, UK, 2016.
91
Brain Sci. 2018, 8, 58
37. Lovett, C.; Yamamoto, T.; Hunter, L.; White, J.; Dargan, P.I.; Wood, D.M. Problematic recreational drug use:
Is there a role for outpatient sexual health clinics in identifying those not already engaged with treatment
services? Sex Health 2015, 12, 501–505. [CrossRef] [PubMed]
38. Stanley, J.L.; Mogford, D.V.; Lawrence, R.J.; Lawrie, S.M. Use of novel psychoactive substances by inpatients
on general adult psychiatric wards. BMJ Open 2016, 6, e009430. [CrossRef] [PubMed]
39. Kapitány-Fövény, M.; Farkas, J.; Pataki, P.A.; Kiss, A.; Horváth, J.; Urbán, R.; Demetrovics, Z.
Novel psychoactive substance use among treatment-seeking opiate users: The role of life events and
psychiatric symptoms. Hum. Psychopharmacol. 2017, 32, e2602. [CrossRef] [PubMed]
40. Csak, R.; Demetrovics, Z.; Racz, J. Transition to injecting 3,4-methylene-dioxy-pyrovalerone (MDPV) among
needle exchange program participants in Hungary. J. Psychopharmacol. 2013, 27, 559–563. [CrossRef]
[PubMed]
41. Brod, M.; Tesler, L.E.; Christensen, T.L. Qualitative research and content validity: Developing best practices
based on science and experience. Qual. Life Res. 2009, 18, 1263–1278. [CrossRef] [PubMed]
42. Green, J.; Thorogood, N. Qualitative Methods for Health Research, 3rd ed.; Seaman, J., Ed.; Sage Publications:
London, UK, 2014.
43. Braun, V.; Clarke, V. Using thematic analysis in psychology. Qual. Res. Psychol. 2006, 3, 77–101. [CrossRef]
44. Gale, N.K.; Heath, G.; Cameron, E.; Rashid, S.; Redwood, S. Using the framework method for the analysis of
qualitative data in multi-disciplinary health research. BMC Med. Res. Methodol. 2013, 13, 117. [CrossRef]
[PubMed]
45. United Nations Ofﬁce on Drugs and Crime (UNODC). Reducing the Harm of Drug Use and Dependence.
Available online: https://www.unodc.org/ddt-training/treatment/VOLUME%20D/Topic%204/1.VolD_
Topic4_Harm_Reduction.pdf (accessed on 11 May 2016).
46. Guirguis, A.; Corkery, J.M.; Stair, J.L.; Kirton, S.B.; Zloh, M.; Schifano, F. Intended and unintended use of
cathinone mixtures. Hum. Psychopharmacol. 2017, 32. [CrossRef] [PubMed]
47. Department for Constitutional Affairs. Mental Capacity Act 2005: Code of Practice; Stationary Ofﬁce: Norwich,
UK, 2007.
48. General Pharmaceutical Council (GPhC). Guidance on Consent; GPhC: London, UK, 2012.
49. Guest, G.; Bunce, A.; Johnson, L. How Many Interviews Are Enough? An Experiment with Data Saturation
and Variability. Field Methods 2006, 18, 59–82. [CrossRef]
50. Harris, C.R.; Brown, A. Synthetic cannabinoid intoxication: A case series and review. J. Emerg. Med. 2013,
44, 360–366. [CrossRef] [PubMed]
51. Schifano, F.; Orsolini, L.; Papanti, D.; Corkery, J. NPS: Medical consequences associated with their intake, in
Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines. In Current
Topics in Behavioral Neurosciences; Springer International Publishing: Basel, Switzerland, 2016.
52. Adams, R.D.; Good, A.M.; Thomas, S.H.L.; Thompson, J.P.; Vale, J.A.; Eddleston, M. TOXBASE and its use in
collecting data on new and uncommon products of interest. Clin. Toxicol. 2015, 53, 398.
53. UNODC. World Drug Report. United Nations Ofﬁce on Drugs and Crime: Vienna, Austria,
2017. Available online: https://www.unodc.org/wdr2017/ﬁeld/Booklet_1_EXSUM.pdf (accessed on
21 March 2018).
54. Chen, C.; Kostakis, C.; Irvine, R.J.; White, J.M. Increases in use of novel synthetic stimulant are not directly
linked to decreased use of 3,4-methylenedioxy-N-methylamphetamine (MDMA). Forensic Sci. Int. 2013,
231, 278–283. [CrossRef] [PubMed]
55. Ralphs, R.; Williams, L.; Askew, R.; Norton, A. Adding Spice to the Porridge11 ‘Porridge’ is British slang for
a prison sentence. e.g., ‘Doing his porridge’. The term is most commonly thought to be an allusion to the
fact that porridge is, or used to be, a common food in prison. The term is also thought to be a pun on the
much older slang word for prison, ‘stir’: The development of a synthetic cannabinoid market in an English
prison. Int. J. Drug Policy 2017, 40, 57–69. [PubMed]
56. Guirguis, A. New psychoactive substances: A public health issue. Int. J. Pharm. Pract. 2017, 25, 323–325.
[CrossRef] [PubMed]
57. Soussan, C.; Kjellgren, A. “Chasing the high”—Experiences of ethylphenidate as described on international
internet forums. Subst. Abuse 2015, 9, 9–16. [CrossRef] [PubMed]
92
Brain Sci. 2018, 8, 58
58. Mounteney, J.; Bo, A.; Grifﬁths, P. The internet and drug markets: Shining a light on these complex and
dynamic systems. In The Internet and DrugMarkets; Mounteney, J., Bo, A., Oteo, A., Eds.; EuropeanMonitoring
Centre on Drugs and Drug Addiction: Lisbon, Portugal, 2016; Chapter 1.
59. Tracy, D.K.; Wood, D.M.; Baumeister, D. Novel psychoactive substances: identifying and managing acute
and chronic harmful use. BMJ 2017, 365. [CrossRef] [PubMed]
60. Kassai, S.; Pintér, J.N.; Rácz, J.; Böröndi, B.; Tóth-Karikó, T.; Kerekes, K.; Gyarmathy, V.A. Assessing
the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.
Harm Reduct. J. 2017, 14, 9. [CrossRef]
61. Assi, S.; Guirguis, A.; Halsey, S.; Fergus, S.; Stair, J.L. Analysis of ‘legal high’ substances and common
adulterants using handheld spectroscopic techniques. Anal. Methods 2015, 7, 736–746. [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
93
brain
sciences
Article
Mechanistic Insights into the Stimulant Properties
of Novel Psychoactive Substances (NPS) and Their
Discrimination by the Dopamine Transporter—In
Silico and In Vitro Exploration of
Dissociative Diarylethylamines
Michelle A. Sahai 1, Colin Davidson 2,3, Neelakshi Dutta 2 and Jolanta Opacka-Juffry 1,*
1 Department of Life Sciences, University of Roehampton, London SW15 4JD, UK;
Michelle.Sahai@ROEHAMPTON.AC.UK
2 St George’s, University of London, London SW17 0RE, UK; CDavidson2@uclan.ac.uk (C.D.);
p0402670@sgul.ac.uk (N.D.)
3 Pharmacy & Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK
* Correspondence: j.opacka-juffry@roehampton.ac.uk; Tel.: +44-(0)20-8392-3563
Received: 2 February 2018; Accepted: 22 March 2018; Published: 7 April 2018
Abstract: Novel psychoactive substances (NPS) may have unsuspected addiction potential
through possessing stimulant properties. Stimulants normally act at the dopamine transporter
(DAT) and thus increase dopamine (DA) availability in the brain, including nucleus accumbens,
within the reward and addiction pathway. This paper aims to assess DAT responses to dissociative
diarylethylamine NPS by means of in vitro and in silico approaches. We compared diphenidine
(DPH) and 2-methoxydiphenidine (methoxphenidine, 2-MXP/MXP) for their binding to rat DAT,
using autoradiography assessment of [125I]RTI-121 displacement in rat striatal sections. The drugs’
effects on electrically-evoked DA efﬂux were measured by means of fast cyclic voltammetry in
rat accumbens slices. Computational modeling, molecular dynamics and alchemical free energy
simulations were used to analyse the atomistic changes within DAT in response to each of the ﬁve
dissociatives: DPH, 2-MXP, 3-MXP, 4-MXP and 2-Cl-DPH, and to calculate their relative binding free
energy. DPH increased DA efﬂux as a result of its binding to DAT, whereas MXP had no signiﬁcant
effect on either DAT binding or evoked DA efﬂux. Our computational ﬁndings corroborate the above
and explain the conformational responses and atomistic processes within DAT during its interactions
with the dissociative NPS. We suggest DPH can have addictive liability, unlike MXP, despite the
chemical similarities of these two NPS.
Keywords: dopamine; DAT; brain; addiction; molecular dynamics; free energy calculation;
autoradiography; voltammetry; diphenidine
1. Introduction
A notable increase in the number of new psychoactive substances (NPS), formerly known
as ‘legal highs’, ‘bath salts’ or ‘designer drugs’ ties in with the growing lines of evidence of their
complex behavioural effects and health risks they may carry. NPS often resemble traditional drugs of
abuse, although their pharmacological properties are unknown. Frequently, through minor chemical
modiﬁcation of the molecular structure of psychoactive drugs, different biological effects can be
achieved, which includes the drug’s addictive liability. The latter links with the stimulant effects of
drugs and involves the neurotransmitter dopamine. Stimulants have been known to raise dopamine
availability in the brain, including the brain’s reward pathway that can be hijacked by stimulant
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drugs [1]. Perceptions of pleasure and reward are associated with the release of dopamine in the
nucleus accumbens as part of the reward pathway; a similar phenomenon is also implicated in
responses to stimulants whose repeated use may lead to drug dependence [2].
The molecular target for stimulants is the dopamine transporter (DAT), which can be obstructed by
the drug that binds to it. DAT belongs to the Solute Carrier 6 gene family (SLC6A3) that encodes several
Na+/Cl−-dependent neurotransmitter transporters (the NSS or neurotransmitter:sodium symporter
family), including transporters for norepinephrine, serotonin, GABA and glycine [3]. NSS proteins
function to couple the transport of Na+ down its concentration gradient with the uphill transport
of the respective substrate. Additionally, several NSS proteins are characterized by co-transport of
Cl− [4]. DAT, like the other members of this family of transporters, has both an intracellular amino-
and carboxyl-termini and twelve transmembrane (TM) helical domains [5–7]. The substrate binding
site is known to be deeply buried in the transporter structure. Referred to as the S1 site, it has been
resolved by X-ray crystallography [6,8,9] and previous computational modeling [10–12] to describe a
site that overlaps with that of dopamine and many of the popular psychostimulants. It is also clearly
distinct from the site observed for antidepressant binding (S2 site) to the leucine transporter (LeuT)
which is found facing the extracellular vestibule nearly 11 Å above the S1 site [13].
A classical example of a drug that binds to DAT and obstructs the S1 site is cocaine [14]. Cocaine
binding to the DAT reduces dopamine re-uptake from the extracellular compartment and leads
to an increase in the synaptic concentrations of dopamine available for neurotransmission in the
pathway affected (mesolimbic/mesocortical) [15]. Alternatively, drugs such as amphetamine, interact
with the DAT when entering the presynaptic compartment where they displace newly synthesised
dopamine [16], which also leads to an increase in basal dopamine concentrations in the synapse.
The elevated concentration of extracellular (synaptic) DA underpins the behavioural response to
stimulants, and with repeated use, may lead to drug dependence.
We have previously demonstrated a range of pro-dopaminergic effects among synthetic
cathinones [17] and benzofurans [12,18] as studied by means of neurobiological methods in vitro,
and also in silico, using molecular modeling of atomistic interactions between drugs and DAT [12].
By means of the in vitro fast cyclic voltammetry technique, we were able to estimate if the stimulant
proﬁle is more similar to that of amphetamine or cocaine. On the basis of radioligand binding studies
we can visualise the drug’s binding at the dopamine transporter in the mesolimbic and mesocortical
pathways of the brain, and we could say that some of the synthetic cathinones, such as bupropion,
ethcathinone or diethylpropion do not act as a substrate releaser at the DAT. That allowed us to
conclude that the wide-ranging pro-dopaminergic effects of cathinones were consistent with their
different behavioural effects and popularity as recreational drugs [17]. Additionally, the varied
and complex atomistic mechanisms of interactions between stimulants and DAT, which result in an
increase in dopaminergic tone typical of stimulant drugs, can be studied by means of virtual methods
of molecular modeling [12], which we apply in the present study to understand how relatively
minor structural differences translate into different pharmacological NPS proﬁles of relevance to their
addictive potential.
Here, we choose to study in silico a class of compounds that rigorously share the core of the
1,2-diarylethylamine structure and an ethylamine nucleus with aromatic substitutions (Figure 1).
We also study two of them, the dissociative NPS, diphenidine (DPH) and its methoxylated derivative
2-methoxydiphenidine (methoxphenidine, 2-MXP/MXP), in vitro using the above neurobiological
methods. DPH and 2-MXP replaced a ketamine-like drug methoxetamine (MXE) which was banned
the UK in 2013; MXE was branded as a bladder-friendly ketamine, while ketamine has been associated
with cystitis and bladder ﬁbrosis [19,20].
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Figure 1. Molecular structures of diphenidine (DPH) and other aryl-substituted 1,2-diarylethylamines
including 2-MeO-diphenidine (2-MXP), 3-MXP, 4-MXP and 2-Cl-DPH.
It is worth noting that DPH and 2-MXP have been described as relatively selective
N-Methyl-D-aspartate receptor (NMDA receptor or NMDAR) antagonists [21–23]. NMDA antagonism
has been accepted to underpin the dissociative state effects that include sensory distortions and
hallucinations, and depersonalization [19,24,25], although monoamine binding sites can also play a
role in the psychoactive proﬁles on these drugs [25]. The recent interest in the pharmacology of these
compounds is justiﬁed by the fact that both DPH and 2-MXP have been associated with adverse health
effects including deaths [21,26–29].
Interestingly, DPH and 2-MXP have different functional potencies (IC50) at the dopamine
transporter, 1.99 μM and 30 μM, respectively [22] and as conﬁrmed in the recent study [30] where
DPH was shown to be an inhibitor of the noradrenaline transporter (NET) (3.3 μM) and DAT (3.4 μM),
while 2-MXP was mainly an inhibitor of the NET, with 7.8 μM inhibition compared to 65 μM at DAT.
The monoamine transporter inhibition can contribute to their psychoactive properties and dictate
addictive potential especially in the case of DPH which has a relatively high afﬁnity (Ki = 0.23 μM)
compared to 4.8 μM for 2-MXP at DAT [30].
Since this study relies heavily on rat in vitro data we endeavoured to be consistent in comparing
the in silico data to the in vitro responses to psychostimulants in the same cellular background.
As such, we utilised a previous homology model of the Rattus norvegicus dopamine transporter
(rat DAT, rDAT) [12] to dock each of the ﬁve compounds (Figure 1). Their relative binding free energies
were then calculated using alchemical free energy molecular dynamics simulations, particularly the
free energy perturbation (FEP) method. The free energy predictions were subsequently compared with
the experimental IC50 values that were reported earlier [22]. By using such in silico approaches we
explored the possibility of predicting the DAT-binding properties, and thus addictive liability among
this class of dissociative NPS. Awareness of addictive potential of NPS is important to both users and
health services.
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2. Methods
2.1. Animals
Eight week old male Wistar rats (Charles River, Harlow, UK) were kept on a 12/12 h light/dark
cycle (lights on at 7 a.m.) with food and water ad libitum. Rats were treated in accordance with the U.K.
Animals (Scientiﬁc Procedures) Act 1986 (related to the 1986 EU Directive 86/609/EEC) and sacriﬁced
by cervical dislocation with no anaesthesia.
2.2. Reagents
All chemicals used were supplied by Sigma Chemicals (Poole, UK) except DPH and 2-MXP which
were a gift from John Ramsey (TICTAC Communications Ltd., London, UK). The radioligand for the
dopamine transporter, [125I]RTI-121 (speciﬁc activity 81.4 TBq/mmol) was purchased from Perkin
Elmer (Beaconsﬁeld, UK).
Radioligand DAT binding study was conducted as previously described [8]. Brieﬂy, brains were
removed and frozen at −40 ◦C in a mixture of methanol and dry ice, then stored at −80 ◦C. Frozen
brains were cut into 20 μm serial coronal sections to harvest the striatum at +1.7 mm to −0.3 mm
versus bregma [31], collected onto polysine-coated slides and stored at −80 ◦C. The autoradiography
procedure was conducted according to Strazielle et al., 1998 [32]: preincubation in 0.05 M NaPB pH 7.4,
incubation with 20 pM [125I]RTI-121 in NaPB pH 7.4 with increasing concentrations of the drugs
tested (0–30 μM) for 60 min at room temperature; non-speciﬁc binding was assessed in the presence
of 200 μM nomifensine. Slides were opposed to Kodak BioMax MR ﬁlms for 4 days; autoradiograms
were analysed using MCID™, Version 7.0, Imaging Research Inc. (St. Catharines, ON, Canada), n = 6
rats. Flat-ﬁeld correction was applied. The striatal regions of interest were sampled in duplicates for
relative optical density; left and right caudate values were averaged, and their means were calculated
to assess the speciﬁc binding.
2.3. Fast Cyclic Voltammetry
Carbon Fibre Microelectrodes. Carbon ﬁbre microelectrodes were constructed by inserting a single
carbon ﬁbre (Goodfellow Cambridge Ltd., Huntingdon, UK), 7 μm in diameter, into a 10 cm long
borosilicate glass capillary tube. The capillary tube was then pulled using an electrode puller (P-30,
Sutter Instruments Co., Novato, CA, USA) and the exposed carbon ﬁbre was cut to approximately
70 μm under a microscope using a scalpel. Microelectrodes were backﬁlled with a saline solution before
a length of copper wire was inserted into the end so it could be connected to the head-stage. A Ag/AgCl
reference electrode and a steel wire auxiliary electrode were also connected to the head-stage and
positioned within the recording chamber ﬂuid, well away from the slice. Carbon ﬁbre electrodes were
calibrated using 5 or 10 μM dopamine in artiﬁcial cerebro-spinal ﬂuid (aCSF).
Fast cyclic voltammetry. A triangular voltage waveform was applied to a carbon ﬁbre
microelectrode, which oxidises dopamine at ~600 mV. Calibrations of electrodes in a known
concentration of dopamine allow the recorded Faradaic current to be converted into the relevant
neurotransmitter concentration. Using a Millar Voltammetric Analyser (PD Systems, West Molesey,
UK) we sampled dopamine at 8 Hz. Changes in the sampled signal were captured using a CED1401
micro3 analogue-to-digital converter (Cambridge Electronic Design (CED), Cambridge, UK), displayed
using Spike2 v7.1 data capturing software.
Electrical stimulation protocol. Bipolar tungsten electrodes, with their tips 400 μm apart, were used
to locally stimulate the core of the nucleus accumbens. Pseudo-one pulse stimulation was used to
avoid the activation of autoreceptors [33] which occurs approximately 500 ms after striatal dopamine
release [34,35]. A train of 10 × 1 ms 10 mA pulses at 100 Hz was applied every 5 min using a Neurolog
NL800 stimulus isolator (Warner Instruments, Hamden, CT, USA) under computer control (Spike,
CED, Cambridge, UK).
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Experimental protocol. To begin an experiment, slices were transferred from the slice saver to a
laminar ﬂow recording chamber that was supplied with aCSF via gravity feed, at a rate of 100 mL/h.
Slices were left to equilibrate in the recording chamber for 30 min before starting stimulation of the
slice, and the tips of both stimulating and recording electrodes were placed in the accumbens to
record monoamine release. Recording took place from the beginning of this 30 min period as large
spontaneous release events of dopamine can occur, which is indicative of poor slice health [36], and on
such occasions (5–10%) the experiments were terminated.
2.4. Statistics
DAT binding data were analysed with a 1-way ANOVA. Voltammetry data were analysed for peak
effects of each drug concentration on each brain slice, which was typically found around 45–50 min
after drug application. Statistical analysis was carried out using SigmaPlot (v. 11.0), a 1-way ANOVA
(independent variable = concentration) was used with post-hoc Tukey’s. In all graphs data are
presented as means ± SEMs and signiﬁcance is set at p < 0.05.
2.5. Computational System Setup
Modeling of the Rattus norvegicus dopamine transporter (rDAT). The construction and reﬁnement of
the homology model of the Rattus norvegicus dopamine (rDAT) transporter has been previously
reported [12] using established protocols used in the construction of a human DAT (hDAT)
model [37–40]. Brieﬂy, we used Modeller 9v17 [41] and the previously published sequence alignment
of the NSS family of proteins to ﬁrst construct the transmembrane (TM) part of the rDAT (residues
57–589) based on the recent crystal structure of the Drosophila melanogaster dopamine transporter
(dDAT) bound to dopamine (PDB ID: 4XP1) [9]. An adaptation of this sequence alignment, created by
the Alignment-Annotator web server [42], is provided in Figure S1—in the Supplementary Material
for convenience. The newly crystallized dDAT structure is well suited as a template for homology
modeling of rDAT because the overall sequence identity is >50% [6], with the sequence identity
between the TM segments of rDAT and dDAT being 61%, and having a Root Mean Square Deviation
(RMSD) of <1 Å for the critical regions of the binding site and ion binding sites, TMs 1, 6 and 8 [12],
which are key to the inferences we describe herein.
For completion, we also used the sequence alignment in Figure S1 and the N- and C-terminal
regions modelled for hDAT from ab initio methods [40] to include Modeller 9v17 [41] homology models
of the terminal domains for rDAT. Based on the align module of Modeller 9v17 [41], two functional
Na+ and one Cl− ion in 4XP1 were also added to the S1 binding site. PROPKA [43] was used to
determine the protonated state of the ionizable Glu490 residue of rDAT while a disulﬁde bond was
introduced in EL2, between Cys180 and Cys189.
Compound preparation and docking. The chemical structures in the (S)-enantiomer of the ﬁve
compounds (Figure 1) were built using the LigPrep module of Schrödinger Release 2017-1 [44] with
the OPLS3 force ﬁeld. The prepared compounds all carried a net positive charge as assigned by
Epik [44]. The rDAT homology model was prepared using the Protein Preparation Wizard module in
Maestro, following which the Induced ﬁt docking (IFD) protocol, in the Schrödinger software suite
was implemented to dock 2-MXP (Figure 1) to the homology model of rDAT. Since 2-MXP is one of
the largest of the ﬁve compounds it was used to create a greater volume in the binding site, that was
subsequently replaced by the other compounds. The residues Phe76, Asp79, Ser149, Val152, Tyr156,
Asn157, Phe326, Val328 and Ser422, previously identiﬁed as important for binding psychostimulants
of comparable size [10,11], were used to deﬁne the docking grid box. Dockings was then performed
using standard precision (SP). Random initial positions and conformations of the ligand were screened
for clashes with the protein and subsequently reﬁned by allowing ﬂexibility of the side-chains in the
binding site.
The bound 2-MXP was then replaced with the other compounds to create the corresponding
complexes (rDAT-DPH, rDAT-CLD, rDAT-3-MXP and rDAT-4-MXP) by aligning the backbone atoms
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to overlap the binding positions, while maintaining the amino (NH) group interaction with Asp 79.
In the absence of a crystal structure of DAT with these compounds we hypothesised that the best
binding pose for these compounds would initially exploit the key interactions of residues Phe76,
Asp79, Ser149, Val152, Tyr156, Asn157, Phe325, Val327 and Ser421, as seen in the crystal structures
of dopamine, amphetamine, MDMA and cocaine [9] and which was also validated and exploited for
docking 5-MAPB and 5-APB in a previous study [12]. The force-ﬁeld parameters for the compounds
were obtained from the Acellera small molecule parameterization tool implemented in the HTMD
1.11.2 suite [45].
2.6. Molecular Dynamics Simulations
The rDAT complexes (rDAT-DPH, rDAT-CLD, rDAT-2-MXP, rDAT-3-MXP and
rDAT-4-MXP) were immersed in biophysically relevant membrane environments, a mixture
of POPE/POPC/PIP2/POPS/cholesterol, closely resembling the neuronal cell plasma membrane,
with explicit water, internal ions and added salts as described previously. See the earlier work for
details of the protocol [12].
For all complexes a previously described multistep equilibration protocol [46] was performed
with the NAMD software, version 2.9 [47] to remove the close contacts in the structure, the backbones
were initially ﬁxed and then harmonically constrained, and water was restrained by small forces from
penetrating the protein-lipid interface. The constraints on the protein were released gradually in three
steps of 300 ps each, changing the force constants from 1 to 0.5, and 0.1 kcal/(mol Å2), respectively,
with a time step of 1 fs. This was then followed by a short (100 ns) unbiased MD simulation performed
with a 2 fs integration time-step and under constant temperature (310 K) maintained with Langevin
dynamics, and 1 atm constant pressure achieved by using the hybrid Nosé-Hoover Langevin piston
method on a ﬂexible periodic cell to capture long-range effects. The simulated system, including the
transporter embedded in a membrane patch and water layers on each side containing Na+ and Cl− ions
(corresponding to a concentration of 150 mM NaCl), was composed of approximately 266,590 atoms in
a box with the ﬁnal dimensions of 138 × 146 × 153 Å.
After this equilibration phase, unbiased production MD simulations were carried out using
GPUS and the ACEMD software [48] with an established protocol [12,39] for a further 300 ns.
Brieﬂy, the simulations employed the all-atom CHARMM27 force ﬁeld for proteins with CMAP
corrections [49] as well as the CHARMM36 force ﬁeld for lipids [50], the TIP3P water model, and the
CHARMM-compatible force-ﬁeld parameter set for PIP2 lipids [51]. The PME method for electrostatic
calculations was used, along with 4 fs integration time-step with standard mass repartitioning
procedure for hydrogen atoms implemented in ACEMD. More details about the computational protocol
can be found in (Khelashvili et al., 2015b). The trajectories were analysed with the R software [52] and
VMD [53] for graphical representation.
In total, at least 3 μs of simulation time including the MD runs and the following free energy
perturbation (FEP) calculations were accumulated.
2.7. Free Energy Perturbation Calculations
To evaluate the change in the binding free energy of the four compounds (2-Cl-DPH, 2-MXP,
3-MXP and 4-MXP) from DPH, we utilized a two-step free energy calculation approach. As an example,
we show in Figure 2 the change in the binding free energy between compounds DPH and 2-MXP.
This can be calculated by either ΔG4 − ΔG1 or ΔG3 − ΔG2. However, the change from ΔG4 − ΔG1 is
computationally more practical. ΔG1 represents the unbound solvent (ligand in water) state while ΔG4
represents the bound (protein-ligand complex in water) state. We are calculating the relative binding
afﬁnity of two compounds rather than the absolute protein-ligand binding free energy calculation
which is more challenging as the introduction of the protein adds signiﬁcantly more degrees of freedom
to the system [54].
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Figure 2. The thermodynamic perturbation cycle between the compounds DPH and 2-MXP. A similar
cycle would apply to the free energy change from DPH to the other three compounds (2-Cl-DPH, 3-MXP
and 4-MXP). Here we highlight the complexity of the full systems in each step of the transformation as
well as the components (compounds, protein, ions and membrane) that are boxed. ΔG1 represents the
unbound solvent (ligand in water) state while ΔG4 represents the bound (protein-ligand complex in
water) state.
Two independent transformations between each of the four compounds (2-Cl-DPH, 2-MXP, 3-MXP
and 4-MXP) and DPH were calculated in both a water-solvent environment with both the protein
(and membrane) present and absent, respectively. The free energy change ΔG of each perturbation was
evaluated by the alchemical free-energy perturbation (FEP) approach [55,56] that has been applied
previously to de novo mutations in the human dopamine transporter [37,38].
The free energy perturbation procedure with a softcore potential implementation was carried out
with the NAMD software version 2.12 [47] and with the same simulation systems with explicit solvent
as described above. For the FEP computation, the coupling parameter λ varied from 0 to 1 such that
each window did not exceed 3 kcal/mol for a total of 400 ps for the full transformation. In the hysteresis
tests the results differed from the annihilation in the same interval by ~1 kcal/mol. Each reported
value is the average of at least three runs starting from different points (after at least 100 ns) of the MD
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trajectories. Table S1 of the Supplemental Information gives the details of the bound (protein-ligand
complex in water) state or ΔG4. Using the restraining potential approach (Wang et al., 2006), a potential
representing the interaction of the atoms being annihilated with the binding residues, including the
crucial salt bridges between the N1 atom of each compound and the CG of Asp 79 and OH of Tyr 156
in the S1 site were applied [10,11]. The ﬁnal solvation energies were calculated as the algebraic sum of
the FEP and restraining energy values. A similar protocol has been described elsewhere [37,46,57].
The aqueous solvation energy of the ligand in the simulation system was calculated for direct
comparison in a 30 × 30 × 30 Å3 water box containing two Na+ ions and one Cl− ion (equivalent to
120 mM NaCl) using exactly the same FEP/MD procedure as above but without restraints.
3. Results
Diphenidine displaced [125I]RTI-121 (RTI) binding in a concentration-dependent manner
(F(4, 29) = 33.26, p < 0.001) with 3, 10 and 30 μM causing a signiﬁcant reduction in RTI binding
(p < 0.05) (Figures 3 and 4A). There was no effect of methoxphenidine on RTI binding (F(4, 29) = 1.47,
p = 0.24). Cocaine was also tested for comparison (autoradiograms not shown); cocaine displaced
RTI binding in a concentration-dependent manner (F(5, 35) = 18.701, p < 0.001. Tukey’s test revealed
that 3, 10 and 30 μM cocaine signiﬁcantly reduced RTI binding (all p < 0.05). A 1-way ANOVA was
used to compare the 3 drugs at 10 μM (the only common concentration used in the dopamine efﬂux
experiments) and there was a signiﬁcant difference between the 3 drugs (F(2, 17) = 72.683, p < 0.001.
Tukey’s showed that both cocaine and diphenidine caused a signiﬁcant reduction in RTI binding vs.
methoxyphenidine (Figure 4A).
Figure 3. Representative autoradiograms showing the binding of the radioligand [125I]RTI-121 in the
brain striatal sections in the presence of increasing concentrations of DPH and 2-MXP (MXP).
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Figure 4. Top panel (A,B): Comparative effects of DPH, 2-MXP (MXP) and cocaine-quantitative in vitro
data: (A) Speciﬁc DAT binding expressed as % of [125I]RTI-121 binding; n = 6 per drug concentration.
(B) peak DA efﬂux as measured by means of fast cycling voltammetry n = 4–7. Bottom panels (C–F):
Representative dopamine efﬂux events after brief electrical stimulation for DPH and 2-MXP (10 pulses
at 100 Hz). (C,E) show control dopamine efﬂux prior to drug application. (D,F) show dopamine efﬂux
60 min after drug administration. 60 s of data is shown for each trace and peak dopamine efﬂux is
~250 nM under control conditions. DAT: dopamine transporter; COC: cocaine; DPH: diphenidine;
MXP: methoxyphenidine. Values are means ± SEM. Panel A: *** p < 0.001 for both COC and DPH vs.
MXP at 10 μM. Panel B: * p < 0.05 for COC vs. DPH and for DPH vs. MXP, *** p < 0.001 for COC vs.
MXP, all for 10 μM drug concentrations. For drug concentrations vs. control statistics see text.
DPH also increased peak dopamine efﬂux after electrical stimulation (F(3, 19) = 14.405, p < 0.001,
with 10 and 30 μM signiﬁcantly increasing dopamine efﬂux vs. controls (both p < 0.05). 2-MXP had no
signiﬁcant effect on peak dopamine efﬂux F(2, 15) = 1.91, p = 0.187. MXP voltammetry was only tested
at 10 and 30 μM. Cocaine also increased dopamine efﬂux (F(3, 21) = 14.907, p < 0.001). Tukey’s revealed
that both 1 and 10 μM signiﬁcantly increased dopamine efﬂux (both p < 0.05). We also compared
drugs at 10 μM using a 1-way ANOVA; F(2, 14) = 19.884, p < 0.001) with post-hoc Tukey’s revealing
that cocaine had a signiﬁcantly greater effect on dopamine efﬂux vs. both diphenidine (p < 0.05) and
methoxyphenidine (p < 0.001) and diphenidine had a signiﬁcantly greater effect on dopamine efﬂux vs.
methoxyphendine (p < 0.05). See Figure 4B. Dopamine efﬂux events after brief electrical stimulation
(10 pulses at 100 Hz) are shown in Figure 4C–F, demonstrating the differences between DPH and
2-MHP in their respective abilities to increase dopamine levels at 30 μM.
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3.1. Relative Binding Free Energies
The binding free energy change from DPH to its aryl-substituted 1,2-diarylethylamines analogs
(Figure 1) are calculated and compared with the previously determined experimental IC50 values from
rDAT (Table 1) [22]. Free energy methods have been shown to have good chemical accuracy [56,58]
in predicting the binding free energy change (ΔΔG), which is the cost in free energy of substituting
one compound with another compound. This is usually in combination with well-tuned force ﬁelds
that have reasonable agreement with experimental results, where the RMSD in hydration free energy
of small organic molecules between calculated and experiment are ~1.0 kcal/mol using the more
common force ﬁelds like CHARMM. Therefore, the hypothetical binding poses for each compound
as described above, which is shared by many other compounds in the binding site should give the
best correlation between the predicted binding free energy and the experimentally measured binding
afﬁnity IC50 values. A positive value would suggest a cost in energy, thus the substituted compound
should be less favourable. Conversely, a negative value means the substituent is more favourable.
Table 1. Calculated binding free energy change (ΔΔG, kcal/mol) of the substituted analogs against
DPH and their experimental IC50 values (μM)* from Wallach et al., 2016. ΔG1 represents the unbound
solvent (ligand in water) state while ΔG4 represents the bound (protein-ligand complex in water) state.
Compound ΔG1 w.r.t. DPH(kcal/mol)
Average ΔG4 w.r.t.
DPH (kcal/mol)
ΔΔG4-1 w.r.t. DPH
(kcal/mol) IC50 (μM)*
DPH 0 0 0 1.99
3-MXP 1.90 ± 0.2 1.25 ± 0.5 −0.65 ± 0.3 0.587
4-MXP 2.64 ± 0.1 1.89 ± 0.5 −0.75 ± 0.4 2.23
2-Cl-DPH −7.19 ± 0.2 −6.84 ± 0.7 0.35 ± 0.5 10.5
2-MXP 11.96 ± 0.2 15.59 ± 0.8 3.63 ± 0.6 30
Based on the initial rDAT complexes constructed by docking, MD simulations were performed to
incorporate conformational ﬂexibility into both rDAT and the corresponding ligands (2-MXP, 3-MXP,
4-MXP, DPH, CLD) to assess the persistence of the key interactions in the S1 site (Phe76, Asp79,
Ser149, Val152, Tyr156, Asn157, Phe326, Val328 and Ser422). As such, the monitored Root Mean
Square Deviation (RMSD) of the transmembrane regions of rDAT showed that the RMSDs reached
equilibration within 100 ns simulation for each complex (Figure S2A). Structural superimposition of
the docking pose and a representative snapshot from the MD simulations for the ﬁve compounds in
the rDAT binding site indicates some ﬂexibility (e.g., the RMSDs of DPH and 2-MXP before and after
MD simulation were 0.56 Å and 0.75 Å, respectively (Figure S2B)), but the key interactions such as
the salt bridge between the protonated nitrogen of ligand and the Asp79 was preserved. As such,
snapshots were taken at 100 ns and subsequently at 150 ns and 175 ns to further estimate the molecular
basis of 2-MXP, 3-MXP, 4-MXP, DPH and CLD binding speciﬁcity to rDAT via the FEP method.
The two oppositely charged pairs of residues, Arg 85–Asp 475 and Arg 60–Asp 435, functioning
as the extracellular (EC) and intracellular (IC) gates respectively, were maintained as well as the
stabilizing hydrogen bond between Asp79 and Tyr156 shown to be important in stabilizing the S1
binding pocket [10,12] (Figure 5A). Additionally, as previously mentioned the binding pose for each
compound was aligned so that they maintained the amine (NH) group interaction with Asp 79. For the
purpose of the free-energy calculations this was aided by the use of distance restraints between the
crucial salt bridge of the N1 atom of each compound and the CG of Asp 79 and OH of Tyr 156.
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Figure 5. (A) Simpliﬁed representation of the molecular model of rDAT and the positions of the
two oppositely charged pairs of residues, Arg 85–Asp 475 and Arg 60–Asp 435, functioning as the
extracellular (EC) and intracellular (IC) gates respectively and the Asp79 and Tyr156 residues shown
to be important in stabilizing the S1 binding pocket (boxed) via a hydrogen bond. rDAT in complex
with (B) DPH (yellow) and (C) 2-MXP (yellow). Each of these distinct compounds occupies a binding
pocket that is deeply buried in the transporter structure. Selected central binding site residues from
each compound are shown in grey and labelled respectively. Additionally, blue and purple spheres
represent the internal sodium and chloride ions, respectively.
Interestingly, the values for ΔΔG reveal ranked predictive binding free energies with respect to
DPH as follows 4-MXP (−0.75 kcal/mol) > 3-MXP (−0.65 kcal/mol) > DPH (0 kcal/mol) > 2-Cl-DPH
(0.35 kcal/mol) > 2-MXP (3.63 kcal/mol).
The ΔΔG values from DPH to 2-Cl-DPH (0.35 kcal/mol) and DPH to 2-MXP (3.63 kcal/mol) are
positive indicating unfavourable substitutions, with the most unfavourable being 2-MXP. This is in
agreement with the IC50 values whereby 2-MXP (30 μM) is less potent at rDAT compared to 2-Cl-DPH
(10.5 μM).
The measured IC50 values for 3-MXP (0.587 μM) and 4-MXP (2.23 μM) while showing
unfavourable changes are quite close to DPH (1.99 μM). While the change in binding free
energies (ΔΔG) are small, they suggest favourable substitutions for the methoxy group in 3-MXP
(−0.65 kcal/mol) and 4-MXP (−0.75 kcal/mol). With 4-MXP ranking slightly more favourable than
3-MXP, which is in disagreement with experimental data as the IC50 values show that 4-MXP is
more potent.
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3.2. Molecular Dynamics Simulations
The extended molecular dynamics simulations also revealed some mechanistic insights into the
different binding properties of each compound. The simulations reveal a number of concerted motions
not only with the IC and EC gates but also distances between the Na1 and Na2 ions and the Asp 79
and Tyr 156 hydrogen bond. We also characterise the IC movements based on the concerted motions
of the intracellular transmembrane TM1a, TM6b, and TM9 segments and additional movements on
the extracellular side by the TM1b and TM6a segments, previously identiﬁed as markers for opening
of the intracellular vestibule [39].
In DPH we see a disruption of the extracellular network with the ionic interaction between
Arg 85 and Asp 475 for DPH (a feature not seen with the other compounds) (Figure 6A). This was
complemented by the movements seen in the extracellular TM6b-TM9 and TM3-TM1b segments
(Figure 6B). This suggests a mechanism involving a conformational change whereby DAT opens
extracellularly. There is no evidence of Na2 ion destabilization or disruption of the hydrogen bond
between Asp79 and Tyr156 during these timescales (Figure 6A) or any effect on the intracellular TM
segments, TM1a-TM6b, TM1a-TM9, and TM6b-TM9 (Figure 6C).
Figure 6. Cont.
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Figure 6. Time evolution in the simulations for rDAT when bound to DPH (A–C) and 2-MXP (D–F).
(A,D) depict the distances between D79 and Y156, Na1 and Na2 and R85 and D475. (B,C,E,F) panels
depict the Cβ-Cβ distances between residues in various extracellular and intracellular transmembrane
(TM) segments respectively for I67 (in TM1a) and L446 (in TM9), I67 (in TM1a) and S332 (in TM6b)
and S332 (in TM6b) and L446 (in TM9); E306 (in TM6a) and F171 (in TM3); and F171 (in TM3) and K92
(in TM1b). (G) The IC and EC segments in the protein TM regions from the middle and bottom panels
are labelled and coloured in orange.
The simulations reveal that 2-MXP changes position in the rDAT binding site in such a way that
its electron-donating, 2-methoxy (-CH3O) group, that is also an ortho-substitution, is oriented away
from the electron-donating phenolic-OH on Y156 (Figure 5C). Here we observe not only destabilization
of the Na2 ion (Figure 6D) but also isomerization to the inward-facing state (as monitored by the
movements in the intracellular TM segments—Figure 6F). There is no evidence of disruption of the
extracellular network, instead the ionic interaction between Arg 85 and Asp 475 becomes more stable
(Figure 6E).
At these timescales there is some evidence of isomerization with respect to 2-Cl-DPH at rDAT
(Figure S1—in the Supplemental Material) as seen in Na1 and Na2 distance change (Figure S3A) and the
increase in distances in the intracellular TM segments (Figure S3C). The extracellular network remains
intact as well as the D79-Y156 hydrogen bond (Figures S3A and S3B). 2-Cl-DPH also changes position
(tilts) in the binding site but it also contains an electron withdrawing chloride in the ortho-position,
giving rise to an electron-poor ring substitution which could also explain its unfavourable IC50 and
ΔΔG values.
With respect to 3-MXP and 4-MXP, the -CH3O group substitutions are classiﬁed as meta- and para-
aromatic substitutions, respectively (Figures S4 and S5). Since we know that chemically the -CH3O
group is described as an activator or electron donor to the ring at these positions this could potentially
explain the more favourable ΔΔG values compared to 2-Cl-DPH and 2-MXP. Similarly, to 2-MXP,
4-MXP not only displays destabilization of the Na2 ion but also isomerization to the inward-facing
state (Figure S5A,C). There is also no evidence of disruption of the extracellular network, instead
the ionic interaction between Arg 85 and Asp 475 becomes much more stable (Figure S5B). At these
timescales, 3-MXP does display evidence of isomerization to the inward-facing state (Figure S4C),
with increased minimum distances changing between the intracellular TM segments, TM1a-TM6b,
TM1a-TM9, and TM6b-TM9 but there is no change in the distance between Na1 and Na2 (Figure 4A)
or the extracellular network (Figure 4B). Longer simulations are needed to fully explore these changes.
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4. Discussion
In the present study, we analysed the mechanism of binding between rat DAT and aryl-substituted
1,2-diarylethylamines using docking and alchemical free energy approaches in conjunctionwith in vitro
neurobiological experimental measurements, which we applied to 2 diarylethylamine NPS of that
class, diphenidine and methoxphenidine. While DPH and 2-MXP exert their dissociative effects via
N-methyl-D-aspartate receptor antagonism [22], their psychoactive effects can also be inﬂuenced by
their binding to the monoamine transporters, with DPH and 2-MXP having their highest afﬁnity for
the DAT, followed by the noradrenaline transporter (NET) and serotonin transporter (SERT) [30]. DPH
and 2-MXP have markedly different functional potencies at DAT, as represented by their IC50 values
of 1.99 μM and 30 μM for DPH and 2-MXP, respectively, at human DAT stably expressed in HEK293
cells [22]. For the sake of comparison, the IC50 of cocaine as the most potent stimulant ranges from
0.4 μM to 1.3 μM at DAT expressed in transfected HEK293 cells, as published in the literature [59].
Our neurobiological ﬁndings suggest that DPH signiﬁcantly increased dopamine efﬂux, as a
result of binding to DAT, demonstrated in the competition with 125-iodine labelled RTI-121 in rat
brain sections, whereas 2-MXP had no signiﬁcant effect on either RTI-121 binding or evoked dopamine
efﬂux in the nucleus accumbens in vitro. Interestingly, despite displacing RTI-121 binding with similar
potency to cocaine, DPH had a signiﬁcantly lesser effect on dopamine efﬂux as measured using fast
cyclic voltammetry. These data, consistent with the IC50 differences reported by Wallach et al., 2016,
suggest that DPH exhibits pro-dopaminergic stimulant-type effects in the brain tissue, and therefore
this NPS can have some addictive liability. In addition to suggesting that DPH might have addictive
liability due to its effects on dopamine efﬂux, we might also tentatively highlight its potential utility as
a pharmacotherapy. Dopamine transporter ligands might be useful as substitution or maintenance
treatments for psychostimulant abuse [60] or as treatments for attention deﬁcit hyperactivity disorder
(ADHD) or even as treatments for depression, for example bupropion. Given DPH is also an antagonist
at NMDA receptors, as well as a DAT blocker, it may even have potential as a fast-acting antidepressant
as seen with ketamine [61]. We have previously reviewed the potential use of novel psychoactive
substances, including dissociatives, such as DPH, in CNS disorders [62].
On the contrary, 2-MXP, despite its apparent chemical similarity to DPH, does not exhibit
pro-dopaminergic stimulant effects as assessed in the brain tissue in vitro. It is most interesting
to understand why subtle structural differences result in such varied stimulant features of novel
psychoactive substances (NPS) and what basic atomistic interactions of DAT as the biological target
for stimulants decide about the discrimination of potential stimulants at DAT.
Therefore, we calculated relative binding free energy of the analogs 2-Cl-DPH and MXP.
That exercise showed unfavourable substitutions when compared to DPH, in agreement with the
experimental IC50 values, and consistent with our in vitro comparison of the pro-dopaminergic effects
of DPH and MXP. While, the calculations using two other compounds 3-MXP and 4-MXP reveal
favourable substitutions, although their IC50 values from Wallach et al. [12] show small unfavourable
changes compared to DPH. Conformational changes emerging over long-scale simulations have also
indicated different structural and dynamic elements of the mechanisms governing the interactions
of these various compounds with DAT. Structural rearrangements in DAT when bound to DPH
show evidence of an outward facing conformation, speciﬁcally the rearrangement of the extracellular
gates, a well-known conformation adopted by inhibitors like cocaine [10,11,63,64]. This observation
is supported by the present in vitro data where DPH acts as a DAT inhibitor but weaker than
cocaine, which can cause a 4-fold increase in DA efﬂux, as previously observed under identical
conditions [65]. In contrast when 2-MXP is bound to DAT, it shows evidence of adopting an inward
facing conformation of DAT, such as the spontaneous release of Na2 and the rearrangement of
the intracellular gates. Although this is a conformation adopted by many substrate releasers like
amphetamine and 5-MAPB [12], 2-MXP does not appear to be a DAT inhibitor nor does it reveal reverse
transport at the concentrations used in this study (up to 30 μM; data not shown) (Figure 4—bottom
panel). Longer atomistic simulations are needed to resolve the rearrangements seen for 2-MXP as
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well as 2-Cl-DPH, 3-MXP and 4-MXP that also show stabilisation of the inward facing conformation
of DAT.
While the free energy pertubation method itself is a good measure of the binding afﬁnity
between two molecules, it does highlight some considerations for future studies, including the size
and position of the substitution. Most importantly, the geometric and dynamic properties of a
modelled protein-ligand complex contribute entropically to the binding mode of ligands. Thus, it is
still challenging to rank with chemical accuracy a series of ligand analogues in a consistent way for
systems where there are considerable ﬂuctuations in the binding mode. In this study we face this issue
calculating relative binding free energies of the aryl-substituted 1,2-diarylethylamines analogs because
of the presence of multiple metastable ligand orientations which can cause convergence problems.
Distance restraints were utilised but the use of orientational restraints may further accelerate the
convergence of these calculations [66]. We aim to further investigate this with other classes of NPS with
different scaffolds and substitutions. Calculating the free-energy of binding from different snapshots
of long atomistic-simulations may also reveal the energy change associated with binding pose changes.
This study also demonstrates the ability of the alchemical free energy approach in combination
with docking and homology modeling to be an effective means of investigating and characterising
novel psychoactive substances. Additionally, these methods highlight that a structural analysis is
important when creating a stimulant proﬁle as it adds to the insights of binding and functional data
derived from functional studies applied in animal models. To our best knowledge, this is the ﬁrst
application of relative binding free energy calculation in the studies on the biological effects of NPS,
and similar approaches are plausible with some other biological targets, which would expand our
understanding of stimulant mechanisms of NPS and other drugs of addiction, as psychoactive effects of
drugs can be inﬂuenced by their binding to other monoamine transporters, namely NET and/or SERT.
It is important to understand the molecular determinants of stimulant actions which may underlie
their distinct pharmacological effects at DAT and also at other transporters like SERT and NET as well
as species effects.
This study considered the responses of both in vitro data and in silico data to psychostimulants in
the same cellular background, rDAT. A previous study by Dawn Han and Howard Gu show that when
popular psychostimulant drugs like cocaine, methylphenidate, amphetamine, methamphetamine and
MDMA are tested for their relative afﬁnities, their sensitivities at the human and mouse transporters
were similar (Ki values are within 4-fold) [67]. Therefore, there is translational signiﬁcance to this study
supporting the use of rodent models to represent pharmacological, functional and now structural
changes of psychostimulants when acting in humans. This is not surprising because rDAT and
mDAT share 99% sequence similarity and identity to hDAT. Nevertheless, there is evidence and
reason to investigate in detail species effects that could be driving potential differences like abolished
reward mechanisms through mutations in mDAT and hDAT [68,69] in further publications and from
longer simulations.
To conclude, our in vitro study with the brain tissue indicates that diphenidine can increase
dopamine efﬂux as a result of its binding to dopamine transporter, whereas methoxphenidine has
no signiﬁcant effect on either RTI-121 binding or evoked dopamine efﬂux. These data suggest
that diphenidine can have some addictive liability, unlike methoxphenidine, despite the chemical
similarities of these two NPS.
The present computational study supports the neurobiological ﬁndings of DPH when compared
with 2-MXP, and provides novel insights into the mechanisms that underpin the pro-dopaminergic,
hence stimulant, interactions between NPS and DAT. Longer atomistic simulations are needed to
conﬁdently resolve whether the DPH stimulant behaves in a cocaine-like manner in terms of its effects
on the conformational rearrangements within the DAT. While this novel in silico approach informs
about the potential addictive effects of a prevalent dissociative NPS, diphenidine, it also tackles the
core physical mechanisms that decide about addictive properties of other NPS, of direct relevance to
the health risks linked with their use.
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Supplementary Materials: The following are available online at www.mdpi.com/2076-3425/8/4/63/s1, Table
S1: The convergence of the calculated free energy change (kcal/mol) in each perturbation for the ﬁve compounds
in the bound (protein-ligand complex in water) state; Figure S1: Alignment of human (hDAT), rat (rDAT),
mouse (mDAT) and fruit-ﬂy (dDAT) amino acid sequences; Figure S2: (A) RMSD graph and superimposition of
compounds at the binding site after docking (cyan) and after 100ns (orange) of unbiased MD for (B) DPH and
(C) 2-MXP; Figure S3: Time evolution in the simulations for rDAT when bound to 2-Cl-DPH, Figure S4: Time
evolution in the simulations for rDAT when bound to 3-MXP, Figure S5: Time evolution in the simulations for
rDAT when bound to 4-MXP.
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Abstract: Recently, a range of prescription and over-the-counter drugs have been reportedly used
as Novel Psychoactive Substances (NPS), due to their potential for abuse resulting from their high
dosage/idiosyncratic methods of self-administration. This paper provides a systematic review of the
topic, focusing on a range of medications which have emerged as being used recreationally, either on
their own or in combination with NPS. Among gabapentinoids, pregabalin may present with higher
addictive liability levels than gabapentin, with pregabalin being mostly identiﬁed in the context
of opioid, polydrug intake. For antidepressants, their dopaminergic, stimulant-like, bupropion
activities may explain their recreational value and diversion from the therapeutic intended use.
In some vulnerable clients, a high dosage of venlafaxine (‘baby ecstasy’) is ingested for recreational
purposes, whilst the occurrence of a clinically-relevant withdrawal syndrome may be a signiﬁcant
issue for all venlafaxine-treated patients. Considering second generation antipsychotics, olanzapine
appears to be ingested at very large dosages as an ‘ideal trip terminator’, whilst the immediate-release
quetiapine formulation may possess proper abuse liability levels. Within the image- and performance-
enhancing drugs (IPEDs) group, the beta-2 agonist clenbuterol (‘size zero pill’) is reported to be
self-administered for aggressive slimming purposes. Finally, high/very high dosage ingestion of
the antidiarrhoeal loperamide has shown recent increasing levels of popularity due to its central
recreational, anti-withdrawal, opiatergic effects. The emerging abuse of prescription drugs within the
context of a rapidly modifying drug scenario represents a challenge for psychiatry, public health and
drug-control policies.
Keywords: drug abuse; novel psychoactive substances; NPS; pharmacovigilance; prescribing
drugs’ abuse
1. Introduction
Novel Psychoactive Substances (NPS; ‘legal highs’ or ‘research chemicals’) are molecules designed
to mimic the effects of legal traditional recreational drugs with intense psychoactive effects and
virtual non-detectability in routine drug screenings. NPS include synthetic cannabinoids, cathinone
derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives,
phencyclidine-like dissociatives, piperazines, psychoactive plants/herbs and a range of prescribed
medications [1]. The term NPS was first used by United Nations Office on Drugs and Crime (UNODC)
to refer to “substances of abuse, either in a pure form or a preparation, that are not controlled by the 1961
Single Convention on Narcotic Drugs or the 1961 Convention on Psychotropic Substances, but which
may pose a public health threat” [2]. At present, the emergence of NPS, typically from outside Western
countries [3], represents a considerable public health challenge. Moreover, in order to circumvent
the present controls and regulations, NPS are constantly diversifying and being replaced [4]. This is
being facilitated by the growing number of anonymous online marketplaces, called ‘cryptomarkets’,
Brain Sci. 2018, 8, 73; doi:10.3390/brainsci8040073 www.mdpi.com/journal/brainsci113
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which host many anonymous sellers whilst using untraceable cryptocurrencies [5]. NPS users
report a range of reasons behind their preference for NPS as opposed to traditional drugs such
as cannabis, cocaine and heroin, including typical lack of detectability, greater affordability, lack
of stigma, and relative ease of online acquisition [6]. Recently, however, the phenomenon of using
prescription drugs in an idiosyncratic way to resemble, or counteract, the effects of NPS, has increasingly
been described. This phenomenon refers not only to high potency opioids (e.g., fentanyl) and
‘exotic’/designer benzodiazepines—molecules already having been reported to be addictive [1]—but
also: gabapentinoids [7], a range of stimulants [1], antipsychotics [8], antidepressants [9] and image- and
performance-enhancing drugs (IPEDS, e.g., anabolic steroids, vitamins, clenbuterol and salbutamol) [10].
Among over-the-counter drugs, the two most common agents reportedly ingested in intentional abuse
cases are the antitussive, dextromethorphan [11], and loperamide, a common antidiarrhoeal drug [12].
Any pharmacovigilance approach aims to detect, assess, understand and hopefully prevent
adverse effects or any other medicine-related problems. From this point of view, there is a growing
attention on prescription drugs and their addictive liability levels/diversion potential [7,8,10,12].
As the intended and the actual use of medicines differ between clinical trials and real-world use,
pharmacovigilance activities are well placed to focus on the post-marketing phase. In Europe, those
activities are coordinated by the European Medicines Agency (EMA) [13] through EudraVigilance
(EV), which is the system for collecting, managing and analyzing information on suspected adverse
reactions to medicines which have been authorized in the European Economic Area (EEA) [14].
This paper aims to provide a systematic review of the available literature relating to a preselected
range of prescription medicines (pregabalin, gabapentin, quetiapine, olanzapine, venlafaxine,
bupropion, loperamide, clenbuterol and salbutamol) previously reported as possibly being misused as
NPS. For each molecule, a range of preclinical, epidemiological, and clinical pharmacological data will
be provided.
2. Materials and Methods
A systematic review was carried out, consistent with the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines [15]. A literature search was performed on PubMed,
Medline/OvidSP (includes Embase), and Web-of-Science; the current search was completed in February
2018 andwas not associatedwith any time restrictions. We focused on pregabalin, gabapentin, quetiapine,
olanzapine, venlafaxine, bupropion, clenbuterol, salbutamol and loperamide [Title/Abstract]. For each
molecule, a number of search terms [Title/Abstract] were considered as follows: ‘misuse’, ‘abuse’,
‘dependence’, ‘withdrawal’, ‘off-label use’ and ‘non-medical use’. In addition, the authors performed
further secondary searches by using the reference listing of all eligible papers. All titles/abstracts were
examined, and full texts of potentially relevant papers obtained. Relevant works were selected in order
to obtain a full representation of the available literature data on the selected topic. Eligible studies
were identified if they possessed a range of characteristics, including (1) peer-reviewed clinical/human
studies; (2) at least an abstract with estimates and/or full availability of results; and (3) focusing on the
misuse/abuse/dependence/withdrawal of pregabalin; gabapentin; quetiapine; olanzapine, venlafaxine,
bupropion, loperamide, clenbuterol and salbutamol. The entire range of literature papers were included,
e.g., experimental and observational studies; case reports; case series; and fatalities’ reports. Although
letters to the editor, conference proceedings, and book chapters were excluded from the systematic
review, they were still considered in the retrieval of further secondary searches. SC independently
extracted and collected relevant data; FS contributed to the analysis of the results and discussed possible
issues and disagreements during the revision of the paper with SC.
From an initial list of 171 studies, 151 were identiﬁed as relevant and appropriate in terms of
quality according to PRISMA checklists. Following this, duplicates, papers lacking an English abstract,
letters to the editor, animal studies and papers unrelated to the topic were excluded, and 128 papers
were ﬁnally considered for the current study. A ﬂow diagram (Figure 1) describes the reasons for study
inclusion/exclusion at each stage, is here provided.
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Figure 1. Selection of retrieved studies.
3. Results
3.1. Gabapentinoids
Recently, the gabapentinoids, pregabalin and gabapentin, have increasingly been reported to
be abused at the EU-wide level, in parallel with increasing levels of prescriptions, related fatalities
and a growing black market [16–19]. Gabapentinoids are anticonvulsants but are also prescribed
for a range of clinical conditions in neurology, psychiatry and rheumatology, whilst being used
off-label for the treatment of benzodiazepine and alcohol dependence. Their effects are the result of
calcium channel binding, resulting in decreased central excitability levels. Compared to gabapentin,
pregabalin’s binding afﬁnity and potency are six times higher; pregabalin’s more signiﬁcant misuse
potential may also be due to its more rapid absorption, faster onset of action, much faster attainment
of maximum plasma concentration and higher bioavailability (>90%, irrespective of the dosage).
Furthermore, gabapentinoids are thought to possess GABA-mimetic properties, whilst possibly having
direct/indirect effects on the dopaminergic ‘reward’ system [7]. Gabapentionoid web enthusiasts
report the ingestion of this compound alone or in combination with other drugs (e.g., cannabis, alcohol,
opioids and other prescribed drugs), at a dosage range of 1000–4800 mg for gabapentin [20], and
750–12,000 mg for pregabalin [7]. Typical psychoactive effects include a sense of well-being/relaxation,
euphoria, and even hallucinations [1]. In 2005, the Drug Enforcement Administration (DEA) placed
pregabalin into Schedule V of the Controlled Substances Act (CSA) because of its potential for
abuse [21] and a similar scheduling approach has recently been approved in the UK. Chiappini
and Schifano [7] recently assessed the EMA EV database of pregabalin and gabapentin misuse-related
Adverse Drug Reactions (ADRs) over the last decade. According to the Proportional Reporting Ratio
(PRR) computation, abuse/dependence issues were more frequently reported for pregabalin compared
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with gabapentin, hence conﬁrming its higher addictive liability levels [7,22]. Furthermore, Emergency
Department presentations involving intentional drug overdoses recorded by the National Self-Harm
Registry (Ireland; 2007–2015), showed that gabapentinoids have been increasingly identiﬁed over
time, with high dosages and polydrug abuse being reported [23]. Indeed, gabapentinoid fatalities
are typically observed when these molecules are associated with other psychoactive drugs, especially
opioids and other sedatives whose effects are potentiated by gabapentinoids [24,25].
3.2. Antidepressants
Consistent with a worldwide rise in antidepressant consumption [26,27], bupropion and
venlafaxine have anecdotally emerged as increasingly being abused [1,28,29]. In examining a range
of online communities and specialized web services, several antidepressant misusers’ experiences
may be identiﬁed [20]. These reports emphasise both bupropion’s stimulant effects and venlafaxine’s
dissociative properties. Indeed, bupropion described as being ingested in very large quantities
(up to 4050 mg/day, roughly 14 times higher than the maximal therapeutic dosage) in order to
achieve an ‘amphetamine-like high’ [30]. In most abuse cases, its recreational use is associated with
oral or nasal administration, but intravenous use has also been reported [28,30–34]. Bupropion
pharmacology relies on its action both as a selective inhibitor of catecholamines (noradrenaline and
DA) reuptake [35,36], and as a non-competitive antagonist of nicotinic acetylcholine receptors, hence
being prescribed as well as an aid in smoking cessation [36]. Bupropion is known to be a cathinone
derivative, that is, a beta-ketone amphetamine analogue with dopaminergic and noradrenergic effects,
which may explain its misuse potential [37,38]. This is a reason for concern since bupropion is also
used ‘off-label’ in a range of conditions, including attention-deﬁcit/hyperactivity disorder, chronic
fatigue, sexual dysfunction, and obesity. The adverse effects of bupropion misuse range from nasal
pain to irritability, agitation, cardiac toxicity, hallucinations and seizures [39,40]. A retrospective
review [41] on bupropion cases of intentional abuse reported to the US National Poison Data System
highlighted an increase of 75% from 2000 to 2012, with the typical effects reported including tachycardia,
seizures, agitation/irritability, hallucinations/delusions, and tremor; similar data were identiﬁed
by the Toxicology Data Network of the US National Institute of Health (Toxnet) [42]. Typical
bupropion abusers may present with a history of drug addiction [38,43,44] and/or are inmates, with
bupropion having been removed from some US prison formularies [45–47]. Conversely, venlafaxine
is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant, indicated [48] for
the treatment of major depressive episodes, generalised anxiety disorder and social phobia, with
off-label use including obsessive-compulsive disorder and chronic pain syndromes. Its reuptake
effects are dose-dependent, with action progressively including serotonin (5-HT), norepinefrine (NE)
and dopamine (DA). Venlafaxine’s main active metabolite, desvenlafaxine, is highly inhibitive of NE
transporter activities, further increasing the rate of DA turnover in the prefrontal cortex [49]. Both
venlafaxine and its metabolite are not associated with monoamine oxidase inhibitory activity, which is
responsible for the degradation of DA. Hence, venlafaxine abuse may be associated with DA increase
in the prefrontal cortex [50], high afﬁnity for D2 receptors adaptive changes in D3 receptors following
its chronic administration and, ﬁnally, with the desensitisation of both 5-HT1A and beta-adrenergic
receptors [51]. Dependence and withdrawal symptoms associated with both SSRIs and SNRIs have
already been described, speciﬁcally with abrupt discontinuation of venlafaxine (including Extended
Release (XR) formulation) after long-term use [9,52–54]. Symptoms range from mild to severe and
include nausea, depression, suicidal thoughts, disorientation, stomach cramps, panic attacks, sexual
dysfunction, headaches and occasional psychotic symptoms [55–59]; a newborn discontinuation
syndrome has been described as well, at times associated with encephalopathy or paroxysmal
episodes [60]. The management of venlafaxine withdrawal includes the use of other antidepressants
(Ads) or venlafaxine tapering doses [61,62]. Furthermore, venlafaxine/‘baby ecstasy’ abuse has been
reported, typically being the result of the intake of very large doses [63–65]. Consistent with this, studies
have assessed drug and pharmaceutical consumption in England through wastewater analysis and
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comparing it to NHS prescription statistics. Discrepancies have been observed in the case of venlafaxine,
suggesting sales of non-prescribed venlafaxine, which are, therefore, not included within NHS data [66].
Furthermore, in a retrospective review of the records of the New Zealand National Poisons Centre over
the period 2003-2012, rapidly increasing levels of enquiries were identiﬁed for a range of prescription
medicines, including venlafaxine [67]. According to the EMA EV database from the last decade [68],
the misuse-/abuse-/dependence- and withdrawal-related ADRs reported respectively for bupropion
and venlafaxine show that bupropion may possess a higher recreational value due to its dopaminergic
and stimulant-like activity, whilst the occurrence of a venlafaxine-withdrawal syndrome may be
a signiﬁcant issue for venlafaxine-treated patients; these data were conﬁrmed by analysis of the
UK-based Yellow Card Scheme [68].
3.3. Antipsychotics
Consistent with their increased prescription and availability [69], second-generation antipsychotic
(SGA) (e.g., quetiapine and olanzapine) abuse has recently been reported [1,70–72]. Quetiapine
appears to be the most documented SGA being abused; it is commonly administered in the
400–800 mg/day range for the treatment of schizophrenia; bipolar disorder; and as an add-on in
major depression and anxiety [73–76]. Quetiapine is anecdotally known as ‘Susie Q’; ‘Quell’; and
‘baby heroin’ [75–79], with ‘Q ball’ and ‘Maq ball’, respectively, being combinations with cocaine, and
marijuana. Crushed quetiapine tablets can be self-administered through nasal insufﬂation [79–81],
although both oral [81–84], and intravenous [85–87] routes of administration have been reported.
Consistent with these anecdotal clinical observations, post-marketing surveillance reports indicate
an increase in quetiapine availability on the black-market [75,79,88–90]. Furthermore, quetiapine, either
on its own or in combination with heroin and/or alcohol [91], is consistently associated with high
rates of ambulance attendances, indicating greater community-level harm relative to other atypical
antipsychotics [92]. Indeed, between 2005 and 2011, quetiapine-related Emergency Department visits
increased in the USA by 90%, from 35,581 to 67,497 attendances [93]. A recent US National Poison
Data retrospective analysis identiﬁed all cases of single-substance SGA exposures coded as ‘intentional
abuse’ [94] during a 10-year period (2003–2013), quetiapine being the most represented molecule,
followed by risperidone and olanzapine. Prison inmates and opioid addicts seem to represent the most
at-risk populations [24,75,76,95–97]. Quetiapine psychotropic effects [86,87] are associated with both
increased levels of DA in the nucleus accumbens (NAc) area [89,98–100] and D2 receptor blockage.
As some pharmacodynamic mechanisms are shared by other non-misused SGAs [101–104], other
factors [105,106] or pharmacological effects explaining the molecule misuse potential may include
norquetiapine-related norepinephrine reuptake blockade [75], 5-HT7 antagonist properties and sigma
receptor activation [107,108]. Quetiapine pharmacokinetics, mediated by the cytochrome CYP3A4, may
play a part, as well, in facilitating its misuse [109]. Its XR formulation may be less frequently abused,
due to the delayed (by approximately 3 h) and blunted (by approximately 67%) serum peak [88];
the tablet coating may also make snorting of the crushed tablets quite problematic [89].
Another SGA, olanzapine, is normally prescribed at a dosage of 5–20 mg oral daily in order to
treat schizophrenia, bipolar disorder and resistant depression. Whilst being widely prescribed, it has
been anecdotally reported, at dosages up to 50 mg, as the ‘ideal trip terminator/modulator’ after
a psychedelic drug binge [110]. According to discussion forums/specialised websites [111], olanzapine
is also being used to treat unwanted ‘comedown’ symptoms from drug/alcohol intake [112,113].
Consistent with this, clients on methadone maintenance treatment attending the National Drug
Treatment Centre (NDTC) in Dublin reported levels of non-medical use of olanzapine, with dosages
of up to 100 mg/day, in order to manage anxiety and improve sleep, and in a minority of
cases, to ‘get stoned’ [114]. Olanzapine activity involves GABA-A receptors [115], hence the
associated sedation, the rewarding glutamatergic stimulation of the ventral tegmental area DAergic
neurons [116], the 5HT2C and histamine/H1 antagonist properties and the potent inhibiting action
on the muscarinic M1 receptors [115,116]. In comparing quetiapine with olanzapine through the UK
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Prescription Cost Analysis and the Drug Analysis Proﬁles of the Yellow Card Scheme, quetiapine
was shown to be slightly less frequently prescribed but associated with a smaller total number of
general reports, and hence, a comparatively higher number of abuse/dependence/withdrawal ADR
reports [117,118]. In line with this, the OPPIDUM French addictovigilance network highlighted the
emerging misuse of prescription molecules, and this included quetiapine as well [119]. Information
from the previous 10 years from the EMA EV database relating to quetiapine and olanzapine
misuse/abuse/dependence/withdrawal-related ADR reports [8] shows a higher misuse risk for
quetiapine in comparison with olanzapine for the selected ADR reports. Indeed, quetiapine
XR formulation was represented in only a smalll proportion of misuse cases, with both nasal
and parenteral administration having been identiﬁed. Of particular interest was, in comparison
with olanzapine, a higher risk of discontinuation/withdrawal syndrome following the abrupt
cessation of quetiapine [75,113,120]. Finally, consistent with previous data [75,82–85,90,121–123],
the quetiapine- and olanzapine-related fatalities reported on the EMA EV database were typically the
result of a polydrug intake, which included opiates/opioids, antidepressants, and over-the-counter
drugs [124,125].
3.4. Image-And Performance-Enhancing Drugs (IPEDs)
Over the last few decades, a range of prescribed and non-prescribed enhancement drugs have
increasingly been self-administered [72] in order to improve the ageing process, and sexual performances,
and to reduce hair loss, fatigue and other physiological conditions which are, at times, considered
pathological in a society that strongly emphasises the importance of physical appearance [126].
Prescribed image- and performance-enhancing drugs (IPEDs) include anabolic-androgenic steroids
(AAS), human growth hormone (hGH), steroid hormones (e.g., androstenedione), insulin, erythropoietin,
diuretics, but also, β-2 agonists (e.g., clenbuterol and salbutamol) [127]. Their misuse is typically
carried out within a polypharmacy context [128] with alcohol, cannabis/cannabinoids, cocaine,
amphetamines/methamphetamines being ingested as ancillary drugs. Moreover, the recent reporting of
IPED injecting practices are a reason for concern [129]; these mostly involve anabolic androgenic steroids,
non-steroidal anabolic hormones (e.g., hGH and insulin), tanning peptides, cosmetic injectables such as
botox and dermal fillers, etc. [130–132]. Among non-steroidal anabolic hormones, insulin seems to be
misused for performance-enhancement purposes through several administration routes (intravenous,
intramuscular and subcutaneous); indeed, insulin may help in achieving a decrease in fat deposition, an
increase in muscle mass and positive mood changes, although serious hypoglycaemic episodes and other
medical sequelae can occur as well [133,134]. Within the IPED group, anti-asthmatic beta-2 agonists
have recently emerged as having potential for misuse, e.g., salbutamol for its performance-enhancing
effects and clenbuterol for its hypertrophic and lipolytic effects. They are both included in the list
of prohibited substances released by the World Anti-Doping Agency (WADA) [135], with salbutamol
being allowed only as a component in the treatment regimen for athletes with asthma. Clenbuterol,
even if different from anabolic steroids, has been also prohibited as an anabolic agent since 2006.
In parallel with this, the Food and Drug Administration (FDA) banned the use of clenbuterol in
food animals in 1991 and the European Union (EU) followed suit in 1996 [136]. Beta-2 agonists are
synthetic molecules with sympathomimetic activity, prescribed as bronchodilators for the treatment
of asthma. Clenbuterol is licensed for human use only in a few countries (Austria, Germany, Italy,
Spain and Mexico), but not in the UK or the USA [137]. Clenbuterol, as a ‘size zero pill’, is popular
and widely available on the web, being considered an ergo/thermogenic drug and hence, an anabolic
burner [138], similar to caffeine, ephedrine, and thyroid hormones. Clenbuterol-associated lypolisis
can occur via both β-2 adrenergic agonism and its specific action on the adipocytes’ β-3 adrenergic
receptors, which further facilitates lipolysis and weight loss [139–141]. While anti-asthmatic clenbuterol
dosage ranges between 20 and 40mcg daily, the typical ‘fat burning’ dose is in the 120–160 mcg daily
range; dosage starts at 40 mcg daily, gradually increases, and then remains at the highest dosage for
a duration of 2–4 weeks [142]. In parallel with this, recent years have seen an increase in clenbuterol
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exposure reported to poison control centres [143], with the molecule being used either as a dietary
supplement [144] or as an adulterant in illicit drugs, such as cocaine [145]. Its adverse effects are
dose-dependent and may include dysrhythmias and myocardial injury, headache, abdominal pain,
nausea, and rhabdomyolysis [136,146–148]. Reports relating to salbutamol misuse have been less
frequently mentioned [149–151]. Similar to clenbuterol, salbutamol’s adverse effects are dose-related
and may include tremor, restlessness, anxiety/agitation, tachycardia, atrial fibrillation, and myocardial
ischaemia, especially in cases of overdosage, chronic use, or intravenous injection [152]. With respect to
salbutamol, clenbuterol’s higher levels of abuse potential could be associated with its pharmacological
characteristics [143], such as its prolonged elimination half-life (35 h) and its higher lipophilicity, which
can be associated with a fast transition through the blood–brain barrier. Consistent with this, salbutamol
has been described as significantly less potent on a reinforcement schedule than clenbuterol [149,152–154].
Clenbuterol abuse-related fatalities have consistently been reported in the literature [136,140,147,155],
whilst salbutamol is considered safer [156]. In this regard, Milano et al. [10] studied the 2006–2016
EMA clenbuterol- and salbutamol-related, misuse/abuse/dependence/withdrawal/overdose/off-label
spontaneous reports. They found that clenbuterol, in comparison with salbutamol, had higher levels of
misuse/abuse. These clenbuterol-related data were most typically from males and were associated with
the intake of steroids [10], hence confirming previous reports [157,158].
3.5. Over-The-Counter (OTC) Medicines—Loperamide
Currently, over-the-counter (OTC) abuse (‘pharming’) is an internationally recognised problem,
and the recent emergence of new forms, including online, of medicine supply, is alarming clinicians
and health authorities nationwide. The EU introduced a strong legal framework for the licensing,
manufacturing and distribution of medicines [159], but no measures have been taken so far for the
distribution of OTC drugs, and it is hence, difﬁcult to quantify their actual misuse and abuse [159–168].
Over previous years, the OTC antidiarrhoeal medicine loperamide has increasingly been reported
as being diverted and used to achieve recreational effects [159–162]. Loperamide acts as a potent
mu-opioid receptor agonist, albeit with predominantly peripheral activity on the myenteric plexus,
hence primarily increasing the intestinal transit time by decreasing propulsive activity. Secondary
peripheral effects are seen at κ-opioid and δ-opioid receptors as well [169,170]. Loperamide was
initially placed by the US FDA in Schedule V of the Controlled Substance Act but then, after having
assessed its safety proﬁle with the conclusion of low levels of physical dependence risk, in 1988,
it was made available for OTC use. In the 2–16 mg daily dosage, loperamide is considered safe
and devoid of misuse abuse potential because of its rapid metabolism and poor blood–brain barrier
(BBB) penetration. In doses of 50–300 mg, however, loperamide ingestion has been associated with
euphoria, central nervous system depression [171–174] and even death [175]. Its diversion potential
may be associated with its use as a relief from opioid withdrawal [176]. Anecdotally described as
the ‘poor’s’ methadone’ [177], detailed loperamide dosage titration regimens are being reported
online [20]. Related misuse case series [178] have reported both extremely high daily intakes (up to
1200 mg), and associated cardiotoxicity issues, such as QTc prolongation and torsades de pointes,
QRS prolongation, ventricular dysrhythmias [179–182], syncope, and cardiac arrest [12,179,183,184].
The cardiotoxicity mechanism of loperamide is not clearly understood, although it may be due to
potent inhibition of cardiac ion channels which is, in turn, associated with delayed repolarisation
and QT prolongation [185–187]. Consequently, the FDA [175] has recently warned clinicians and
users about the combination of loperamide with other drugs or herbal products that are known to
prolong the QT interval, including Class 1A (e.g., quinidine, procainamide) or Class III drugs (e.g.,
amiodarone, sotalol) antiarrhythmics, antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine,
ziprasidone), antibiotics (e.g., moxiﬂoxacin), and methadone. Loperamide ingestion has also been
reported in association with P-glycoprotein (P-gp) substrates (e.g., quetiapine, cetirizine, oxycodone)
or inhibitors (e.g., ﬂuoxetine, citalopram, sertraline, omeprazole, quinine, quinidine, propranolol,
ritonavir). These associations are associated with an increase in the low bioavailability of loperamide,
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normally being <2%; plasmatic concentration; levels of euphoric effects; the capacity of possible
contrasting opioid withdrawal symptoms [186–189]; and toxicity effects [175]. Concurrent use of
loperamide with CYP3A4 inhibitors (e.g., itraconazole, grapefruit juice, omeprazole, tonic water
and cimetidine) or CYP2C8 inhibitors (e.g., gemﬁbrozil) can increase its plasma levels as well, with
recurrent ventricular tachycardia having been reported in a patient who was taking large recreational
doses of both loperamide and the CYP3A4 inhibitor, famotidine [190]. Treatment of loperamide
intoxication involves the use of naloxone, which may not be able to directly reverse loperamide
cardiotoxic effects [191,192].
4. Discussion
The ever-increasing number of NPS emerging worldwide and the parallel changes in drug
scenarios represent a challenge for psychiatric, public health and drug-control policies [193]. In line
with this, the current systematic review has focused on a different range of prescribed medications
which are indeed being used as NPS [1]. Within both online drug forum communities and social
networks, there are some educated/informed users (the ‘psychonauts’) [194] who typically ‘test’
a range of psychotropics, including prescribed drugs, to achieve speciﬁc mindsets and eventually,
share this information with peers [193]. However, in parallel with recently increased levels of access to
the web, a large number of vulnerable subjects, including both children/adolescents and psychiatric
patients, have been exposed to a range of ‘pro-drug’ information, and this is a reason for concern [193].
Although a number of online ‘rogue’ pharmacies have been shut down, this typically prompts the
sellers to move to servers in overseas countries, leading to a growing black market [195].
It is intriguing that, for the range of prescription molecules discussed, including the fairly recently
introduced gabapentinoids, pre-marketing processes were not been able to appropriately identify their
abuse/misuse potential. However, similar to what happened with benzodiazepines and z-hypnotics,
this potential has ﬁnally emerged over time. Present data seem to suggest that abuse liability-focused,
pre-marketing laboratory testing may need to consider interaction studies with alcohol and/or other
drugs [194,196]. Furthermore, post-marketing surveillance for substance abuse [197] should routinely
be carried out to assess the abuse potential of newly released drugs, especially those with activity on
the central nervous system (CNS) [198]. Indeed, lack of information on the abuse/misuse potential
of a new medicine’s interaction with the CNS does not mean that a speciﬁc medicine does not
actually produce these effects. Furthermore, in order to look at how medicines are actually used in
real life, modern pharmacovigilance should identify a range of technical tools and approaches to
go beyond spontaneous reporting systems. Physicians should be vigilant when prescribing drugs
with an abuse/misuse/diversion potential and carefully evaluate the possibility for some clients
(inmates; people with a personal history of misuse or abuse) to be more vulnerable to these misuse
activities. Finally, while a continuum of related professional training is needed, it may be important to
consider a strategy to increase clients’ access to treatment services, possibly through enhanced links
between community pharmacists, who are the ﬁrst professionals to identify a repeat supply issue, and
prescribers/clinicians [198].
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Abstract: Self-prescribing of sexual hormones for gender afﬁrmation is a potentially widespread
and poorly studied phenomenon that many clinicians are unaware of. The uncontrolled use
of hormones poses signiﬁcant health hazards, which have not been previously reported in the
literature. We have collected seven clinical cases in general adult psychiatry settings (both inpatient
and outpatients), describing transgender and gender non-conforming individuals’ (TGNC)
self-prescribing and self-administering hormones bought from the Internet without any medical
consultation. Among these cases, two were taking androgens, and the rest were taking oestrogens.
The main reason for self-administration of hormones seems to be the lack of access to specialised
care due to discrimination and long waiting lists. We advocate for clinicians to be aware of
the phenomenon and proactively help TGNC individuals by enquiring about self-prescribing of
hormones, providing information and referring to the most appropriate treatment centre as well
as encourage a public debate on the discrimination and the stigma that TGNC population suffer
from. Overall, there is an urgent need for the implementation of different and innovative health care
services for TGNC individuals as well as more targeted prevention strategies on such underreported
and highly risky behaviours. Furthermore, it is necessary for every clinician involved in the care for
TGNC people to be aware of their special needs and be able to be an allied and an advocate to help in
reducing stigma and discrimination that affect the access to care for this often underserved population.
Keywords: transgender; gender reassignment; gender afﬁrmation; self-medication; hormonal
replacement therapy (HRT); LGTBQ health; gender dysphoria; do it yoursfelf (DIY); identity; barriers
to care; discrimination
1. Introduction
A signiﬁcant proportion of the population deﬁnes themselves as transgender, intersex non-binary
or gender non-conforming (in this paper, we will use “TGNC” for “transgender and gender
nonconforming” people as recommended by the American Psychological Association (APA)
guidelines [1]). A recent demographic study estimates that in the USA 0.39% (about one million
people) of the population deﬁne themselves as TGNC [2]. The exact number, however, might be bigger,
and it is very difﬁcult to quantify the precise number due to the complex methodology in estimating the
numbers when gender non-conforming individuals are also considered in the statistics [3]. To estimate
the same data in the UK, it is more difﬁcult because the Ofﬁce for National Statistics (ONS) does
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not produce estimates of the number of TGNC people living in the United Kingdom (Ofﬁce for
National Statistics [4]). The Gender Identity Research and Education Society (GIRES) estimates a
prevalence of 1% TGNC individuals in the UK adult population [5]. TGNC people are individuals that
do not identify or exclusively identify with the sex assigned to them at birth. Intersex individuals are
people with a less common combination of hormones, chromosomes, and anatomy that are used to
assign sex at birth. There are many examples such as Klinefelter Syndrome, Androgen Insensitivity
Syndrome, and Congenital Adrenal Hyperplasia. Non Binary people are individuals that do not
identify themselves completely as female/male or woman/man. Gender non-conforming people are,
according to the American Psychological Association “those who have a gender identity that is not
fully aligned with their sex assigned at birth” [1].
A signiﬁcant number of these individuals often decide to undergo a gender afﬁrmation process.
This process consists of using sexual hormones and often undergoing surgery to afﬁrm to the gender
that they belong to. In the UK, the prevalence of the population that has sought medical care is
estimated to be 0.025%, and about 0.015% are likely to have undergone a transition [5].
A recent survey made by the University of California, Los Angeles (UCLA) Centre for Health
Policy and Research showed that 27% of youth between 12 and 17 in California are gender
non-conforming [6]. According to another document from the same institution, such a population
typically presents a “conﬂict between a person’s physical or assigned gender and the gender with which
he/she/they identify. People with gender dysphoria may be very uncomfortable with the gender they were
assigned, sometimes described as being uncomfortable with their body (particularly developments during
puberty) or being uncomfortable with the expected roles of their assigned gender” [7].
It could be, therefore, be argued that gender afﬁrmation is a very important procedure to improve
the quality of life and mental wellbeing of TGNC individuals. However, very little attention has been
paid to this phenomenon.
A recent prospective study [8] assessing the psychopathology during the gender afﬁrmation
process has shown that the psychoneurotic distress measured with the Symptom Checklist-90 Revised
SCL-90-R, improves after the start of the hormonal treatment, and anxiety, depression, interpersonal
sensitivity, and hostility also tend to improve. This progress is so important that after the completion of
the gender afﬁrmation procedure via hormonal treatment and surgery, the psychopathology (assessed
with a speciﬁc scale) is comparable to the one of the general population [8]. Another prospective
study has also demonstrated that people with gender dysphoria treated with hormones presented a
signiﬁcant improvement at the Body Uneasiness Test (BUT) compared to the non-treated condition [9].
The use of hormones, however, might have signiﬁcant side-effects or may lead to severe medical
complications [10]. In particular, Cross-sex Hormone Therapy (CHT) female tomale has been associated
with a potential risk of cardiovascular disease, cancer (breast, ovarian and endometrial), osteoporosis;
in the case of male to female therapy, there is a risk of venous thromboembolism, and potentially
cardiovascular disease and cancer [10].
In clinical settings, gender afﬁrmation is a complex and long-lasting procedure, involving
many different healthcare professionals including psychiatrists, psychologists, endocrinologists,
plastic surgeons, speech and language therapists, and counsellors. This procedure also needs a
multidisciplinary approach with a schedule that allows time for physical and social transition [11–13].
The World Professional Association for Transgender Health (WPATH) published the most commonly
accepted clinical guidelines and ‘Standards of Care’ for TGNC [14], including established general
eligibility criteria for feminising or masculinising hormone therapy. These include (a) persistent,
well-documented gender dysphoria; (b) capacity to make a fully informed decision and to consent
for treatment; (c) age of majority in a given country; (d) if signiﬁcant medical or mental concerns are
present, they must be reasonably well-controlled.
The aim of this article is to raise awareness among mental health professionals about a
phenomenon that is already known in specialist settings (e.g., gender afﬁrmation clinics and substance
misuse services) but less well known in different settings. Central to this paper is a collection of different
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clinical cases collected in inpatients and outpatients National Health Service (NHS) clinics in Suffolk
(a rural county north east of London) and London (Camden and Islington Boroughs). It is also desirable
that by raising awareness, TGNC patients will ﬁnd that mental health clinicians are not only therapists
but also advocates and allied in their gender afﬁrmation journey. In response to the existing lack of
knowledge among the health professionals, NHS England recently released [15] a document assessing
the individual suitability for endocrine and other pharmacological treatments. Suggested arrangements
for medical practitioners include: (a) prescription of endocrine and other pharmacological interventions
for the purpose of harm reduction and acting in the best interest for reducing gender dysphoria; (b) the
assessment of risks, beneﬁts and limitations of such a pharmacological intervention and the assurance
that the individual meets the relevant eligibility criteria set out by the World Professional Association
for Transgender Health Standards of Care (2011); (c) the provision of patient-speciﬁc prescribing
guidance to the General Practitioner (GP), including adequately-detailed information about the
necessary pre-treatment assessments, and advice on dosages, administration, initiation, duration
of treatment among others; (d) the preparation of written advice to the GP when the individual
is discharged. Further details on speciﬁc treatments have been outlined in Table 1. An additional
statement by the General Medical Council (GMC) clariﬁes that GPs can prescribe hormones to TGNC
individuals [16].
Table 1. Types of treatment for masculinisation and feminisation [15]
Aim Type of Preparation Notes Recommendations
Medications for
masculinisation Testosterone preparations
Include testosterone injections and
transdermal gels
Avoid smoking (risk
of thrombosis)
Medications to suppress
hyptolamic-pituitary-gonadal
activity
Avoid smoking (risk
of thrombosis)
Medications for
feminisation Estradiol preparations
Doses necessary to achieve serum
estradiol levels typical of
pre-menopausal woman. Include oral
estradiol and transdermal estradiol as
patches and gels (for people over
40 years old). Ethinylestradiol will not
be recommended
Avoid if Body Mass
Index > 40; avoid
smoking (risk of
thrombosis)
Medications to suppress
hypothalamic-pituitary-gonadal
activity and endogenous
testosterone release
Include gonadotropin releasing
hormone analogues and 5-alpha
reductase inhibitors
Avoid if Body Mass
Index > 40; avoid
smoking (risk of
thrombosis)
Ornithine decarboxylase
inhibitors
May be recommended as an adjunct
to facial hair reduction interventions
Avoid smoking (risk
of thrombosis)
Despite the availability of such clinical guidance and advice, TGNC individuals still do not
receive the care they often need because of stigma, discrimination, and lack of awareness in health
care settings [17,18]. A large population study from the 2014-5 Behavioural Risk Factor Surveillance
System by Gonzales et al. found that “TGNC adults were more likely to be uninsured and have unmet
health care needs and were less likely to have routine care, compared to cisgender (non-transgender)
women”. Reasons for such barriers to health care included discrimination in health care, health
insurance policies, employment and inadequate health policy and regulations [19]. Although very few
population surveys of this kind have been carried out, another study in Ontario conﬁrmed that 43.9%
of TGNC individuals experienced inequalities in the access to healthcare and remained medically
unsupervised [20].
An additional element of concern to this phenomenon is the self-administration of CHT without
clinical supervision. Evidence of such hazardous behaviour emerged from studies among TGNC
population in Canada [21] and from patients attending gender reassignment clinics in the United
Kingdom. In the latter case, it has been estimated that 23% of individuals referred to gender
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reassignment clinic were self-administering hormones, mainly bought online (70%). Such behaviour
appeared to be more common among trans women, as 32% of the female sample was using hormones
at the moment of referral. Alarmingly, individuals that were purchasing hormones online appeared to
be less informed about the risks and the side effects of hormonal therapy [22].
The growing number of illicit online pharmacies selling counterfeited products, including
“Performance and Image-Enhancing Drugs” (PIEDs) and sexual enhancers [23] taken to enhance human
abilities in a myriad of spheres, is another important emerging faucet within this [24–27]. PIEDs include
substances with a perceived ability to enhance physical performance, psychological status and
appearance, cognitive abilities and social relations, and as such, are sometimes referred to as ‘lifestyle
drugs’. It has been estimated that approximately 97% of websites selling pharmaceutical products are
of illicit nature [26]. Individuals can purchase a wide range of unregulated and untested medicines in
these websites which are freely sold without a prescription, and at discounted prices [27,28].
2. Clinical Cases
A number of TGNC patients cases that have started the gender afﬁrmation process without
any medical/specialist support were collected in two general adult psychiatry assessment clinics
(outpatients) in London and Suffolk between 2014 and 2018. Information was obtained as part of the
routine history taking during a psychiatric assessment and no speciﬁc questionnaire was designed
for the psychiatry interview. The patients were informed at the moment of the assessment that some
of the information given in an anonymised version would be used for a case presentation and a
case report article. The patients that were included in the article were requested to give informed
consent. The assessment clinics are the ﬁrst point of contact with mental health where new referrals
from GPs and other health professionals are seen. Suffolk is a rural county, predominantly a white
English population, with chronic lack of access to mental health and other specialist health services
that are conversely available in London, where most of the specialist and national health services are
located. Consulted patients were either attending the clinics, or inpatient in psychiatric wards for the
assessment and treatment of mental health conditions unrelated to their gender deﬁnition. The clinics
and the wards were for general adult patients only. During the psychiatric interview, it emerged,
worryingly that a certain number of TGNC individuals were purchasing hormones through illegal
on-line pharmacies and were using them without any medical advice or monitoring (not even at
General Practitioner level) using CHT protocols that were available online or receiving advice from
online forums and blogs.
The length of the current clinical procedure, which involves long waiting lists, various passages
of assessment and treatment, was criticized and perceived as a barrier for receiving the standard
treatment. Patients preferred to purchase the hormones online and advocated a quick and easy CHT
while trusting unsolicited online protocols from non-medical professionals for a faster result. Mistrust
of medical professionals has also been previously reported as a potential cause [29]. Resilience on
the Internet for medical advice concerning injecting practices and dosages among other features
also indicates an underlying lack of engagement with medical professionals and limited practitioner
knowledge regarding these patterns of use [30].
Hormone therapy in gender afﬁrmation may affect different organs and systems [31]. For this
reason, any hormonal treatment should be prescribed and supervised by a specialist and should also
be discussed in depth with the patient to prepare him/her for the treatment. In this way, it is possible
to monitor and manage the treatment effectively as well as to address any of the side effects described
above. Hormonal treatment with oestrogens also requires diuretics to counteract the water retention
associated with their use. Diuretics should also be used under medical supervision, and the renal
function and electrolytes of the patients should be checked regularly to prevent, especially in summer,
potentially dangerous dehydration and electrolytes imbalances.
In this paper, seven cases of TGNC individuals are described. They were assessed in a psychiatric
clinic or admitted onto a psychiatric ward for different reasons, and they were using hormones
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and other drugs for gender afﬁrmation without any medical supervision and purchasing all these
medications through unlicensed online dealers.
2.1. Oestrogens
Case 1 is a 24-year-old trans woman, working as a plumber, and single. She was referred for
a psychiatric screening as the ﬁrst step for the referral pathway to the Gender Identity Clinic after
she disclosed to her GP that she was using hormones purchased online. The patient has no previous
history of mental or physical illness, she described herself as TGNC since age 14 and started the
transition, without medical supervision two years before the assessment. The patient joined on line
forums where she received the information regarding the hormonal protocols and the websites selling
hormones. She started the treatment on her own and subsequently asked the GP to be referred for
gender reassignment/gender afﬁrmation. At the time of the assessment, the patient did not present
any comorbid psychiatric or physical conditions.
Case 2 is a 22-year-old trans woman with a previous history of depression at the age of 14 that
was successfully treated with a Serotonin Reuptake Inhibitor (SSRI). The patient stated that she felt
like a person “trapped in the wrong body” ever since she could remember. She complained of being
bullied at school for this reason, and she thinks that the bullying and the non-acceptance from her
friends caused the depressive episodes in her teens. She started the protocol online and asked the
GP to continue prescribing, and the GP asked for a psychiatric opinion before proceeding. She had
been using oestrogens, ﬁnasteride, and spironolactone intermittently in the last two years. The patient
also has type I diabetes, treated with insulin. According to the GPs notes, the compliance with the
insulin treatment and the control of his diabetes is not optimal. The mental state examination was
unremarkable; the patient presented, however, traits of emotionally unstable personality disorder.
Case 3 is a 19-year-old trans woman, a college student, and single. She was referred by the GP
for a psychiatric assessment following numerous suicidal attempts and self-harm episodes. She had
a provisional psychiatric diagnosis of Emotionally Unstable Personality Disorder—Borderline type.
During the psychiatric assessment, she disclosed using oestrogens and ﬁnasteride purchased online in
order to proceed with the transition. She also reported that since she started using these hormones
the emotional instability became more severe and was partly responsible for the deterioration of her
clinical presentation.
Case 4 is a 26-year-old trans woman, living with a partner and working as an administrator.
She was referred by her GP for psychiatric assessment as part of the procedure for a referral to
the Gender Identity Clinic. The patient had no previous history of mental illness, no medical
comorbidity. During the interview she disclosed using oestrogen cream and ﬁnasteride tablets
purchased online although she did not disclose it before (even with the GP). The mental state
examination was unremarkable.
Case 5 is a 36-year-old TGNC woman, single and unemployed. She was referred by the GP for a
psychiatric assessment due to low mood and polysubstance misuse (cocaine, cannabis, amphetamine
and gamma-Hidroxybutyric acid (GHB). During the interview, the patient stated that she has been
taking oestrogen, spironolactone and ﬁnasteride for 15 years. A year ago, she was referred to the
gender reassignment clinic where she was diagnosed with moderate depression and generalised
anxiety disorder, but she was asked to see a general adult psychiatrist for the treatment. The patient
complained that the main contributing factors to her depression were the stigmatisation and the lack
of acceptance, in which she felt that she was victimised mainly by members of her family and her
community. She also was frustrated with the length of the waiting list.
2.2. Androgens
Case 6 is a 25-year-old TGNC man, unemployed, living with his partner. The patient was referred
for a psychiatric assessment after he disclosed to the GP about using androgens without medical advice
and supervision. The patient complained of The Gender Identity Research and Education Society
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feeling “uneasy with his body” since the age of 12. He started to purchase androgens online, 2 years
before the psychiatric assessment, following a protocol available online. The patient also has stage 4
renal failure, and he was under the care of the renal team.
Case 7 is a 27-years-old TGNC man and a university student. He was admitted to an inpatient
psychiatric unit after a suicidal attempt. The patient was presenting with moderate depression,
on admission, he reported of using androgens purchased online while on the waiting list for an
assessment by the Gender Reassignment Clinic. The patient was using the hormones without any
medical advice or supervision. The low mood and the suicidal attempt were linked to his stressful
situation at the university (where he struggled to cope with academic pressure) rather than to the
hormonal treatment, that he also stated that he found the hormones to be beneﬁcial. He was also
frustrated by the long waiting list before he was able to start his gender afﬁrmation process.
3. Discussion and Conclusions
In our paper, we discussed the clinical cases collected by the same clinician in his clinical practice
in different settings, over the span of 4 years. We are aware that it is a very limited picture and we
do not think that it is necessarily representative of the entire United Kingdom. We think, however,
that this raises the question of access to gender afﬁrmation treatment and the role of every clinician as
an advocate for our patients. We are aware that this phenomenon has been described before, but we
believe that many clinicians are not aware of it.
Self-prescribing of sexual hormones is a widespread, but poorly studied phenomenon.
As highlighted in our work, the lack of access to specialised centres, stigmatisation and marginalisation
of the TGNC population as well as the motivations underlying DIY hormonal treatment, deserve
further consideration.
To the best of our knowledge, this is the ﬁrst report of DIY hormonal treatment in general
adult psychiatric settings. Previous articles that have described the trend of self-prescribing and
administrations of hormones came from sexual health clinics and gender afﬁrmation clinics [19,20].
Psychiatric assessment clinics and psychiatric inpatient wards are often the ﬁrst port of call of
individuals in distress. It is very important, therefore, that the staff working in these services are aware
of the particular needs of the TGNC individuals. In particular, the need to establish an environment of
respect and non-stigmatisation is very important in developing an effective therapeutic relationship.
It is important that the terminology used is appropriate and respectful. This applies particularly to the
pronouns and it is always important to check with the patients which pronouns they prefer. It is also
important to tactfully ask if they have started the gender afﬁrmation process on their own without any
clinical supervision. Psychiatrists, GPs, Sexually Transmitted Diseases’ (STD) specialists and all other
clinicians should be informed about this under reported trend while encouraging the safe prescribing
practice of sexual hormones.
As suggested by NHS England [15], the current assessment needs to be improved by proactively
asking TGNC patients whether they are taking hormones and where they are sourcing them from.
The role of mental health services is particularly important because, before the gender afﬁrmation
process, TGNC individuals suffer from a higher rate of mental illnesses and mental discomfort (often
due to stigma, discrimination and non-acceptance by family and society). For this reason, mental
health professionals are more likely to encounter TGNC individuals in need of support but also have a
crucial role to play as an advocate. It is, therefore, important when assessing TGNC individuals to
respectfully enquire whether they have started the transition and if this is happening under medical
care or not. If not, it is necessary to ask if they are sourcing hormones and other medications online
or from other unlicensed sources. If this is the case, clinicians have the duty not only to inform the
patients of the risk but also to suggest safer alternatives and support if necessary, the individuals in
this process.
A common theme that emerged from our case studies was the use of hormones purchased
online without any clinical guidance or supervision before and during the treatment. As previously
135
Brain Sci. 2018, 8, 88
argued [28,32], the Internet often provides a channel for accessing peer-group experiences and
disseminating such risky behaviours. The underlying interpersonal trust embedded in such
sub-cultural groups, as seen for instance on discussion fora or social networking, can reinforce
the establishment of risk taking norms, especially among early adopters. In addition, the intake
of previously untested and unregulated medicinal products can expose users to a series of unwanted
side-effects, especially in potentially risky, if unsupervised, medical practices such as intramuscular
(IM) injections [33,34]. The shipping process is also questionable with the risk that even where the
product is genuine, it may arrive in a condition that renders it unsafe for use. Buyers may also receive
counterfeited products and, therefore, using compounds that may be toxic or even lethal. It is also
concerning that substances like hormones which have a signiﬁcant effect on the body and the mind,
are used without guidance and monitoring of the side effects. Furthermore, the route of administration
(e.g., IM) can lead to additional health risks, both chronic and acute [33].
Further studies need to be carried out to evaluate the motivation underlying such a poorly
researched trend. The main reason for such behaviours seems to be due to the difﬁculty in
accessing gender reassignment/gender afﬁrmation treatments, leaving a signiﬁcant part of the TGNC
population in a condition of discomfort that make them more vulnerable to the onset of psychiatric
illnesses (depression, anxiety) as well as other unhealthy conditions or practices (e.g., smoking,
drug intake) [18,35,36]. Furthermore, as their need for medical assistance may grow [36], trans
individuals often experience problematic accesses to healthcare in terms of professionals’ education
and discriminatory practices [37]. This is also due to the length of the waiting lists (up to three years)
that pushes TGNC individuals into obtaining hormones online [38]. Despite the various efforts made
by NHS England, the GMC and the Royal Colleges to improve the situation, a signiﬁcant group of
individuals still do not receive the care that they need and deserve in the United Kingdom. This may
also be due to the chronic lack of funds for these services despite recent years’ additional funding [39].
Gender afﬁrmation is not the treatment of an illness but is a procedure that improves the wellbeing of
TGNC and non-binary individuals and, therefore, should be appropriately funded and supported by
every clinician [40].
It is necessary, therefore, to address such gaps in public health policy and clinical practice
knowledge regarding gender afﬁrmation and establish alternative services. Local clinic services,
complementary to the NHS provided treatment, may be crucial to the wellbeing of individuals who
are feeling disenfranchised and are not attending the gender reassignment/gender afﬁrmation clinics
while considering the treatment [41]. Examples of such services can be found in the United States with
the Transgender Health Services program (STRIDE) based in San Francisco, which is structured as
a peer-based model providing hormone therapy and support for the general and the psychological
health of TGNC individuals [42]. Different gender reassignment/gender afﬁrmation programs are also
available in Canada. In British Columbia and Ontario projects like Trans Care BC (British Columbia)
and Trans Health Connection (Ontario) aim to facilitate the access to care for TGNC by providing
information and support for the TGNC community [43,44].
In summary, we believe that increasing the access to gender afﬁrmation services alone, however,
is not enough and it is necessary to raise awareness among every clinician about the special needs
that TGNC individuals have when accessing healthcare. It would be necessary, to achieve this goal,
to design and disseminate among all clinicians, a questionnaire regarding their attitude towards TGNC
individuals, their knowledge about the gender afﬁrmation process and the speciﬁc clinical needs that
the TGNC population has. In this way, it would be possible to establish the educational needs that
clinicians have and, therefore, consider speciﬁc training. This would enable improvement of access to
care for TGNC individuals by ﬁghting stigma and creating a more inclusive service. This approach
should be across all the services that might care for TGNC individuals. Furthermore, disseminating
knowledge and raising awareness might have another beneﬁcial effect by transforming conscious
clinicians in health to advocate for the TGNC population. In this way, it may be possible to address not
only the problem highlighted in this article (the difﬁculty of accessing gender afﬁrmation clinics) but
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also the more widespread discrimination that TGNC individuals face when accessing various health
care services.
As we have seen in our study, the implementation of such different and innovative health care
services for TGNC individuals as well as more targeted prevention strategies on such underreported
and highly risky behaviours have become a necessity in the United Kingdom and elsewhere. Closer
attention should also be paid to the online market of DIY hormones, and an open dialogue with
LGBTQ organisations should be established to support TGNC individuals and better understand their
unmet needs.
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Abstract: Drugs incorporated into hair are exposed to the environment, and cosmetic and chemical
treatments, with possible decreases in their content. Knowledge concerning the effect of sunlight on
drug content in hair can be helpful to forensic toxicologists, in particular, when investigating drug
concentrations above or below pre-determined cut-offs. Twenty authentic positive hair samples were
selected which had previously tested positive for amphetamines and/or ketamine. Washed hair were
divided into two identical strands, with the former exposed at 765 W/m2 (300–800 nm spectrum of
irradiance) for 48 h in a solar simulator, and the latter kept in the dark. Hair samples were extracted
and analyzed by liquid chromatography high-resolution mass spectrometry detection. The percentage
of photodegradation was calculated for each analyte (i.e., amphetamine, methamphetamine,
methylendioxyamphetamine, ketamine, and norketamine). In parallel, photodegradation processes
of standard molecules dissolved in aqueous and organic solutions were studied. In 20 hair samples
positive for the targeted analytes, exposure to artiﬁcial sunlight induced an appreciable decrease
in drug concentrations. The concentration ranges in the non-irradiated hair samples were 0.01–24
ng/mg, and 65% of samples exhibited a decrease in post-irradiation samples, with reduction from 3%
to 100%. When more drugs were present in the same hair sample (i.e., MDMA and ketamine) the
degradation yields were compound dependent. A degradation product induced by irradiation of
ketamine in aqueous and methanol solutions was identiﬁed; it was also found to be present in a true
positive hair sample after irradiation. Ketamine, amphetamines, and their metabolites incorporated in
the hair of drug users undergo degradation when irradiated by artiﬁcial sunlight. Only for ketamine
was a photoproduct identiﬁed in irradiated standard solutions and in true positive irradiated hair.
When decisional cut-offs are applied to hair analysis, photodegradation must be taken into account
since sunlight may produce false negative results. Moreover, new markers could be investigated as
evidence of illicit drug use.
Keywords: hair; solar light; photodegradation; amphetamines; MDMA; ketamine
1. Introduction
The main advantage of hair as a testing matrix is the ability to provide information relating
to historical drug exposure. Hair analysis has many applications within forensic (e.g., drug-related
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deaths, drug-facilitated crimes (DFCs), child protection) and clinical toxicology (e.g., drug rehabilitation
programs, workplace drug testing) [1–4].
The stability of drugs in hair, however, is affected by exposure to sunlight and weathering,
cosmetic chemical treatments (i.e., oxidative dyeing, bleaching, or permanent wave), and physical
damage [5–7]. In particular, exposure to sunlight and/or artiﬁcial light for many hours per day
can induce photodegradation (i.e., photolysis) of licit/illicit drugs through the formation of free
radicals (produced by the drug itself or formed by eumelanin and pheomelanin, and their oxidative
products oxyeumelanin, and oxypheomelanin) or photosensitization reactions by intermolecular
energy transfer. [8]
Previous studies on this matter have been published by Skopp et al. [9] in which cannabinoids
detected in hair and affected by solar radiation were shown to reduce in concentration. More recently,
Favretto et al. [10] evaluated the effect of light exposure on methadone, cocaine, and heroin metabolites
in hair.
In order to better understand the role and underlying mechanisms of solar light exposure
on decreasing concentrations of drugs in hair, and following our previous [10] photodegradation
studies on UVA- and UVB-induced changes, the aim of the present work was to evaluate the
photodegradation of several common stimulant drugs (i.e., amphetamines and ketamine (KET))
in true positive hair samples exposed to the whole spectrum of sunlight in a solar simulator. The use of
a solar simulator, including visible light (400–800 nm) and part of UV radiation from 400 nm to 3 μnm
(UVA = 400–315 nm, UVB = 315–280 nm), mimics exposure to environmental sunlight.
Amphetamine-based drugs are illegal synthetic stimulants that share a common structural
backbone. The four amphetamines considered in the present work are the most used in Europe:
amphetamine (AMF), methamphetamine (MA), 3,4-methylenedioxymethamphetamine (MDMA),
and 3,4-methylenedioxyamphetamine (MDA).
Amphetamine can be metabolized along two pathways: either by hydroxylation of the aromatic
ring to 4-hydroxyamphetamine or by deamination of the side chain to benzyl methyl ketone, which
can then be degraded to benzoic acid. Methamphetamine is metabolized by cytochrome P450 (CYP),
mainly by the CYP2D and CYP3A subfamilies, leading to the production of 4-hydroxyamphetamine
and AMF. The half-life of MA is about 10 h, and 35–45% of a dose is excreted unchanged in the urine
over a period of several days. Other metabolites, such as 4-hydroxymethamphetamine, norephedrine,
and 4-hydroxynorephedrine, can also be found in urine in substantial quantities [11–13].
In addition, MDMA (i.e., 3,4-methylenedioxymethamphetamine, ecstasy) is a widely abused
psychostimulant drug that acts as a powerful releaser and/or reuptake inhibitor of serotonin (5-HT),
dopamine (DA), and norepinephrine (NE). Its metabolism depends on the following main metabolic
pathways: (1) O-demethylenation followed by catechol-O-methyltransferase (COMT) methylation
and/or glucuronide/sulfate conjugation; and (2) N-dealkylation, deamination, and oxidation. MDMA
N-demethylation gives rise to 3,4-methylenedioxyamphetamine (MDA). The elimination half-life of
MDMA is about 8–9 h, lower than those reported for MA (10–12 h) or AMF (12–15 h) [14,15].
Ketamine is a dissociative anesthetic drug that functions as an antagonist of the
N-methyl-D-aspartate receptor and enhances the antinociceptive effects of conventional opioid
analgesia, binding to μ opioid and σ receptors. Ketamine is increasingly misused as a recreational
and “club drug” because of its hallucinogenic and stimulant effects, and also as a “date-rape”
drug (to facilitate sexual assault). Ketamine is metabolized in the liver by the P450 system, and
CYP3A4 is the main enzyme responsible for transforming N-demethylation into norketamine
(NKET), 4-hydroxy-ketamine, and 6-hydroxy-ketamine. The elimination half-life is about 2 h, and the
predominant metabolite of urinary excretion over a 72 h period is dehydronorketamine (DHNK) (16%),
along with conjugates of hydroxylated ketamine metabolites [16,17].
The consumption of alcohol and/or drugs is associated with an increased risk of being the victim
of a sexual assault. A retrospective case series in London on 1014 cases of claimed drug-facilitated
sexual assaults (DFSAs) showed that in 34% of samples (blood and/or urine), an illicit drug (with or
141
Brain Sci. 2018, 8, 96
without alcohol) was found, of which 10.8% contained cocaine, 4.6% “ecstasy” (MDMA), and 2.3%
AMF [18,19]. In DFC cases, alleged victims are often unconscious leading up to the assault due to the
amnesiac effects of the drug(s) administered, thus a considerable amount of time may be spent before
the victim reports the incident. Consequently, hair analysis is of primary importance compared to
blood and urine analysis, particularly when the occasional consumption is sufﬁciently high; however,
exposure to the environment may affect the stability of drugs in the keratin matrix.
For these reasons, reliable interpretation of the analytical results is fundamental for a correct
interpretation of a positive or negative result, and general knowledge of the photostability of drug
analytes in the biological matrix must be considered. However, no data have been published until now
on the effect of light on KET and amphetamines, and their respective metabolites in the keratin matrix;
only morphine and 6-monoacetylmorphine (6-MAM) photodegradation have been studied by UVA
and UVB irradiation [20].
In the present paper, levels of AMF, MA, MDMA, MDA, KET, and NKET were determined
by means of liquid chromatography high-resolution mass spectrometry (HPLC-HRMS) [21,22] in
authentic hair samples from drugs users before and after irradiation under the whole spectrum of
sunlight in a solar simulator.
Although the photodegradation of a molecule not only depends on the wavelength used, but
also on its physical state (solid or liquid) and the environment in which it is irradiated (i.e., solvent,
polarity, pH, and the presence of salts, oxygen, and other compounds in the sample), we tested the
same analytes in a pure methanol and water solution irradiated under the whole spectrum of sunlight
to gather general information on their behavior and to study their kinetics of photodegradation.
2. Experiments
2.1. Chemicals
Amphetamine, MA, MDMA, MDA, KET, and NKET were purchased from LGC Promochem
Cerilliant (Teddington, Middlesex, UK) as pure solutions in methanol at 1.0 mg/mL. The internal
standards (IS) MA-D5, AMF-D5, MDMA-D5, MDA-D5, and KET-D3 were methanol solutions also
from LGC Promochem at 1.0 mg/mL.
Methanol, dichloromethane, and acetonitrile (Merck, Darmstadt, Germany) were
high-performance liquid chromatography (HPLC) grade. Triﬂuoroacetic acid (TFA) was from
Sigma (Sigma-Aldrich, Milan, Italy). High-performance liquid chromatography water was prepared
using a Milli-Q Plus (Millipore, Molsheim, France) system. All other reagents were from Sigma-Aldrich
(St Louis, MO, USA).
2.2. Hair Samples
Authentic positive hairs were selected from samples at the laboratory that had previously tested
positive for amphetamines and/or KET. Hair samples were collected with scissors from the posterior
vertex and cut as close to the scalp as possible, wrapped in aluminum foil, and kept at room temperature
until analysis. As recorded in donor interviews, all samples had not been submitted to previous
cosmetic or chemical treatments.
2.3. Irradiation Procedure
Irradiation was performed in a Suntest CPS+ (Atlas, Linsengericht, Germany) equipped with
a 1.8 kW xenon lamp and a glass ﬁlter (cut-off 310 nm) according to Option 1 of ICH Guideline
Q1B (European Medicines Agency, London, UK, ICH Topic Q1B–Photostability testing of new active
substances and medical products, 1998). The dark samples were maintained at solar box temperature
during irradiation.
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2.4. Photolysis Experiments in Solution (In Vitro Study)
Solutions of the compounds at concentrations ranging from 10−5 to 10−4 M in methanol and
water were irradiated in the Suntest CPS+ with times increasing from 1 h up to 3 h.
Photolysis was evaluated using Cary 50 UV-Vis spectrophotometer (Varian, Milan, Italy) analyzing
the change in the original spectrum upon irradiation, as already described [20], and by high-resolution
mass spectrometry (HRMS). At selected UV doses, the solutions were diluted to 10−6 M in methanol
and water, and analyzed by direct injection HRMS to measure the photodegradation of the analytes by
recording the decrease of the ion signal of protonated molecules obtained by electrospray ionization
(ESI) of solutions kept in the dark. The results are the mean of at least three experiments.
2.5. Photolysis Experiments in Hair Samples (In Vivo Study)
Hairs 5–7 cm long were divided into two approximately identical strands: the former was put
between two 5 × 5 cm optical glasses and exposed at 765 W/m2 (spectrum of irradiance: 310–800 nm)
for 48 h in the solar simulator to an endpoint corresponding to two months exposure under the
sunlight, and the latter was kept as a dark control in the same chamber of irradiation covered with an
aluminum foil.
2.6. Hair Sample Preparation and Extraction
Hair samples were decontaminated with 3 mL of water and 3 mL of methanol. Pulverization was
applied by the automatic homogenizer Precellys® Evolution (Bertin Technologies, Genoa, Italy) at a
speed of 6000 RPM, cycle 9 × 30 s, pause 30 s. Solid phase extraction (SPE) was performed by Oasis
MCX (Waters, Milford, MA, USA) cartridges. Sample preparation consisted of the addition of 2 ng/mg
of IS and 3mL of amethanol/TFA (90:10, v/v) solution to 25mg powdered hair samples, ultrasonication
for 1 h, and incubation overnight at 45 ◦C. After centrifugation, the methanolic solutions were dried
under a stream of nitrogen at 40 ◦C. The residues were reconstituted in 3 mL of 0.1 M phosphate buffer
pH 6 and subjected to SPE. After, cartridges of the sample conditioned with 3 mL methanol and 3 mL
0.1 M phosphate buffer pH 6 were loaded. Cleanup was accomplished by sequential washes with 3 mL
of water, 3 mL of 0.1 N hydrochloric acid, and 3 mL of methanol. Cartridges were dried for 10 min
under vacuum before elution with 2 mL of dichloromethane: 2-propanol (80:20, v/v) 2% ammonium
hydroxide. Eluates were evaporated to dryness with nitrogen at 40 ◦C, reconstituted in 200 μL of water
(0.1% formic acid)/acetonitrile 9:1 mixture, and 25 μL were injected into the LC-HRMS system.
2.7. High-Resolution Mass Spectrometry (HRMS)
All measurements were performed on an LTQ-Orbitrap (Thermo Fisher Scientiﬁc, Bremen,
Germany) high-accuracy, high-resolution mass spectrometer operating in positive ESI mode and
equipped with a Surveyor MS Pump.
2.8. Electrospray Ionization HRMS
For the analysis of pure standard solutions, direct injection analysis was performed with a syringe
pump delivering solutions at 10μL/min directly into the ESI source. The positive ion ESI parameters
were as follows: capillary voltage 10 V, sheath gas ﬂow rate 20 (arbitrary units, a.u.), auxiliary gas
(N2) ﬂow rate 5 (a.u.), sweep gas ﬂow rate 5 (a.u.), and capillary temperature 275 ◦C. Proﬁle full-scan
mass spectra were acquired in the Orbitrap in the m/z range 120–700 with a target mass resolution of
100,000 (FWHM as deﬁned at 400 m/z) and a scan time of 0.65 s.
2.9. High-Performance Liquid Chromatography HRMS
For the determination of drug concentrations in hair and in standard solutions, 25μL of solutions
or extracts were injected into an Atlantis T3 (150 × 1.0 mm, 3 μm) column (Waters Corporation,
Milford, MA, USA). High-performance liquid chromatography separation was achieved by gradient
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elution at a constant ﬂow rate of 300 μL/min. High-performance liquid chromatography conditions:
A (water, 0.1% formic acid) and B (methanol, 0.1% HCOOH); initial conditions 10% B, linear gradient
to 25% B in 4min, 25% B hold from 4 min to 7 min, then ramped to 40% B in 5min, to 60% B in
4min and to 90% B in 2min; 90% B hold from 18 min to 26 min. The column temperature was 40 ◦C.
Mass spectrometry conditions were: positive ion ESI; capillary voltage 10 V, sheath gas ﬂow rate 50
(arbitrary units, a.u.), auxiliary gas (N2) ﬂow rate 5 (a.u.), sweep gas ﬂow rate 5 (a.u.), and capillary
temperature 275 ◦C. Proﬁle full-scan mass spectra were acquired in the Orbitrap in the m/z range
120–700 with a target mass resolution of 60,000 (FWHM as deﬁned at 400 m/z) and a scan time of 0.45 s.
Detection of the analytes and the IS was based on retention time, accurate mass measurements of MH+
ions, and correspondence of the observed isotopic pattern to the calculated one. Drug concentrations
were determined from peak area ratios of analyte to its IS compared to calibrator curves of peak area
ratios to concentrations. The method was fully validated exhibiting a linear range from 0.1 ng/mg to
50 ng/mg (determined from regression with 1/x2 weighting utilizing six calibration points), lower
limits of quantiﬁcation of 0.01 ng/mg and limits of detection of 0.005 ng/mg for all the target analytes,
intra-day imprecision, inaccuracy always lower than 19% and 20%, and inter-day imprecision and
inaccuracy always lower than 21% and 22%, respectively. Extraction efﬁciency was determined in the
range of 85–100% for the different substances.
3. Results
3.1. Photodegradation in Methanol and Water Solutions Exposed to Suntest CPS+
Preliminary, stock methanol, and water solutions for all the analytes diluted to 10−4 M
were irradiated inside the photostability test chamber from 1 h to 3 h (each hour corresponding
to about 70 J/cm2), and their absorption spectra before and after irradiation were recorded
(Supplementary Figures S1A1–S1F2).
Amphetamine dissolved in methanol was characterized by the only band at around
205–210 nm, mainly corresponding to the solvent, thus remaining unmodiﬁed in all the irradiated
solutions (see Supplementary Figure S1A1). However, a shift to 205 nm and a small increase in
spectral intensity were detected by increasing irradiation. When irradiated in water, AMF was
characterized by two bands (around 220nm and 240 nm) decreasing as irradiation dose increased
(see Supplementary Figure S1A2).
Methamphetamine, both in methanol and water (Figures S1B1 and B2, respectively), presented
curves similar to AMF, with the unique difference being the absorption at 205 nm in water which
increased under irradiation.
In addition, MDA in methanol (Figure S1C1) was characterized by three bands at 208 nm, 235 nm,
and 285 nm. The irradiated solutions presented similar curves with increasing absorption and a small
blue shift at 230 nm and 280 nm. Similar spectra were obtained for MDA in water (Figure S1C2), with
two bands at 230 nm and 285 nm increasing in relation to irradiation time.
Furthermore, MDMA in methanol showed two bands centered at 235 nm and at 285 nm, indicating
a small absorption increase and a small blue shift (Figure S1D1). A new band of absorption (300–340 nm)
appeared which increased upon irradiation. In water, MDMA presented the same absorption band
with a higher increase at 235 nm than at 285 nm, and the appearance of a band at 320 nm (Figure S1D2).
Ketamine in methanol was characterized by a single absorption band (205–230 nm).
When irradiated, this band slightly increased and a shoulder (230–270 nm) appeared, as evidenced in
Supplementary Figure S1E. On the contrary, in water, KET did not change its absorption spectrum
upon irradiation (Figure S1E2). Absorption spectrum of NKET in methanol increased upon irradiation
at 210–220 nm and in the range of 240–250 nm (Figure S1F1). In water, NKET showed a similar behavior
upon irradiation for the band 240–250 nm, with slight changes (Figure S1F2).
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3.2. Identiﬁcation of New Photoproducts
All the irradiated solutions in the solar simulator, including the control solutions kept in the
dark, were diluted to 10−5 M either in methanol or water, and analyzed by direct infusion HRMS,
with the aim of identifying the compounds eventually formed upon irradiation. Interestingly, for KET
and NKET only, some new species were observed in irradiated solutions. In HRMS spectrum of KET
irradiated in water solution, its [M+H]+ ion at 238.0993 m/z (C13H17ClNO) was accompanied by a new
ionic species at 220.0888 m/z (C13H15ClN), corresponding to the loss of H2O. In methanol, two species
were observed at 220.0888 m/z and at 252.0786 m/z (C13H15ClNO2), with the latter corresponding
to the loss of H2 and to the photo-addition of one oxygen atom. The proposed structures of KET
photoproducts are shown in Figures 1 and 2. It must be highlighted that the ionic species identiﬁed
were new protonated molecules present in solution, and they are not fragment ions produced by
collisional experiments on precursor ions.
Figure 1. Proposed structures of ketamine (KET) photoproducts formed in a water solution upon
irradiation for 3 h.
Figure 2. Proposed structures of KET photoproducts formed in a methanol solution upon irradiation
for 3 h.
In HRMS spectrum of the methanol solution of NKET irradiated in the solar simulator, [M+H]+
ions at 224.0837 m/z (C12H15ClNO) were accompanied by a new species at 206.0731 m/z (C12H13ClN),
corresponding to the loss of H2O. The proposed structure of NKET photoproducts formed in methanol
is shown in Figure 3 analogously to KET. However, differently from KET, no photoproduct was
detected in HRMS spectrum of NKET irradiated in water solution.
Vice versa, for all the other analytes (i.e., AMF, MA, and MDMA), both in water and methanol
solutions, no photoproducts were evidenced by direct HRMS analysis. To avoid ionization suppression
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phenomena that could occur in a mixture and shield the presence of less abundant species, irradiated
solutions were also analyzed by HPLC-HRMS. The ratios of peak areas observed for samples upon
irradiation vs those analogous samples kept in the dark were calculated as “percent degradation”.
In Figure 4, the yields of photodegradation obtained for all the analytes after 1 h, 2 h, and 3 h of
irradiation are reported.
Figure 3. Proposed structures of norketamine (NKET) photoproducts formed in a methanol solution
upon irradiation for 3 h.
As may be observed, AMF and MA in water show the highest photostability: the
photodegradation was 1% and 4%, respectively, while in methanol it increased up to 15%. In addition,
MDMA and MDA in methanol and water both presented similar photodegradation with a linear
relationship with irradiation time: MDMA from 23% to 42% and MDA from 13% to 36%. For KET and
NKET, the photodegradation yield was signiﬁcantly higher in methanol (KET 61%; NKET 36%) than
in water (KET 16%; NKET 13%) after 3 h.
Figure 4. Relative degradation of target drugs in methanol and water solutions with increasing time of
irradiation in the solar simulator (% photodegradation calculated using the peak area of protonated
molecules in solutions kept in the dark as controls for 0% degradation).
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3.3. Photodegradation in Hair Exposed to Solar Box
The main goal of the study was to observe the photo-induced degradation of drugs in hair.
In Figure 5, the concentrations of each drug for all seventeen hair samples irradiated in the solar
simulator or kept in the dark (control) are presented.
Figure 5. Drug concentrations in hair samples with their physical characteristics calculated by
high-performance liquid chromatography high-resolution mass spectrometry (HPLC-HRMS) in both
aliquots kept in the dark or irradiated in the solar simulator. -: absent at limit of detection (LOD,
0.005 ng/mg); (−) observed % increase.
In Figure 6, the percentages of photodegradation are reported. Calculations were made using the
concentrations of samples kept in the dark as control:
% photodegradation = (drug conc.dark − drug conc.irradiatied)/drug conc.dark × 100.
Figure 6. Percentage of photodegradation, average, standard deviation, and range of drugs in hair
samples irradiated at 765 W/m2 in the solar simulator.
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When comparing results from three poly-drug abusers, photodegradation of all the analytes was
generally obtained, with the highest comparable photodegradation yields observed in sample Brown 3
(see Figure 7).
Figure 7. Percentage of photodegradation of amphetamine (AMF), KET, and NKET in three different
hair samples. In these three samples, photodegradation seems to depend on the hair owner.
4. Discussion
From our results, a clearly different behavior of KET and NKET was evidenced when compared
to all the other drugs and metabolites under study. Indeed, these drugs seem photo-unstable,
both in solution and in hair matrix. In particular, for the experiments in solution, KET and NKET
photo-induced products were identiﬁed; in hair samples their degradation was higher (average 42%
and 29%) than all the other compounds (average 8–30%).
No color effect seems to be present, although no fair hair samples were present in this study,
and the number of samples was limited. It is well known that the color of hair depends on the
relative amount of pheomelanin (red) and eumelanin (black), the ﬁrst defense against UV in human
hair and skin [23–26]. Generally, a part of the light is absorbed by the hair matrix itself without any
photochemical effect. In dark hair, the eumelanin can protect the drugs/metabolites with a higher
degree than in fair hair. However, melanin may also react with oxygen under irradiation, producing
reactive species, such as superoxide anion, that can induce photolysis of melanin itself [27], thus
weakening the photoprotective effect of the pigment. In this context, no clear-cut interpretation of the
role of hair color can be made.
Regarding MA and AMF, on the basis of the in vitro experiments, they were expected to
photodegrade less readily than KET and NKET. Unexpectedly, the experiments in hair revealed
an average degradation of 30% and 31% for MA and AMF, respectively, with a range of 13–47% and
25–35%.
The presence of photoproducts was also investigated in irradiated hair samples. In one sample,
the species at 220.08750 m/z, corresponding to the photoproduct of KET shown in Figure 1, could be
identiﬁed by LC-HRMS as evidenced in Figure 8.
The importance of this ﬁnding must be highlighted, since no previous study has identiﬁed stable
photoproducts in hair for KET, nor for any other substance previously investigated (i.e., cannabinoids,
cocaine, opiates, methadone [9,10,20,21]).
The “apparent production” of NKET upon irradiation of sample Brown 11 was at ﬁrst sight
surprising, but could be reasonably related to the physical decomposition of the matrix, leaving KET
more labile during the irradiation experiment and favoring its transformation to the metabolite.
Furthermore, the increase of MDMA in sample Black 1 and Brown 7 upon irradiation can be
rationalized (as already demonstrated in previous studies) by a greater lability of the keratin matrix
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with consequent greater yield during the extraction of the analytes in the liquid acid phase with access
to deeper layers of the hair structure.
Figure 8. LC-HRMS analysis of hair sample Black 1 taken in the dark and after irradiation in the solar
simulator. In the irradiated sample, the presence of a KET photoproduct with 220.08750 m/z is evident.
5. Conclusions
Amphetamine, MA MDA, MDMA, KET, and NKET incorporated in hair undergo degradation
when irradiated by artiﬁcial sunlight, suggesting that they can suffer photodegradation under natural
sunlight. With this work, for the ﬁrst time, the presence of a photoproduct of KET was evidenced in
one true positive sample.
Since the detection of drugs in hair is often used as evidence of illegal acts with consequences on
the freedom of persons, the UV-Vis effects on the integrity of the drugs and their metabolites should be
considered when single administration needs to be evidenced. When decisional cut-offs are applied
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to hair analysis (e.g., for granting a driving license, a job, or a child custody), it must be taken into
account that hair exposed to sunlight may produce false negative results and lead to misjudgment.
When possible, the detection of photoproducts of a drug under investigation can be a key factor in a
case management.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3425/8/6/96/s1,
Fig S1A1/A2. UV spectrum of AMF (10-4 M) in methanol/water, by increasing exposure time in solar simulator;
Fig S1B1/B2. UV spectrum of MA (10-4 M) in methanol/water, by increasing exposure time in solar simulator;
Fig S1C1/C2. UV spectrum of MDA (10-4 M) in methanol/water, by increasing exposure time in solar simulator;
Fig S1D1/D2. UV spectrum of MDMA (10-4 M) in methanol/water, by increasing exposure time in solar simulator;
Fig S1E1/E2. UV spectrum of KET (10-4 M) in methanol/water by increasing exposure time in solar simulator;
Fig S1F1/F2. UV spectrum of NKET (10-4 M) in methanol/water, by increasing exposure time in solar simulator.
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Abstract: In the last decade, the trend of drug consumption has completely changed, and several new
psychoactive substances (NPS) have appeared on the drug market as legal alternatives to common
drugs of abuse. Designed to reproduce the effects of illegal substances like cannabis, ecstasy, cocaine,
or ketamine, NPS are only in part controlled by UN conventions and represent an emerging threat
to global public health. The effects of NPS greatly differ from drug to drug and relatively scarce
information is available at present about their pharmacology and potential toxic effects. Yet, compared
to more traditional drugs, more dangerous short- and long-term effects have been associated with
their use, and hospitalizations and fatal intoxications have also been reported after NPS use. In the
era of cyberculture, the Internet acts as an ideal platform to promote and market these compounds,
leading to a global phenomenon. Hidden by several aliases, these substances are sold across the web,
and information about consumption is shared by online communities through drug fora, YouTube
channels, social networks, and smartphone applications (apps). This review intends to provide an
overview and analysis of social media that contribute to the popularity of NPS especially among
young people. The possibility of using the same channels responsible for their growing diffusion to
make users aware of the risks associated with NPS use is proposed.
Keywords: psychoactive drug marketing; sales channels; Internet; social networks; YouTube;
Facebook; Twitter; Instagram
1. Introduction
In the last 10 years, an increasing number of new psychoactive substances (NPS) has ﬂooded the
drug market. NPS are drugs of misuse not included in the International United Nations Conventions,
which can easily bypass the supply reduction strategies of law enforcement agencies and sanctions
related to the use and sale of illicit substances. The advent of NPS has contributed to the appearance
and growth of a new “drug scenario” characterized by an increased number of drug users among
young people and the consumption of drugs with unknown effects or safety proﬁles. At the initial
stage of the phenomenon, NPS are typically used by a small group of people. After the use of these
substances becomes well-known, their widespread marketing through media and Internet sales begins.
This sequence of events causes the beginning of an epidemic diffusion that is eventually prevented by
law enforcement agencies that perform important actions and ﬁght against the trafﬁcking and sale of
NPS. Unfortunately, the subsequent legal control of these substances only initiates the reformulation
of NPS, which induces a typical loop that is highly dangerous to public health. In order to understand
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the full spectrum of the complex issue of NPS, we provide here an updated overview of the speciﬁc
ﬁeld of sales and advertising channels of NPS that represent an important ring in this chain of events.
2. The Complex Issue of the New Psychoactive Substances (NPS)
NPS are synthetic compounds that are very popular worldwide, as shown by the alarming number
of NPS (779) reported between 2008 and 2017 by 111 countries and territories [1–4]. Designed in order
to substitute classical drugs of abuse with legal surrogates, their expansion leads to an endless effort
made by governments and law enforcement agencies to try to contain this phenomenon. A mix of
features makes them very attractive, including the difﬁculty to detect them in human ﬂuid samples by
standard drug screening test, their ambiguous legal status, and, as in the case of synthetic cannabinoids,
the perceived low risk despite their toxic effects and abuse liability [5,6]. Noteworthy, the exponential
increase in the market size of these compounds has been facilitated by the World Wide Web (WWW),
where information about their purchase and use are shared, advertised, and spread to everyone.
In light of the changing scenario for drug marketing and advertising, the aim of this review is to
analyze the role of the web in this emerging trend, focusing on social networks and smartphone
applications (apps).
In the current world where communication is based on the Internet and social networks,
online sites operate on both the surface and deep web [7–10] to supply NPS labeled as “not for
human consumption” and sold as plant fertilizers, incense, bath salts, or with other aliases in
order to avoid legislative controls [11]. The dark net plays a key role in this “super safe drug
dealing”, which buyers and sellers can access anonymously to provide drugs and pay for them
with a virtual wallet [2]. Essentially, a few clicks are enough to supply highly psychoactive substances,
cheaply and in a low-risk way [12,13], even through smartphone apps [14,15]. Therefore, NPS can
be sold to everyone, including very young people, in complete anonymity and easily avoiding
law enforcement [10,16,17]. Along with the emergence of new psychoactive drugs in the world
drug market, new concepts are emerging to better describe this new, global phenomenon and its
associated health consequences. That is, the term “spiceophrenia” has been proposed by Papanti and
collaborators [18] to describe the psychotic symptoms (e.g., hallucinations, delusions) that likely occur
in chronic users of synthetic cannabinoids. It has been reported that the use of Spice/K2 drugs may
exacerbate psychotic symptoms in vulnerable individuals or trigger psychosis in individuals with
no previous history of psychosis [19]. The synthetic cannabinoids present in these products may
also induce important adverse neuropsychiatric consequences, including acute and lasting psychosis,
since their pro-psychotic effects are likely related to the activity of the CB1-receptor on dopaminergic,
serotoninergic, and glutamatergic pathways [20].
Similarly, within the e-health context, the term “e-addictology” has been recently used to indicate
new technologies for assessing pathological dependencies and intervening on addictive behaviors,
including computerized adaptive testing, e-health programs, web-based interventions, and digital
phenotyping [21]. Importantly, new technologies can profoundly change not only the way illegal
drugs are supplied, but they can also improve our understanding of drug addiction and favor the
development of new interventions for addictive disorders [21].
Because not everyone has the ﬁnances or the technical skills to create or manage an Internet
site, Facebook is often used as an alternative channel for sales and for advertising the use of these
kinds of products [8]. On several drug fora, such as www.drugs-forum.com or www.erowid.org, these
compounds are promoted and their subjective effects are discussed [9], but drug-related contents also
exist on virtually all social networking sites, picture- and video-sharing services, and drug-dedicated
apps. Drug selling through social media has also been reported, often using drug slang and jargon [22].
The changing policy on marijuana use in some states in North America, i.e., legalization of medical
cannabis, led to an increased rate of cannabis use both in young people and adults [23,24] even though
the causal effect of legalization has not been ﬁrmly assessed [25]. On the other hand, for young people,
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is it difﬁcult to recognize the risk of marijuana consumption if the law allows its use for medical
purposes, and this might represents a “gateway of curiosity” [26].
3. The Deep Web and the Surface Web: Market Resilience
By typing a keyword in a search engine query such as Google, Bing, Yahoo, or others, web surfers
can obtain a list of results belonging to the “surface web”, while other, nonsearchable contents are
referred to as the “deep web” or “invisible web” (see Figure 1). The deep web is often confused with
the “dark net”, but the two terms are not synonymous and overlap only partially. Basically, the deep
web contains all the information stored online which is not indexed by search engines, with most
information hidden simply because it is irrelevant for most users. Access to the deep web does not
require special tools and a visitor can use specialized search engines or directories to locate the data for
which he or she is looking. The dark web, instead, represents a small part of the deep web containing
information hidden on purpose, and it typically requires special tools to enter. Like the surface web,
the dark web is scattered among servers around the world and represents the portion of the Internet
most frequently known for illicit activities. The most common way to access it is through The Onion
Router (TOR) and the Invisible Internet Project (I2P).
Figure 1. NPS marketing, advertising, and communication network.
Developed in 2010 by the U.S. Army, the TOR browser is able to encrypt a user’s IP address [27],
thus making all the operations untraceable. In this way, the anonymous identities of administrators,
sellers, and customers are protected [28–31] and the safe payment of any illicit good is guaranteed
by of the use of cryptocurrencies, mainly bitcoins and litecoins, i.e., virtual money not controlled by
government [32]. The peer-to-peer software I2P, instead, was created in 2003 purposely for illegal
activities [31] in order to provide anonymous access and to bypass police and law enforcement
surveillance. I2P uses a “.i2p” domain, different from TOR’s classic Internet domain (WWW), to allow
users to host services by I2P’s homepage. The anonymous status in the web is also maintained by
encryption of e-mails, ﬁles, and messages using different cryptosystems such as Pretty Good Privacy
(PGP), the Amnesiac Incognito Live System, and the Tails [33].
Recently, online drug dealing has started replacing the old way of supplying drugs of abuse.
Surﬁng in both the surface and deep web, it is possible to buy traditional illicit drugs but also
temporarily legal NPS [1].
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In this hidden world, the most famous platform is the Silk Road hub. Born but shutdown by
the Federal Bureau of Investigation (FBI) in October 2013, it impressively reappeared after a month
under the name Silk Road 2.0 in order to supply to demanding customers [34]. Although Silk Road
2.0 was closed in November 2014, it got back on track in May 2016 and is now available as Silk Road
3.0. Moreover, in recent years, many cryptomarkets became available for buying and selling NPS,
including Dream Market [33] and others such as Alphabay, Nucleus, and Valhalla, which were shut
down in 2016 and 2017, respectively. In addition, a collection of data from drug fora and blogs on
the surface web shows that people who possess the knowledge for using the deep web are also able
to access drug marketplaces and buy drugs, including NPS [31]. Since the late 2000s, a number of
studies have investigated the online supply of NPS through online shops, among which was the
two-year, European Commission-funded “Psychonaut 2002 project”, coordinated by Fabrizio Schifano,
that provided a quantitative and qualitative assessment of the online supply of NPS in a time-speciﬁc
context, i.e.,“snapshot” [35]. More recently, another European project, the I-TREND (Internet Tools
for Research in Europe on New Drugs) project, coﬁnanced by the Drug Prevention and Information
Programme of the European Union, monitored the evolution of online shops and online user fora,
conducted an online survey focused on NPS users, and, based on the analysis of samples and the
exchange of reference standards among laboratories, ultimately produced a “top list” of NPS at the
national level [22].
However, since the deep web remains inaccessible to everyone, research of NPS occurs also on
the surface web, where several websites are currently selling them, advertising the products as incense,
bath salts, fresheners, plant fertilizers, etc. Notably, when inserting into classical searching engines,
such as Google, keywords like “legal highs” or “herbal highs”, many websites are listed that offer
drugs which are still legal thanks to the time that typically elapses from the appearance of a new
substance into the market and its introduction in the list of regulated substances [13]. Few of these
websites explicitly sold NPS; gaudy pictures, reduced price for ﬁrst purchase, proposals for use of new
equipment (e.g., vaporizers or smoking pipes), gift ideas, and holidays sales are only some examples
of the tricks they use to capture the attention of young consumers. Everyone who is looking for a new
sensorial experience and willing to try a psychoactive substance is encouraged to make the purchase
with guaranteed secure payment and fast shipment.
4. Sharing Information: Drug Fora and YouTube
A large proportion of the world’s population uses social networking websites, especially young
adults. Therefore, it is not unexpected that conversations about drug use have transferred onto Internet
drug fora and message boards [36]. The nature of conversations on drug fora (e.g., www.drugs-
forum.com, www.erowid.org) varies signiﬁcantly. Indeed, drug fora are used for many purposes,
including sharing methods of using drugs and learning about new drugs but also for harm reduction
purposes [37]. Notably, many users declare to access drug fora primarily to learn how to handle drugs
more safely. As a matter of fact, some users claim to be experts and provide detailed guidelines on
doses and routes of administration for each drugs class, advising against dangerous drugs interactions
as well [38]. The types of visitors and/or participants to drug fora are diverse, but many of them
can be considered recreational users who do not consider themselves drug addicts, do not look for
treatment, and are not planning to discontinue drug use [39,40].
Drug fora are also very popular among NPS consumers. They are used to report their
experiences of the positive and negative effects of substances and to provide advice on doses, routes of
administration, and on how to obtain them easily [39], frequently sharing their favorite substances
using pharmacological language.
The impact of conversations on drug fora on drug-use behaviors is not known, but it is reasonable
to argue that monitoring such discussions could help policy and law enforcement agencies to identify
emerging trends in drug use and markets [41]. In addition to drug fora, it is very common to ﬁnd
trip reports on YouTube, the most popular video-sharing site used by teenagers (among other users),
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and also on the picture-sharing sites Flickr and Instagram. Previously used to report marijuana-,
tobacco-, and alcohol-related experiences [42,43], a number of videos of various NPS are now available
on YouTube, in which consumers describe in ﬁrst person all proven effects including negative aspects
of their experiences. Sometimes live streams after ingestion of the drug are posted. Many videos
can be classiﬁed as “cautionary videos” (better known as vernacular prevention videos), others as
“hedonistic/celebratory videos” (but not for crystal meth or heroin), and some are “do-it-yourself”
(DIY) videos where, for example, detailed instructions on how to grow your own cannabis are
provided [44]. Considering the novelty-seeking propensity of young people, this easily available
online information might promote the use of these substances. Concern has been expressed for the
potential negative impact of social media content depicting drug use and related behaviors [45].
5. Social Networks and Smartphone Apps
In these times, the way to surf the Internet has radically changed and social networks are the new
leaders of this trend, with a large percentage of use by teenagers [17]. According to a recent survey
from a leading global information and measurement company [46], Internet users engage longer in
social media sites and apps than in activity on any other type of website. The same survey estimated
that the social networking giant Facebook has currently more than 1.6 billion registered users, that the
video-sharing site YouTube has more than 1 billion active users, while the social streaming site Twitter
has more than 500 million registered users worldwide. Given these numbers, all these platforms have
inevitably attracted the interest of drug suppliers, which strictly follow their evolution and diffusion
among young people over time. In the last few years, several social networks have acquired important
roles in market places for both NPS and illicit drugs [33] (see Figure 2). Simply looking on Facebook,
it is now possible to ﬁnd information and direct links to proceed with the purchase of several NPS
or to simply share your experiences in groups created for drug-users only. Even the picture- and
video-sharing service Instagram, despite its different use compared to the more famous Facebook,
is used to look for new possible customers [47]. Several ambiguous proﬁles are used to post pictures
of their products with hashtags such as #cannabiseeds, #headshop, #herbalicense, and #over18sonly.
In 2014, drugabuse.com, for example, published on Instagram an infographic documenting drug-dealer
activity [48].
Figure 2. Keywords and hashtags in social networks with explicit content on NPS.
On Twitter, by simply typing #legalhighs, it is possible to buy “the blue stuff”, otherwise known
as methamphetamine, of the famous Breaking Bad television series as well as other #ResearchChemicals,
with free shipping offers and credit/debit card payments accepted. All the users, indeed, can be
part of a #highsociety, allowing them to share their #proudstoners daily states of mind. Very
recently, epidemiologists and linguistic scientists used Twitter to test the feasibility of producing
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a fully-automated “drug term discovery” system capable of tracking emerging NPS terms in real
time [49], which conﬁrms that data collected on Twitter may be used to explore trends in NPS
selling and use [50]. Along with other cyber drug communities (e.g., blogs, drug fora, Facebook),
Twitter allowed the identiﬁcation and characterization of a new generation of NPS users, the so-called
“e-psychonauts”, that considered themselves as psychedelic researchers, mind navigators, or chemicals
experimenters [51].
In a technological world where about 2.4 billion people use a smartphone and an increasing
number of people use apps, drug dealers adapt their activity accordingly and create simple apps that
make buying any kind of psychoactive substance easier, including NPS. Although some apps are
designed to prevent drug use, such as “Your Face on Meth” (where you can upload your picture and
see its physical degradation over time potentially resulting from using methamphetamine), many apps
are created speciﬁcally to promote drug use [52].
In North America, the number of cannabis-related smartphone apps is very impressive. In 2014,
the number of apps returned from searches using terms like “cannabis” and “marijuana” were 124
and 218, respectively, in Apple’s Store, and 250 for both on Google Play [14]. These apps have several
content codes, contain information on different cannabis strains and synthetic cannabinoids mixture
(e.g., K2, Spice), advice for growing cannabis, and recipes for cooking “special meals”. Several apps
create a connection with medical marijuana doctors to obtain a prescription, while other apps, such as
Eaze, Nugg, Meadow, and Weed Maps, offer to trace medical dispensaries of marijuana, indicating
to users the closest spot based on their location in addition to ﬁnding the closest doctor that will
recommend medical marijuana [14,15]. Additionally, using the app High There, for instance, it is
possible to match people to smoke together, while other apps, similar to Instagram and used mostly in
Europe and the United States, are utilized for posting photos, videos, or texts related to marijuana or
psychoactive substances. Noteworthy, apps useful for making untraceable calls to drug dealers are
becoming very popular.
6. Conclusions
New psychoactive substances are very popular among young people and online communities,
but very little information about toxicological and side effects are available on the Internet.
The web-based open sale of unregulated NPS has shown a steady increase in recent years; the easy
availability of NPS and the ﬂuctuating dynamics of this new drug market represent a public health
concern and an intricate regulatory issue. Research in the ﬁeld is increasing, and several groups of
clinical and preclinical researchers worldwide are investigating the central and peripheral effects
of synthetic cannabinoids and synthetic cathinones [1,53–58], synthetic opioids and ketamine-like
compounds [59,60], and many others [61,62]. Yet, it is fundamental to share scientiﬁc evidence on
risks related to the consumption of these compounds using the same channels that promote them.
Analyses of social media may represent a new approach to uncover and track changes in drug terms
and markets in near real time. In conclusion, the NPS phenomenon is intricate and still very difﬁcult
to control. Using the same channels responsible for their growing diffusion to disseminate information
and scientiﬁc knowledge about the risks associated with their use could represent a potential new
approach to limit the diffusion of these dangerous substances.
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Abstract: Background: Novel Psychoactive Substances (NPS) are a heterogeneous class of synthetic
molecules including synthetic cannabinoid receptor agonists (SCRAs). Psychosis is associated with
SCRAs use. There is limited knowledge regarding the structured assessment and psychometric
evaluation of clinical presentations, analytical toxicology and clinical management plans of patients
presenting with psychosis and SCRAs misuse. Methods: We gathered information regarding the
clinical presentations, toxicology and care plans of patients with psychosis and SCRAs misuse
admitted to inpatients services. Clinical presentations were assessed using the PANSS scale. Vital
signs data were collected using the National Early Warning Signs tool. Analytic chemistry data were
collected using urine drug screening tests for traditional psychoactive substances and NPS. Results:
We described the clinical presentation and management plan of four patients with psychosis and
misuse of SCRAs. Conclusion: The formulation of an informed clinical management plan requires a
structured assessment, identiﬁcation of the index NPS, pharmacological interventions, increases in
nursing observations, changes to leave status and monitoring of the vital signs. The objective from
using these interventions is to maintain stable physical health whilst rapidly improving the altered
mental state.
Keywords: synthetic cannabinoids; SCRAs; NPS; novel psychoactive substances; NPS testing;
antipsychotics; mental health; physical health; nursing care; psychosis
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1. Introduction
Recent statistics in England have reported an increased number of hospital admissions with a
primary diagnosis of drug-related mental health/behavioural disorders and poisoning by illicit drugs,
respectively of 12 and 40% compared to statistics released in 2006/07 [1]. Over the last ﬁve years deaths
involving Novel Psychoactive Substances (NPS) have sadly increased, with a further 8% increase in
2016 [2]. NPS represent an emerging and concerning global phenomenon [3–5] mainly due to: (1) the
difﬁculties posed in the clinical management, of both mental and physical health; and (2) the absence
of a clear and formal/structured description of the clinical presentation of patients using NPS, with
obvious repercussions on clinical management.
NPS are a heterogeneous class of typically synthetic molecules including: synthetic cannabinoid
receptor agonists (SCRAs), synthetic cathinones, amphetamine-derivatives, psychedelic phenethylamines,
ketamine derivatives, novel tryptamines, synthetic opioids and sedatives (GABA-A/B agonists) [3,6,7].
Trends in illicit drug use over the last decade clearly show that adolescents and young adults give
preference to NPS instead of traditional psychoactive substances (TPS) (e.g., cannabis, cocaine, heroin,
amphetamines, LSD, ecstasy, ketamine, etc), because NPS are cheap and easily available either on the
street or from websites [6–8]. They are difficult to identify in blood or urine drug screening (UDS) [9].
Lifetime NPS consumption was reported by 8% of young individuals in 2015 [10] up from 5% in 2011 [6].
Young adults (aged 16 to 24) are around twice as likely to have used an NPS in their lifetime compared
to older adults (aged 16 to 59) [11]. It has recently been reported that the three psychiatric diagnoses
most frequently associated with NPS use are bipolar disorder (23.1%), personality disorders (11.8%), and
schizophrenia and related disorders (11.6%) [12].
In comparison to TPS users, poly NPS users are more likely to be young males [11], with daily use
of traditional cannabis, weekly or more use of ecstasy, recent LSD use, higher levels of poly drug use,
and a history of overdose on any drug in the past year [13]. Young adults attending nightlife events
in pubs and discos are also more prone to poly-substance use, mainly combining NPS with alcohol
and cocaine [14]. NPS users also tend to have a forensic history and a history of promiscuous sexual
activity (e.g., chem-sex) [13].
Few studies have attempted to provide a psychopathological description of the clinical
presentation of NPS users in acute settings. For example, in an observational cohort study enrolling
consecutive adult patients presenting to an Emergency Department (ED) in London, the most common
clinical features identiﬁed were seizures and agitation [15]. In a recent study looking into the impact
of NPS misuse on admissions to an acute psychiatric facility in London, increased levels of violence
in the group of NPS users were identiﬁed ([16]. Data collected in the Accident and Emergency
departments (A&Es) of ten European countries have shown that the association between NPS use and
the occurrence of psychosis varied considerably, depending on the type of drug used [17]. In particular,
psychotic symptoms were noted in 6.3% of a large sample (5529 consecutive cases), with psychosis
being more common amongst NPS users that had used tryptamines, methylenedioxypyrovalerone
(MDPV), methylphenidate, SCRAs and amphetamine-type compounds [17]. A mounting range of
evidence suggests that SCRAs can trigger the onset of acute psychosis in vulnerable individuals and/or
exacerbate psychotic episodes in those patients with a previous psychiatric history. The literature
reports a wide range of psychopathological issues such as paranoid thoughts, increases in aggressive
and combative behavior, together with confusion, agitation and suicidal thoughts [18]. It has
been suggested that SCRAs may have a higher psychosis-inducing potential compared to natural
cannabis [19] because of the lack of cannabidiol—a substance associated with the medicinal effects of
cannabis. For a review on existing studies and models of cannabis induced psychosis see a review
from Murray et al [20].
Professionals usually report feeling less conﬁdent about managing NPS compared to TPS users,
speciﬁcally because of the lack of clear guidance regarding the clinical management and the increased
risk of toxicity [10–18,21]. For example, with the ingestion of NPS with high serotonergic activity (e.g.:
psychedelic phenethylamines), misusers may present with hyperthermia, seizures, and hyponatraemia.
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Conversely, NPS with high dopaminergic activity (e.g., methylphenidate-like drugs such as some
synthetic cathinones) are highly addictive and associated with prolonged stimulation, insomnia,
agitation, and psychosis [22,23]. Furthermore, most SCRAs are at times associated with medical
emergencies such as hypertension, myocardial infarction, renal failure [24], elevated heart rate,
hyperglycaemia, nausea, vomiting, hypokalaemia, and seizures [18]. Moreover, in view of the increased
use of latest generation of sedatives or ultra-high potency fentanyl derivatives, the assessment of vital
parameters is of paramount importance when NPS users are presenting to an emergency or acute
facility [3–6].
The implementation of an appropriate and safe clinical management plan is commonly based
on patients’ accounts on which kind of NPS have been used. Acute mental health and emergency
services are not routinely equipped with urine drug screening tests (UDS) for NPS in order to identify
and provide an appropriate toxicological conﬁrmation [15]. This causes considerable limitations
when offering a targeted treatment strategy that can address patients’ presentations and potentially
life-threatening intoxications [9,13,25].
At present, there is a dearth of detailed information relating to the clinical presentation of NPS
users in acute mental health settings, especially in terms of: (1) descriptions of behavioural and
psychopathological features using structured assessment and psychometric scales; (2) analytical
toxicology and identiﬁcation of the index NPS used; and (3) appropriate and evidence-based clinical
management plans. This results in a range of difﬁculties in formulating targeted/individually tailored
treatment plans.
The aims of this case series are: (1) to offer a standardized description of NPS users’ clinical
presentations to provide clinicians with objective and measurable clinical pictures aimed at shaping
protocols and standard operating procedures when NPS use is suspected and/or detected; (2) to
provide best practice advice in the management of mental state alterations and medical complications,
with the goal of reducing the number of serious adverse outcomes associated with NPS use.
2. Materials and Methods
2.1. Study Design and Recruitment
Data on presentation and clinical management of 4 cases, selected amongst patients consecutively
admitted to two acute psychiatric wards from June 2017 to June 2018 at Highgate Mental Health
Centre—Camden & Islington NHS Foundation Trust—were retrospectively collected using a database.
Patients were aged 18 and 65 years and admitted because of presenting with psychotic illnesses and
with a history of NPS use before or during admission. Data were collected using a standardized
database to capture a range of information at baseline i.e., the time of the admission, and then during
and after NPS intake. The information collected revolved around: (1) the clinical presentation, with a
formal description of the psychotic symptoms; (2) the type of recreational drug(s) used; (3) the physical
health outcomes; (4) the levels of psychiatric inpatient observation and leave status.
The clinical presentation was identiﬁed with the help of clinical notes and corroborated by the
retrospective scoring of the Positive and Negative Syndrome Scale (PANSS), a multi-item questionnaire
widely used to quantify disease severity in schizophrenia and psychosis [26]. Monitoring data of
vital signs were collected using the National Early Warning Signs tool (NEWS) [27]. Data on the type
of substance used were collected using routine drug screening tests for traditional psychoactive
substances whilst a more thorough analysis (urine and/or oral ﬂuids tests; Alere Laboratories
technologies) was carried out to identify the index drug(s) used by both NPS and TPS patients.
All subjects identiﬁed received medications included in the British National Formulary (BNF), such as
benzodiazepines (BZO) and antipsychotics (ﬁrst and second generation), with the choice guided by
the clinical presentation and the drug testing results. Levels of nursing care, such as close or general
observations, were also recorded together with the possibility of leave in the hospital grounds , either
accompanied by staff (escorted) or alone (unescorted).
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2.2. Participants
2.2.1. Inclusion Criteria
Cases were selected amongst patients with recent or current histories of NPS use, aged 18–65 years,
presenting to acute services with a psychotic illness classiﬁed by the International Classiﬁcation of
Diseases, Mental and Behavioral Disorders [28] as schizophrenia, schizotypal, delusional, and other
non-mood psychotic disorders (ICD-10 codes: F20-29), mood (affective) disorders (ICD-10 codes:
F30-39), and mental and behavioral disorders due to psychoactive substances (ICD-10 codes: F10-19).
2.2.2. Exclusion Criteria
Patients were excluded from the study if: (1) the psychotic symptoms were precipitated by an
organic cause; (2) they had moderate or severe learning disability; (3) they suffered from a medical or
neurological illness or (4) had an insufﬁcient command of the English language.
2.3. Measures
2.3.1. Psychometric Measures
The Positive and Negative Symptoms Scale (PANSS) is a multi-item questionnaire widely used to
quantify disease severity in schizophrenia and to assess the severity of positive (or productive) and
negative (or deﬁcit) symptoms of psychosis [26]. PANSS is easy to administer and is based on the
clinician’s interview with the patient; data are gathered looking at the patient's mental state over the
previous week, with the patient's family and/or his/her acquaintances being able to provide further
information. PANSS consists of 30 items and takes 45–50 min to be completed by the clinician.
The National Early Warning Score (NEWS; Royal College of Physicians, London, UK) [27] is a
standardized system for the assessment of acute illness in adults. It is based on six vital signs such as
respiratory rate, oxygen saturation, temperature, blood pressure, pulse/heart rate, and alertness. Each
parameter yields a score of between 0 and 3 so that when the scores for all the parameters are summed
a total NEWS score of between 0 and 18 is achieved. A score of 7 or greater indicates that a patient is
likely to be critically medically unwell.
2.3.2. Laboratory Measures
Standard urine drug screening tests were used to detect TPS such as heroin, cocaine, amphetamine,
THC, and methadone. For NPS, the Alere drug screening urine and oral ﬂuids tests were used.
The urine tests provided a rapid screening of 30 synthetic cannabinoids at once whilst the oral
screening test was able to detect mephedrone.
3. Clinical Vignettes
3.1. Case 1—Mr A
28 years old Caucasian male, single and unemployed, living alone, with a positive forensic history
and a diagnosis of Paranoid Schizophrenia. The patient had a 4 years’ history of psychosis with
frequent relapses (5 admissions in 4 years). He was transferred to an acute treatment ward from
a psychiatric intensive care unit (PICU). At the time of the transfer the patient was stable and on
treatment with Risperdal Consta 37.5 mg fortnightly + Olanzapine 10 mg daily + Pregabalin 100 mg
daily. The PANSS score was 73/210 and his psychopathology was mainly characterized by positive
symptoms: delusional mood, persecutory and grandiose delusions and second and third person
auditory hallucinations. The UDS was initially negative but, one week after the transfer, Mr A’s mental
state deteriorated suddenly and he became very agitated and verbally and physically aggressive.
He presented with a bizarre and repetitive behaviour consisting of stopping and remaining immobile
for a few minutes and then running fast along the ward corridor. He also had second and third person
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auditory hallucinations, persecutory delusions and thought disorganization. He started to fear the
hospital ward’s electronic ﬁre alarms. He believed that the ﬁre alarms were cameras that were spying
on him and he was very preoccupied with speciﬁc members of the staff whom he believed were there
to kill him. The hallucinations also became very severe and he was responding to internal stimuli
constantly throughout the day. The total PANSS score was 109/210 and the UDS was positive for
SCRAs. We decided to increase Olanzapine to 20 mg, daily and to add Clonazepam 8 mg, daily to
manage the agitated behaviour and the psychotic symptoms. We also increased the level of monitoring
of his vital measures by completing the NEWS scores twice a day. NEWS scored 2 with increased
heart rate and ﬂuctuating blood pressure. We considered a transfer to PICU but since the patient
was starting to respond well to the new treatment plan and the reason for the relapse was evident
(NPS intake), we decided to continue to treat the patient on the acute ward. Mr. A responded well to
the change/increase of medications, his symptoms improved in 24 h and within 7 days from the acute
intoxication the PANSS scores reduced to 74/210.
3.2. Case 2—Ms T
32 years old Caucasian woman, single and unemployed, living alone, with no forensic history
and a diagnosis of Schizoaffective Disorder and poly-substance misuse (mainly crack cocaine and
heroin). Ms T was stabilized on a combination of Aripiprazole 30 mg, daily + Lithium carbonate
800 mg, at night. The PANSS score was 95/210 and the UDS was negative for all illicit substances.
Four weeks later, the patient’s mental state deteriorated suddenly. She became physically and verbally
very aggressive with severe features of sexual disinhibition. The patient presented with delusional
mood and with complex grandiose and persecutory delusions such that she believed she was part
of a secret army and she had powers to kill people with her thoughts. She also believed she was
being chased by the Albanian maﬁa and had to ﬁght for her life. The patient also became very
aggressive with members of staff and on four occasions it was necessary to call the emergency team to
provide extra sedation. The PANSS score was consistent with the deterioration of her mental state,
scoring 115/210 and the UDS tested positive for both SCRAs and THC. The clinical team felt that
the patient needed a more robust pharmacological treatment plan and therefore Haloperidol 10 mg
daily + Clonazepam 8 mg daily were added. The patient remained acutely unwell for more than
72 h. Ten days after the intoxication Ms T remained still irritable and agitated. The PANSS score was
115/210, 10 points higher than the baseline, and the UDS continued to test positive for SCRAs. NEWS
were increased to twice a day but the score was always within range (0 or 1) with tachycardia being
the only altered parameter. Meanwhile, other patients on the ward tested positive for SCRAs and it
was suspected that Ms T was bringing SCRAs to the ward. At that stage, leave was suspended and a
stricter search policy was enforced on the ward. The patient’s mental state improved further and ten
days later her urine tests were negative for SCRAs.
3.3. Case 3—Mr Y
20 years old Black-Caribbean male, single and unemployed, living with friends and with no
forensic history, was quickly re-admitted to a treatment ward following the sudden onset of bizarre
behaviour after an earlier discharge from another ward. The diagnosis was First Psychotic Episode
in the context of poly-substance misuse. On admission, Mr Y was on Haloperidol Decanoate 50 mg,
monthly + Haloperidol 10 mg, at night (on reducing regime). He appeared severely thought-disordered,
sexually disinhibited and aroused, approaching other patients for sex or suddenly becoming physically
aggressive by spitting on others. The PANSS score was 116/210 with prominent positive symptoms
(positive symptoms subscale 40/49). He presented as being severely disruptive, chaotic, and intrusive
into other patients’ care, attacking staff and other patients, urinating on the ﬂoor and spitting at other
people’s faces. Mr Y was therefore treated with Aripiprazole 9.75 mg three times a day + Clonazepam
6 mg daily in divided doses. Observation levels were increased to 2:1 arms’ length to reduce risks of
retaliation from others due to sexually inappropriate and aggressive behaviour. NEWS monitoring
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was increased to hourly to monitor any possible deterioration in physical health. UDS were positive
for benzodiazepines and SCRAs. The patient remained unwell. Observation levels were maintained at
2:1 arms’ length and NEWS monitoring decreased to TDS once physical outcomes remained stable for
12 h. After 72 h the clinical condition improved with a reduction of PANSS score to 98/210. Eventually,
because of the continued high risk of retaliation from others Mr. Y was transferred to a Psychiatric
Intensive Care Unit (PICU).
3.4. Case 4—Mr G
39 year old Asian British man, married and unemployed, living with his family and with a long
forensic history. Mr G had a long-standing history of Bipolar Disorder since the age of 28. He had a
history of numerous admissions, was non-compliant with his medications, and engaged poorly with
his community team. He presented with a long-term history of poly-substance misuse (e.g., alcohol,
cocaine, MDMA, cannabis, “legal highs”). He had previously been treated with a mood stabilizer
(Sodium Valproate); Zuclopenthixol and Risperidone Depot (both stopped due to sexual dysfunction);
Olanzapine and Quetiapine (both stopped due to poor response). At the time of his admission to
Highgate Mental Health Centre, he was administered Abilify Depot 400 mg, monthly with no or
little efﬁcacy. He was transferred from another ward on Section 3 due to a manic relapse, with no
leave and a diagnosis of Bipolar Affective Disorder (BPAD, current episode manic). Mr. G had a
long history of violence towards staff and patients (he broke a nurse's nose and stabbed another
patient with a pen). At the time of the admission, he was very agitated, aggressive and intimidating,
banging his ﬁst on the table and threatening staff with a glass bottle. He also showed bizarre behavior,
e.g., wearing sunglasses whilst indoors, holding pieces of paper with some incomprehensible notes
on Hitler, quantum physics and aliens. He was thought disordered with grandiose delusional beliefs
regarding him being the King of Egypt and able to cause a nuclear war. It proved very difﬁcult to
verbally de-escalate him and he did not agree to change his medication regime as he believed that
he should be treated “only with love”. The PANSS score was 108/210. Abilify was withdrawn and
Zuclopenthixol started whilst he continued the rest of his medications. On admission, UDS was
negative for both NPS and TPS. A week later, UDS was positive for both benzodiazepines and SCRAs,
and NEWS was increased to TDS. Two weeks later, UDS continued to be positive to SCRAs, no changes
to his leave status were made, with garden leave being maintained. Three weeks after admission, UDS
was positive for benzodiazepines and THC and four weeks later the admission UDS was positive
for THC and SCRAs. After admission, his mental state remained unsettled with refractory manic
positive symptoms and a poor response to medication. The PANSS score was 123/210. Hence, his
leave was stopped and, a week later, his UDS became negative for all substances, SCRAs included.
His positive symptoms started to improve with a reduction of PANSS to 66/210. Over the following
four weeks Mr. G appeared well kempt and settled on the ward, with no grandiose delusions and no
further episodes of aggression. He showed a satisfactory response to Zuclopenthixol 300 mg, weekly
+ Sodium Valproate 1200 mg. UDS was negative for all substances and, therefore, Mr. G was safely
discharged to the community team.
4. Discussion
NPS misuse is a recent phenomenon and knowledge of its effects, either in the short or the
long term, on the population is relatively poor [3]. There is an increasing amount of knowledge
regarding the effect that NPS have on individuals with severe mental illness [12]. However, well
documented evidence of the negative impact are limited and most cases have not been corroborated
by analytic chemistry evidence of the NPS used [15]. Furthermore, there is a paucity of data to guide
the monitoring and management of patients with severe mental illness who take NPS, and then suffer
from acute psychopathology and physical ill-health [3].
To the best of our knowledge, our case series is the ﬁrst and only attempt made at describing, with
the use of a speciﬁc psychometric scale (PANSS), the effects of acute intoxication with NPS (mainly
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SCRAs) identiﬁed through UDS in an acute hospital setting in patients suffering from severe psychotic
disorders. All four cases show how clinically signiﬁcant the impact of SCRAs use was on their mental
states. The cases showed marked and sudden clinical deteriorations, with intense exacerbations of
positive symptoms, psychomotor agitation, sexual disinhibition, verbal/physical aggression, and poor
responses to medications. The latter phenomenon makes the clinical and risk management of these
patients more difﬁcult, and it is therefore necessary to develop appropriate management plans to
minimize such risks.
In order to set up an appropriate and safe Informed Clinical Management Plan (ICMP) (Table 1),
the ﬁrst step advised here is to establish, whenever possible, which NPS is responsible for the
intoxication due to their wide range of effects. We advocate, therefore, the use and further development
of reliable drug tests to identify the speciﬁc NPS types associated with particular clinical presentations.
Accurate testing for NPS would assist in establishing clear diagnoses, formulating ICMPs and
identifying the most effective treatments for intoxications with particular NPS.
Table 1. Description of the Camden & Islington—Informed Clinical Management Plan (ICMP).
Camden & Islington—Informed Clinical Management Plan (ICMP)
MENTAL STATE assessment
Using a psychometric scale (PANSS) Monitoring mental state
NPS detection
Using speciﬁc analytic toxicology to detect NPS
(UDS and/or oral swabs)
Monitoring access to substances and leaves
(reduced/suspended—escorted/unescorted)
MEDICATION & PHYSICAL HEALTH monitoring
Using benzodiazepines (BDZ) and/or second
generation antipsychotics (SGA) when possible
Monitoring physical health (NEWS)
Levels of nursing observations
The cases described here were all characterized by acute SCRA intoxications. The clinical
presentations were characterized by an acute onset of agitation and aggressive behavior; the symptoms
decreased in intensity and frequency in no less than 72 h. The management of acute intoxications was
by identifying the substances responsible for the sudden deteriorations, and by treating the symptoms
with benzodiazepines and antipsychotic medications. In addition vital parameters were monitored,
nursing observations were increased, and leave statuses were changed. These measures led to rapid
and successful resolutions of symptoms and reduced the need for transfer to more intensive care
settings. Furthermore, they promoted more rapid step-down and recovery in the community.
In general terms, pharmacological treatment remains the mainstay of treatment. However,
the novelty of the use of medications according to our protocol is that pharmacological interventions
are guided by NEWS and toxicology results. For example, haloperidol should be avoided in patients
that have used cathinones for the toxic effect on cardiac rhythm; and benzodiazepines should be
avoided in patient with a NEWS score of 3 because of low oxygen saturations levels.
In terms of pharmacological treatment, the use of BDZ has been recommended with or
without a second-generation antipsychotic (SGA) to reduce the risk of cardiac side effects [22,23].
Benzodiazepines remain the ﬁrst line treatment, although their use needs to be weighed against the
risk of respiratory depression when given to subjects who have ingested alcohol and/or unknown
substances [6–18]. Amongst the SGAs, whilst aripiprazole is probably the safest antipsychotic to be
used in such scenarios because of its negligible effect on QTc, olanzapine has proven to be effective in
treating psychotic symptoms caused by NPS [29].
5. Limitations
We are aware that four cases are not representative of the multi-faceted spectrum of presentations
with NPS use/intoxication and observation of a wider sample size is necessary. However, we believe
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that this study is important in generating hypotheses that may lead to more comprehensive projects
such as case control studies.
Furthermore, although the four cases presented were objectively described by using the PANSS
to provide an objective measurement of the clinical observation, this was made retrospectively. We are
also aware that the patients described were intoxicated with SCRAs. No other NPS such as cathinones
or mephedrone were detected in our sample population. Therefore, our clinical description-albeit
exhaustive and comprehensive-is limited to a subgroup of NPS users using only SCRAs. Moreover
unfortunately, the UDS screening tests that were available were not able to identify with higher
speciﬁcity the type of SCRAs used.
It is worth noting how in terms of diagnostic categories our patients sample was not homogenous
as one of the four patients was presenting with bipolar disorder. This may be an additional confounding
factor; and, in a large enough sample, patients should be divided according to diagnoses.
Finally, a randomized controlled trial (RCT) to establish which ICMP is necessary to establish
which treatment plan is most effective in the management of individuals with a severe mental illness
intoxicated with NPS would be helpful.
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Abstract: Background: New Psychoactive Substances (NPS) constitute a broad range of hundreds of
natural and synthetic drugs, including synthetic opioids, synthetic cannabinoids, synthetic cathinones,
and other NPS classes, which were not controlled from 1961 to 1971 by the United Nations drug
control conventions. Among these, synthetic opioids represent a major threat to public health.
Methods: A literature search was carried out using public databases (such as PubMed, Google
Scholar, and Scopus) to survey fentanyl-, fentanyl analogs-, and other synthetic opioid-related deaths.
Keywords including “fentanyl”, “fentanyl analogs”, “death”, “overdose”, “intoxication”, “synthetic
opioids”, “Novel Psychoactive Substances”, “MT-45”, “AH-7921”, and “U-47700” were used for
the inquiry. Results: From our literature examination, we inferred the frequent implication of
fentanyls and synthetic opioids in side effects, which primarily affected the central nervous system
and the cardiovascular and pulmonary systems. The data showed a great variety of substances and
lethal concentrations. Multidrug-related deaths appeared very common, in most reported cases.
Conclusions: The investigation of the contribution of novel synthetic opioid intoxication to death
should be based on a multidisciplinary approach aimed at framing each case and directing the
investigation towards targeted toxicological analyses.
Keywords: fentanyl; NPS; synthetic opioids; MT-45; AH-7921; U-47700; forensic pathology
1. Introduction
New Psychoactive Substances (NPS) are a heterogeneous class of non-controlled substances
available on the global illicit drug market (e.g., smart shops, internet, “darknet”). The use of NPS, often
consumed along with other drugs of abuse and alcohol, has resulted in a signiﬁcantly growing number
of emergency admissions due to overdoses and a high number of deaths. By July 2017, 739 different
NPS were reported to United Nations Ofﬁce on Drugs and Crime (UNODC) [1]. According to the The
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)report, with an overall total
of 38 substances, synthetic opioids have become the fourth largest group of substances monitored in
2017, after synthetic cannabinoids (179 substances), cathinones (130), and phenethylamines (94) [2].
The class of synthetic opioids include fentanyl, its analogs used in medical therapy (e.g., sufentanil,
alfentanil, and remifentanil) [3], and novel non-pharmaceutical fentanyls not approved for human
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medical use (e.g., acetylfentanyl, acryloylfentanyl, carfentanil, α-methylfentanyl, 3-methylfentanyl,
furanylfentanyl, 4-ﬂuorobutyrylfentanyl, 4-methoxybutyrylfentanyl, 4-chloroisobutyrylfentanyl,
4-ﬂuoroisobutyrylfentanyl, tetrahydrofuranylfentanyl, valerylfentanyl, cyclopentylfentanyl,
and ocfentanil), and compounds with different chemical structures, such as MT-45
(1-cyclohexyl-4-(1,2-diphenylethyl)piperazine), AH-7921 (3,4-dichloro-N-{[1(dimethylamino)
cyclohexyl]methyl} benzamide) and U-47700 (3,4-dichloro- N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-
N-methylbenzamide) [4,5]. They are used on their own or more often in combination with heroin
or other opioids [6,7]. This paper critically examines the literature on deaths related to fentanyls
and synthetic opioid overdose, alone or in combination with other psychoactive drugs (i.e., cocaine,
benzodiazepine, alcohol, and other opioids) and investigates the characteristics and complexity of
such deaths, analyzing all data useful for the forensic pathologist.
2. Materials and Methods
A literature search was carried out using public databases (such as PubMed, Google Scholar, and
Scopus) to revise fentanyl-, fentanyl analogs- and others synthetic opioids-related deaths. Keywords
including “fentanyl”, “fentanyl analogs”, “death”, “overdose”, “intoxication”, “synthetic opioids”,
“Novel Psychoactive Substances”, “MT-45”, “AH-7921”, and “U-47700” were used for the inquiry. The
data were collected from 1990 to June 2018. Only deaths were considered. There were no language
restrictions. All types of papers were included. We also reviewed the reference lists of the identiﬁed
publications and PubMed suggestions. The full texts of all the eligible papers were obtained. Finally,
128 articles were included in this review. The examined data included the circumstances of death
(e.g., trauma, external injuries) and drug exposure (pharmaceutical versus illicit drug use). With regard
to the concentrations of the compounds, blood and, when stated, liver, urine, stomach content, kidney,
brain, vitreous humor, and nasal swab concentrations were reported.
3. Results
3.1. Synthetic Opioid Overview
Novel synthetic opioids, similar to the classical opioids morphine and heroin, selectively bind
to the μ-, δ-, and κ-opioid receptors in the peripheral and central nervous system (CNS), thereby
simulating the effects of endogenous opiates. However, they generally show greater selectivity
towards the μ-opioid receptor subtype than morphine [8]. Stimulation of the μ-opioid receptor
promotes the exchange of GTP (Guanosine Triphosphate) for GDP (Guanosine Diphosphate) in
the G-protein complex and subsequently inhibits adenylate cyclase in cells causing a decrease in
intracellular cAMP (Cyclic Adenosine Monophosphate). In addition, the activation of the μ-opioid
receptors inhibits calcium and potassium ion channel conductance [8]. All these molecular events cause
cellular membrane hyperpolarization and inhibit tonic neural activity with a consequent reduction in
the release of several neurotransmitters, such as substance P, GABA, dopamine, acetylcholine, and
noradrenaline [9].
These neurochemical changes are mainly responsible for the pharmaco-toxicological effects
induced by synthetic opioids. Typically, acute intoxication induced by “classical” and novel synthetic
opioids is characterized by miosis (but later the pupils may become dilated), a reduced level of
consciousness (CNS (central nervous system) depression), respiratory depression, hypoxia, acidosis,
hypotension, bradycardia, shock, gastric hypomotility, paralytic ileus, pulmonary edema, lethargy,
coma, and even death.
In the last few years, the novel fentanyls have become a serious concern. These substances
currently dominate the synthetic opioid group, with a total of 28 reports since they ﬁrst surfaced in 2012.
Fentanyl, which is the prototypical compound of this class, is a synthetic, lipophilic phenylpiperidine
opioid agonist. It was developed in the 1960s by Paul Janssen in Belgium, and it is now available
therapeutically as an intravenous, transbucal, or transdermal preparation, commonly used for surgical
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anesthesia and to treat severe chronic pain [10]. Because of its highly potent opioid euphoric effects,
fentanyl leads addicts to rapidly abuse this drug through a variety of different methods, including the
oral abuse of transdermal fentanyl patches [4]. The clinical effects are dose dependent, ranging from
the induction of analgesia alone by serum concentrations of 0.3–0.7 ng/mL to the loss of protective
airway reﬂexes and CNS depression by serum concentrations >3 ng/mL [11]. In addition, fentanyl
and its analogs produce drowsiness and euphoria [12]. The most common side effects may include
nausea, dizziness, vomiting, fatigue, headache, and constipation. The repeated use of fentanyls leads
to the development of tolerance and dependence [13]. Typical withdrawal symptoms involve sweating,
anxiety, diarrhea, bone pain, abdominal cramps, and shivers or goose “ﬂesh” [12,14].
From a pharmacological point of view, fentanyl and its analogs are signiﬁcantly more potent
than morphine, with effects’ magnitudes ranging from 1.5–7 times (butyrylfentanyl) to 10,000 times
(carfentanil) those of morphine [14], and are characterized by high lipid solubility, rapid onset of action,
and short duration of action. Like other types of opioid analgesics, such as morphine, methadone,
and heroin, fentanyls produce their main effects by stimulating at nanomolar afﬁnity the μ-opioid
receptor [15–18]. In particular, they induce acute analgesia, relaxation, euphoria, sedation, bradycardia,
hypothermia, depression of the central nervous system and respiratory function [16,19–21]. The last
of the listed side effects poses the greatest danger to users and it is responsible for fentanyls-related
signiﬁcant morbidity and mortality [22]. The timely administration of the antidote naloxone [23] can
rapidly reverse the severe respiratory depression caused by fentanyls [24], although multiple naloxone
doses may be required [25]. The rapid administration of naloxone following fentanyl’s overuse is
essential, because of the rapid onset of action of the drug that can cause respiratory depression within
two minutes [26]. The optimal dose range and methods of administration of naloxone are still not
clear. The UK Department of Health recommends the following naloxone dose regimen: an initial
dose of 0.4 mg intravenously, followed by up to two doses of 0.8 mg. If the latter two doses are
ineffective, a further 2 mg dose should be provided [27]. In fact, despite the fact that fentanyl shows
an afﬁnity for μ-opioid receptor (Ki ~ 1.346 nM) similar to that of morphine (Ki ~ 1.168 nM) [28], it
displays a greater potency (EC50 ~ 0.15 nM) than morphine (EC50 ~ 2.4 nM) in functional biological
assays [29]. On this basis, higher naloxone doses may be necessary to reverse the adverse effects of
fentanyls (i.e., lofentanil) with greater μ-opioid receptor afﬁnity (Ki ~ 0.023 nM) [30] and potency
(EC50 ~ 0.03 nM) [29].
Because of the narrow therapeutic index of fentanyl (and, presumably, of its analogs) its
recreational use is highly dangerous, especially in opioid-intolerant users. High doses might
hasten death due to respiratory arrest and pulmonary edema. Fentanyl analogs are clandestinely
developed for recreational use [15,30–34]. These compounds have been synthesized by modiﬁcation or
replacement of the fentanyl’s propionyl chain or by replacement of its ethylphenyl moiety. The obtained
analogs have been further modiﬁed by substitution with ﬂuoro, chloro, or methoxy groups at the
N-phenyl ring. Among fentanyl analogs, carfentanil [methyl 1-(2-phenylethyl)-4-(N-propanoylanilino)
piperidine-4-carboxylate] is considered one of the most lethal opioids, showing an extremely high
clinical potency. It is used in research and, in some countries, as a veterinary medicine to immobilize
large animals. Between November 2016 and April 2017, carfentanil was involved in at least 61 deaths
in eight European countries. The vast majority of those deaths are related to heroin consumption [2].
Fentanyls have been found in a range of physical and dosage forms in Europe. The most common
form is powder, but they have also been detected in liquids and tablets. E-liquids containing fentanyls
that can be vaped using electronic cigarettes have also been reported [2].
These forms are easily absorbed through more convenient administration routes than injection,
yet provide the consumers with psychoactive effects similar to those obtained with injectable forms.
However, their use may pose a high risk of accidental overdose. In fact, nasal sprays and e-liquids
could make fentanyls use more attractive and socially acceptable, promoting their spread and usage.
In addition to fentanyls, other novel synthetic opioids with chemical structures different
from fentanyl, i.e., MT-45, AH-7921, and U-47700, have appeared on the recreational drug
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market and are causing intoxication and potentially fatal outcomes in consumers. MT-45
(1-cyclohexyl-4-(1,2-diphenylethyl) piperazine)), also known as IC-6, CDEP, AC1L8SAC, and NSC
299236, has shown particular effects, such as paresthesia in limbs, hand weakness, balance disturbances,
vision impairments, and hearing impairment or loss [35]. In three cases, unusual side effects have been
reported, such as loss and depigmentation of hair, folliculitis and dermatitis, painful intertriginous
dermatitis, and elevated liver enzymes [36]. MT-45 has been associated with many reports of fatal
intoxications in Europe; in particular, Sweden reported 28 analytically conﬁrmed deaths between
November 2013 and July 2014 [37,38]. In vitro and in vivo metabolism studies have shown that
MT-45 is biotransformed into active hydroxylated compounds [39] that may contribute to the overall
pharmaco-toxicological proﬁle of MT-45 in vivo [40]. AH-7921 (3,4-dichloro-N-[1(dimethylamino)
cyclohexyl] methyl benzamide) belongs to a series of compounds known as cyclohexylamines [41].
The drug exhibited similar potency to morphine in preclinical studies [42]. The compound is taken
orally, nasally, by smoking, and, less commonly, by intravenous injection [43]. The main clinical effects
included hypertension, tachycardia, and seizures. The ﬁrst death associated with AH-7921 use was
reported by Norway in December 2012 [43]. There has been one conﬁrmed fatality from AH-7921 in
the United States, but a number of deaths have been associated with this drug in Europe [44,45].
U-47700 (3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)yclohexyl]-N-methylbenzamide) is a
structural isomer of AH-7921. It is also known as “fake morphine” or “U4” in the recreational drug
market and it is sometimes also referred to as “pink”, because impurities in its synthesis cause the
drug powder to be slightly pink in color. In preclinical studies, U-47700 is about 1/10 as potent as
fentanyl, but 7.5 times more potent than morphine [46,47]. During 2016, a signiﬁcant number of
U-47700 acute intoxication cases were reported in the USA. The clinical symptoms are consistent with
those of traditional opioids [5]. U-47700 has caused at least 46 deaths from overdose in the United
States [48–51].
3.2. Circumstantial Data and External Examination
It is very important to sample any potential drug-containing material in the area around a dead
body, taking into account the numerous opioid administration routes (drug paraphernalia, powders,
syringes, vials, pills, patches etc.). It is also important to look for signs of administration on the body,
considering, however, that about 20% [52] of subjects take fentanyl or analogs by inhalation, ingestion,
or, rarely, transdermal route, therefore puncture marks are not always evident.
Even in the absence of external signs speciﬁc for opioid intoxication, it is possible to observe
non-speciﬁc signs of asphyxia, such as petechiae [53].
3.3. Autopsy-Pathological Findings
The data from the literature review showed that the new synthetic opioids produce similar clinical
effects as the traditional ones [54]; therefore, we sought the typical ﬁndings of heroin intoxication
trying to capture the differences and identify additional typical ﬁndings of fentanyl- and synthetic
opioid-related deaths. The autopsy ﬁndings collected from the case reports treated in the literature
were homogeneous with respect to the detected ﬁndings. The routine histological data were not very
speciﬁc and did not reveal indicative signs of intoxication [13,55].
3.3.1. Central Nervous System
The major autoptic relief found in the CNS was cerebral oedema. This ﬁnding was reported
for several drugs (fentanyl [56,57], acetylfentanyl [58], butyrylfentany [59], furanylfentanyl [60,61],
ocfentanil [62], AH-7921 [63], U-47700 [64], MT-45 [65]). A case of fatal cerebral hemorrhage induced
by acetylfentanyl was reported [66], and another case of a 19-month-old girl poisoned by a transdermal
administration of fentanyl who developed leukoencephalopathy was described [67]; in this case, the
girl survived, however, investigators declared that this is not always the outcome [55].
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3.3.2. Cardiovascular System
A reported uncommon intoxication symptom is chest pain mimicking acute coronary syndrome
with non-speciﬁc T-wave changes on the electrocardiogram [68]. It is necessary to distinguish the
alterations induced acutely by the drug from those due to pre-existing pathologies. Most of the
observed cardiovascular pathological ﬁndings, such as hypertrophy [69], cardiomegaly [56,70,71],
cardiac ﬁbrosis [72,73], atherosclerosis [69,74], are not attributable to an acute intoxication but, in some
cases, they may be compatible with chronic drug intake. The presence of pericardial petechiae [53] can
be interpreted as a generic sign of asphyxia, due to opioid-related respiratory failure.
3.3.3. Pulmonary
The main effect of fentanyl and its analogues on the respiratory system is respiratory depression.
Furthermore, fentanyl can cause chest wall rigidity and apnea, particularly with rapid intravenous
administration [75], a factor that can contribute to respiratory failure. Rare adverse effects after
fentanyl usage include diffuse alveolar hemorrhage immediately after insufﬂating fentanyl powder [72].
The major pathological ﬁndings are pulmonary congestion [53,54,69,70,73,74,76–82] and pulmonary
oedema, which are common to all the investigated drugs [57,58,70,73,74,78–81,83]. Signs found
occasionally are petechiae on the pleura [57,82] and aspiration of gastric contents inside the trachea
and bronchi [57,76,81].
A few cases of fentanyl patch aspiration have been reported, where the patch was found in the
airways [71,84]. Microscopically, small amounts of foreign material have been reported in the lungs,
consistent with prior intravenous drug abuse [80].
3.3.4. Others
Another common sign is generalized visceral congestion [51,60,65]. Hepatic parenchyma
alterations, such as liver cirrhosis [74], chronic active hepatitis [82], fatty degeneration [62,70,84],
hepatomegaly [62,70], are common but due to pre-existing conditions or chronic abuse of narcotics.
3.4. Sampling
The samples commonly taken for toxicological analysis consisted of peripheral blood [84], central
blood [85], urine, and liver. Less commonly collected samples were vitreous humour [78], brain,
kidney, bile, and gastric content.
Among these, the least susceptible site to post-mortem redistribution is the liver (in relation to
fentanyl) [86]. However, there is currently no consensus on the ideal sampling site [87].
3.5. Lethal Concentrations
The lethal concentrations found in the literature are reported in Table 1. For each drug, the routes of
administration and relative potency compared to morphine are shown, in addition to the dose (and the
corresponding tissue). Table 2 shows the concentration data reported in multidrug-associated deaths.
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4. Discussion
This review deals with human pathological ﬁndings that are directly attributable to the known
toxic actions of fentanyls and other synthetic opioids. In the past few years, it has become more
and more evident that fentanyls and other synthetic opioids are potentially extremely harmful.
Fentanyl-related deaths have increased over the years [47,52], so it is necessary to review the data
available on these analog NPS. The results from our literature analysis revealed the lethal potential of
fentanyls and other synthetic opioids; a large number of different routes of substance administration
have also surfaced, through which all of these compounds are potentially lethal.
In addition, a broad range of side effects associated with fentanyls and other synthetic opioids
have emerged, posing serious health issues, which primarily concern the central nervous system,
cardiovascular and pulmonary systems, and liver. Macroscopic examinations, autopsy data, and
histopathological elements were collected from the literature, leaving evidence that mainly refers to
opioid intoxication. The investigation of the cause of death provoked by fentanyl or other synthetic
opioid abuse was based on a multidisciplinary approach aimed at framing each case and directing the
investigations towards targeted toxicological analyses. This approach should be adopted in all cases of
death from uncertain or questionable causes [66,70]. Past medical history and ante-mortem distribution,
crime scene investigation, post-mortem toxicology examination, and toxicology ﬁndings should be
carefully analyzed and considered on a case-by-case basis in light of all other data [11,98,105–107].
The examination of the literature showed that a large number of deaths associated with fentanyl
and other synthetic opioids involved the abuse of other psychoactive substances. In a previous
review [22] of various case studies of fentanyl-related deaths, it was speculated that the deaths were
associated with drugs of abuse such other opiates (up to 64%), cocaine (up to 65%), cannabinoids
(up to 50%), amphetamines (up to 40%), but also ethanol (up to 22.9%) and medicines like barbiturates
(up to 27%), benzodiazepines (up to 52.2%), antidepressants (up to 48%). These data can lead to a series
of considerations. The ﬁrst is inherent in the contribution to the deaths of the substances detected
together with synthetic opioids. Animal studies have shown that some classes of substances, such as
benzodiazepines, have a synergistic effect with opioids.
Although the pharmacokinetic and pharmacodynamic interactions between benzodiazepines
and opioids are not yet fully understood [108], pre-clinical studies suggest a synergistic effect on
opioid-induced respiratory depression (measured as % increase in pCO2) [109]. Forensic data show
the risks of this drug combination: the concomitant use of benzodiazepines and “traditional” opioids
is associated with the occurrence of opioid overdoses [110,111]. This occurrence is very common, and
the co-use of opioid and benzodiazepine could be aimed at amplifying the subjective effects of the
opioid [112,113]. However, the current knowledge does not permit to establish the exact contribution
of benzodiazepines in opioid-related deaths, considering that many opioid addicts are also chronic
benzodiazepine users [114,115].
Regarding the co-administration of ethanol and opioids, it can be dangerous because it enhances
the positive subjective effects that contribute to the abuse and affects physical and cognitive functions.
It is no coincidence that alcohol and opioid abuses often coexist [116]. Fatal intoxications involving
opioids are frequently associated with alcohol use and are likely due to combined CNS- and
respiratory-depressant effects [117,118].
Concerning the co-administration of cocaine and synthetic opioids, animal studies have shown
that combinations of cocaine and remifentanil can lead to a strong additivity [119], maybe for their
synergistic action on the mesolimbic dopaminergic system [120]. Unfortunately, data on humans are
not yet reported in the literature. Recently, there has been an increase in cocaine-related overdoses;
however, a large part of this increase is due to the simultaneous intake of opioids, especially synthetic
ones [121]. Often, the use of a synthetic opioid is accidental, due to an unknown contamination of a
cocaine stock [122,123].
The same assumption can be formulated for the deaths from the co-administration of heroin and
fentanyl. A recent study showed a strong association between the number of tested samples of seized
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drugs where fentanyl was detected and unintentional overdose deaths in which fentanyl was also
identiﬁed [124]. This data are consistent with previous studies that have shown that a signiﬁcant
proportion of drug users unintentionally consume fentanyl, which is present in the substances they
are taking [7,122,125]. However, the real diffusion of illicit fentanyl use in the general population is
difﬁcult to assess, because routine toxicology screens will not detect synthetic opioids that have little
structural homology to morphine and other commonly tested opioids [14].
5. Conclusions
In Conclusion, the conﬁrmation or exclusion of opioid overdoses is one of the major challenges
for forensic pathologists, considering what has been said and that autopsy ﬁndings are not speciﬁc.
It is therefore necessary that the forensic pathologist have a broader approach and, on the basis of the
data collected, request a chemical-analytical analysis to point out NPS [87].
The role of the forensic pathologist in close collaboration with the forensic toxicologist is very
important: together, they can identify new cases of fentanyl and synthetic opioid intoxication.
The identiﬁcation of NPS is essential to stop the social problems related to the spread of these new
dangerous and highly addictive substances among our population.
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